1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Parkinson Disease in 972 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine if the beneficial effects of transient desflurane application mitigates inflammation and decrease associated signaling induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in mice." | 8.12 | Beneficial effect of transient desflurane inhalation on relieving inflammation and reducing signaling induced by MPTP in mice. ( Ge, Z; Li, W; Qin, G; Yu, Z, 2022) |
| " Specifically, we aimed to explore the mechanism by which puerarin prevents inflammation and apoptosis in neurocytes." | 7.83 | Puerarin prevents inflammation and apoptosis in the neurocytes of a murine Parkinson's disease model. ( Gao, Y; Jiang, M; Niu, G; Shi, F; Yu, S; Yun, Q, 2016) |
| "To investigate the use of diffusion-tensor imaging (DTI) to detect denervation of the nigrostriatal pathway in a nonhuman primate model of Parkinson disease (PD) after treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 7.81 | Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. ( Ando, K; Hikishima, K; Inoue, T; Itoh, T; Kawai, K; Komaki, Y; Momoshima, S; Okano, H; Okano, HJ; Yamada, M; Yano, R, 2015) |
| "The angiogenic factor, angiogenin, has been recently linked to both Amyotrophic Lateral Sclerosis (ALS) and Parkinson Disease (PD)." | 7.79 | Angiogenin in Parkinson disease models: role of Akt phosphorylation and evaluation of AAV-mediated angiogenin expression in MPTP treated mice. ( Ding, H; Slone, SR; Standaert, DG; Steidinger, TU; Yacoubian, TA, 2013) |
| "The protective effect of puerarin on the Parkinson disease (PD) mice with decreased estrogen level was investigated in order to develop a new potential medicine as a substitute for estrogen for preventing and treating PD." | 7.72 | Experimental study on the protective effect of puerarin to Parkinson disease. ( Li, X; Sun, S; Tong, E, 2003) |
| "Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease." | 7.67 | The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985) |
| "In the murine model of early Parkinson's disease, the balance between dopamine and 5-hydroxytryptamine systems varied among brain regions." | 5.91 | Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease. ( He, L; Huang, H; Shi, J; Xie, S; Yang, R; Yang, Y; Ye, S; Zhang, S; Zhang, Y, 2023) |
| "However, the mechanisms and treatment of pain in PD have not been well studied." | 5.72 | Dexmedetomidine alleviates pain in MPTP-treated mice by activating the AMPK/mTOR/NF-κB pathways in astrocytes. ( Chen, Y; Cheng, O; Cui, J; Li, C; Li, Y; Zhu, D, 2022) |
| "Brain bioavailability of drugs developed to address central nervous system diseases is classically documented through cerebrospinal fluid collected in normal animals, i." | 5.43 | Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease. ( Bezard, E; Contamin, H; Li, Q; Thiollier, T; Wu, C; Zhang, J, 2016) |
| "Morphine has been found to elevate dopamine levels, which indicates a potential therapeutic effect in PD treatment that has not been investigated previously." | 5.40 | Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. ( Hu, X; Huang, B; Li, H; Ma, Y; Rizak, JD; Yan, T; Yang, S, 2014) |
| "Neuroinflammation is thought to be one of the major pathological mechanisms responsible for Parkinson's disease (PD), and has been a primary target in the development of treatment for PD." | 5.38 | Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation in vitro and in vivo. ( Ha, SK; Ju, MS; Kim, HG; Kim, SY; Lee, H; Oh, MS, 2012) |
| "Haloperidol has recently been found to be metabolized to its pyridinium ion (HP+)." | 5.29 | Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. ( Fang, J; Yu, PH; Zuo, D, 1995) |
| " Using a chronic regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid (MPTP/p) in mice, dopamine cell loss exceeds 60%, extracellular glutamate is elevated, cytoplasmic inclusions are formed and inflammation is chronic." | 4.84 | Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. ( Meredith, GE; Potashkin, JA; Surmeier, DJ; Totterdell, S, 2008) |
| "To determine if the beneficial effects of transient desflurane application mitigates inflammation and decrease associated signaling induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in mice." | 4.12 | Beneficial effect of transient desflurane inhalation on relieving inflammation and reducing signaling induced by MPTP in mice. ( Ge, Z; Li, W; Qin, G; Yu, Z, 2022) |
| " Then, in mouse models, we assessed whether dextran sodium sulfate-mediated colitis could exert lingering effects on dopaminergic pathways in the brain and whether colitis increased vulnerability to a subsequent exposure to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 4.02 | Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology. ( Caudle, WM; Chang, J; Houser, MC; Joers, V; Kannarkat, GT; Kelly, SD; Keshavarzian, A; Oliver, D; Shannon, KM; Tansey, MG; Yang, Y, 2021) |
| " The aim of this study was to investigate the effect of chronic cerebral hypoperfusion (CCH) on cognitive dysfunction, structural abnormalities of the hippocampus and white matter (WM), and levels of inflammatory cytokines in control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mouse models." | 3.91 | Hippocampal damage and white matter lesions contribute to cognitive impairment in MPTP-lesioned mice with chronic cerebral hypoperfusion. ( Feng, S; Gao, L; Gao, Y; Huang, Z; Nie, K; Tang, H; Wang, L; Zhang, Y; Zhao, J; Zhu, R, 2019) |
| " In our previous study, we have shown that brain-specific microRNA-124 (miR-124) is significantly down-regulated in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD and that it can also inhibit neuroinflammation during the development of PD." | 3.91 | MicroRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson's disease. ( Lu, G; Qian, C; Sun, X; Wang, B; Wu, J; Xie, L; Yao, L; Zhang, H; Zhang, S; Zhang, Y; Zhu, Z, 2019) |
| "The present study is to investigate the neuroprotective effect of ibuprofen by intranasal administration of mucoadhesive microemulsion (MMEI) against inflammation-mediated by dopaminergic neurodegeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease (PD)." | 3.83 | Design and evaluation of mucoadhesive microemulsion for neuroprotective effect of ibuprofen following intranasal route in the MPTP mice model. ( Chuttani, K; Mandal, S; Mandal, SD; Sawant, KK; Subudhi, BB, 2016) |
| " Specifically, we aimed to explore the mechanism by which puerarin prevents inflammation and apoptosis in neurocytes." | 3.83 | Puerarin prevents inflammation and apoptosis in the neurocytes of a murine Parkinson's disease model. ( Gao, Y; Jiang, M; Niu, G; Shi, F; Yu, S; Yun, Q, 2016) |
| "To investigate the use of diffusion-tensor imaging (DTI) to detect denervation of the nigrostriatal pathway in a nonhuman primate model of Parkinson disease (PD) after treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 3.81 | Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. ( Ando, K; Hikishima, K; Inoue, T; Itoh, T; Kawai, K; Komaki, Y; Momoshima, S; Okano, H; Okano, HJ; Yamada, M; Yano, R, 2015) |
| "The angiogenic factor, angiogenin, has been recently linked to both Amyotrophic Lateral Sclerosis (ALS) and Parkinson Disease (PD)." | 3.79 | Angiogenin in Parkinson disease models: role of Akt phosphorylation and evaluation of AAV-mediated angiogenin expression in MPTP treated mice. ( Ding, H; Slone, SR; Standaert, DG; Steidinger, TU; Yacoubian, TA, 2013) |
| " We examined the role of Ranbp2 haploinsufficiency on cellular and metabolic manifestations linked to tyrosine-hydroxylase (TH(+)) dopaminergic neurons and glial cells of the brain and retina upon acute challenge to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a parkinsonian neurotoxin, which models facets of Parkinson disease." | 3.78 | Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Cho, KI; Ferreira, PA; Searle, K; Webb, M; Yi, H, 2012) |
| " P7C3 blocks 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated cell death of dopaminergic neurons in the substantia nigra of adult mice, a model of Parkinson disease (PD)." | 3.78 | Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. ( Britt, J; De Jesús-Cortés, H; Drawbridge, J; Estill, SJ; Huntington, P; McKnight, SL; Melito, LM; Morlock, L; Naidoo, J; Pieper, AA; Ready, JM; Tesla, R; Tran, S; Wang, G; Williams, NS; Xu, P, 2012) |
| "As an index of terminal serotonin innervation density, we measured radioligand binding to the plasma membrane serotonin transporter (SERT) in levodopa-treated dyskinetic and nondyskinetic subjects, using brain tissue from both rat and monkey models of Parkinson disease as well as parkinsonian patients." | 3.76 | Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. ( Bezard, E; Cenci, MA; Descarries, L; Dovero, S; Lees, AJ; O'Sullivan, SS; Parent, M; Rylander, D, 2010) |
| "Current evidence suggests a role of neuroinflammation in the pathogenesis of Parkinson's disease (PD) and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of basal ganglia injury." | 3.76 | Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. ( Caniglia, S; Impagnatiello, F; L'Episcopo, F; Marchetti, B; Morale, MC; Serra, PA; Testa, N; Tirolo, C, 2010) |
| " In this study, we investigated the effect as well as the molecular mechanism of geldanamycin (GA), an inhibitor of Hsp90, on 1-methyl-4-pheny-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity, a mouse model of Parkinson disease." | 3.73 | Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. ( Chen, JF; He, JC; Huang, QY; Shen, HY; Wang, Y, 2005) |
| "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is commonly used to create animal models of Parkinson disease." | 3.73 | Evidence of apoptosis in the subventricular zone and rostral migratory stream in the MPTP mouse model of Parkinson disease. ( Doi, K; Dong, M; He, XJ; Nakayama, H; Ueno, M; Uetsuka, K; Yamauchi, H, 2006) |
| "The protective effect of puerarin on the Parkinson disease (PD) mice with decreased estrogen level was investigated in order to develop a new potential medicine as a substitute for estrogen for preventing and treating PD." | 3.72 | Experimental study on the protective effect of puerarin to Parkinson disease. ( Li, X; Sun, S; Tong, E, 2003) |
| " Acidic FGF was injected stereotaxically into the striatum of young (2-month-old) and aging (12-month-old) C57BL/6 mice that were treated 1 week before with systemic injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 3.68 | MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF). ( Date, I; Felten, DL; Felten, SY; Notter, MF, 1990) |
| "The long-term effect of the parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central monoaminergic neurons in young (2-3 months) and aging (12 months) C57BL/6 mice has been studied using neurochemical and immunocytochemical techniques." | 3.68 | Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. ( Date, I; Felten, DL; Felten, SY, 1990) |
| "We investigated the effect of GM1 gangliosides on a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of Parkinson disease." | 3.68 | GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice. ( Albert, ML; Davoudi, H; Durso, R; Fazzini, E; Szabo, GK, 1990) |
| "Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease." | 3.67 | The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985) |
| "Among the popular animal models of Parkinson's disease (PD) commonly used in research are those that employ neurotoxins, especially 1-methyl- 4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)." | 2.72 | MPTP-induced mouse model of Parkinson's disease: A promising direction of therapeutic strategies. ( Mat Taib, CN; Mustapha, M, 2021) |
| "Parkinson's disease (PD) and Alzheimer's disease (AD) are the most common chronic neurodegenerative disorders, characterized by motoric dysfunction or cognitive decline in the early stage, respectively, but often by both symptoms in the advanced stage." | 2.66 | Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease. ( Barilar, JO; Homolak, J; Knezovic, A; Perhoc, AB; Riederer, P; Salkovic-Petrisic, M, 2020) |
| "Models of Parkinson's disease (PD) can be produced in several non-human primate (NHP) species by applying neurotoxic lesions to the nigrostriatal dopamine pathway." | 2.52 | Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates. ( Fox, SH; Johnston, TM, 2015) |
| "Animal models of Parkinson's disease (PD) have been widely used in the past four decades to investigate the pathogenesis and pathophysiology of this neurodegenerative disorder." | 2.48 | Animal models of Parkinson's disease. ( Armentero, MT; Blandini, F, 2012) |
| "The classical animal models of Parkinson's disease (PD) rely on the use of neurotoxins, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine and, more recently, the agricultural chemicals paraquat and rotenone, to deplete dopamine (DA)." | 2.46 | alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach. ( Bazzu, G; Calia, G; Debetto, P; Desole, MS; Grigoletto, J; Miele, E; Migheli, R; Puggioni, G; Rocchitta, G; Serra, PA; Spissu, Y; Zusso, M, 2010) |
| "The sex difference in Parkinson's disease, with a higher susceptibility in men, suggests a modulatory effect of sex steroids in the brain." | 2.45 | Neuroprotective actions of sex steroids in Parkinson's disease. ( Bourque, M; Di Paolo, T; Dluzen, DE, 2009) |
| "Functional models of Parkinson's disease (PD) have led to effective treatment for the motor symptoms." | 2.44 | Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. ( Jenner, P, 2008) |
| "Nonhuman primate models of Parkinson's disease (PD) have been invaluable to our understanding of the human disease and in the advancement of novel therapies for its treatment." | 2.43 | Neural repair strategies for Parkinson's disease: insights from primate models. ( Kordower, JH; O'Malley, J; Soderstrom, K; Steece-Collier, K, 2006) |
| "Current research into Parkinson's disease (PD) is directed at developing novel agents and strategies for improved symptomatic management." | 2.42 | The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. ( Jenner, P, 2003) |
| "Parkinson's disease is a neurodegenerative disorder of unknown pathogenesis." | 2.42 | Nitric oxide and reactive oxygen species in Parkinson's disease. ( Ischiropoulos, H; Przedborski, S; Tieu, K, 2003) |
| "The development of animal models of Parkinson's disease is of great importance in order to test substitutive or neuroprotective strategies for Parkinson's disease." | 2.42 | Animal models of Parkinson's disease in rodents induced by toxins: an update. ( Breidert, T; Cohen-Salmon, C; Feger, J; Hirsch, EC; Höglinger, G; Launay, JM; Parain, K; Prigent, A; Rousselet, E; Ruberg, M, 2003) |
| "One major goal of current research in Parkinson's disease (PD) is the discovery of novel agents to improve symptomatic management." | 2.42 | Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. ( Linazasoro, G, 2004) |
| "The symptoms of Parkinson's disease (PD) were first described nearly two centuries ago and its characteristic pathology identified nearly a century ago, yet its pathogenesis is still poorly understood." | 2.41 | An inflammatory review of Parkinson's disease. ( Halliday, GM; Orr, CF; Rowe, DB, 2002) |
| "In conclusion, the aetiology of Parkinson's disease remains unknown." | 2.41 | [Genetics and environmental factors of Parkinson disease]. ( Broussolle, E; Thobois, S, 2002) |
| "Apomorphine has a far more broad neuroprotective activity in the various models as compared with 1-selegiline and may therefore be an ideal drug to study neuroprotection in parkinsonian subjects with the use of PET or SPECT." | 2.41 | Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. ( Gassen, M; Gross, A; Grünblatt, E; Mandel, S; Youdim, MB, 2000) |
| "Recent genetic studies in familial Parkinson's disease and parkinsonism show several gene mutations." | 2.41 | The parkinsonian models: invertebrates to mammals. ( Akaike, A; Kitamura, Y; Shimohama, S; Taniguchi, T, 2000) |
| "The "MPTP story" hypothesizes that Parkinson's disease may be initiated or percipitated by environmental and/or endogenous toxins by a mechanism similar to that of MPTP in genetically-predisposed individuals." | 2.40 | [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease]. ( Matsubara, K, 1998) |
| " We further found that oral CoQ10 was well absorbed in parkinsonian patients and caused a trend toward increased complex I activity." | 2.40 | A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. ( Beal, MF; Haas, RH; Shults, CW, 1999) |
| "The cause of Parkinson's disease (PD) is unknown, but reduced activity of complex I of the electron-transport chain has been implicated in the pathogenesis of both mitochondrial permeability transition pore-induced Parkinsonism and idiopathic PD." | 2.40 | Mitochondrial dysfunction in Parkinson's disease. ( Greenamyre, JT; MacKenzie, G; Peng, TI; Stephans, SE, 1999) |
| "Research on Parkinson's disease has led to new hypotheses concerning the mechanisms of neurodegeneration and to the development of neuroprotective agents." | 2.39 | Neuroprotection by dopamine agonists. ( Gsell, W; Lange, KW; Naumann, M; Oestreicher, E; Rausch, WD; Riederer, P, 1994) |
| "Selegiline (L-deprenyl) has been shown to delay the need to initiate levodopa therapy in early PD, and selegiline has also been suggested to increase the survival of PD patients." | 2.38 | Nigral degeneration in Parkinson's disease. ( Rinne, JO, 1993) |
| "The biochemical process underlying Parkinson's disease is dopamine cell death of the nigrostriatal system." | 2.38 | Type B monoamine oxidase and neurotoxins. ( Maruyama, W; Naoi, M, 1993) |
| "Since the original description of Parkinson's disease (PD) more than 170 years ago, there have been major advances in the understanding and treatment of PD." | 2.38 | Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease? ( Poirier, J; Thiffault, C, 1993) |
| " Regular dosing with levodopa or apomorphine reliably resulted in peak dose dyskinesia." | 2.38 | The use of thalamotomy in the treatment of levodopa-induced dyskinesia. ( Page, RD, 1992) |
| "Selegiline has been used in the therapy of Parkinson's disease since 1986." | 2.38 | Selegiline--an overview of its role in the treatment of Parkinson's disease. ( Szelenyi, I; Wessel, K, 1992) |
| "The cause of dopamine cell death in Parkinson's disease remains unknown." | 2.38 | Oxidative stress as a cause of Parkinson's disease. ( Jenner, P, 1991) |
| "The etiology of Parkinson's disease remains an enigma." | 2.37 | Etiology of Parkinson's disease: current concepts. ( Duvoisin, RC, 1986) |
| "Neurochemical studies in Parkinson's disease have greatly contributed to the understanding of the neurobiology of the meso-telencephalic dopamine (DA) system; in addition, these studies have significantly influenced our concepts regarding the general principles of brain function." | 2.37 | [The life history of brain dopamine]. ( Hornykiewicz, O, 1985) |
| "MPTP is oxidized to its toxic metabolite MPP+ by MAO B in both primate and rodent brains and this reaction can be inhibited by (-)-deprenyl." | 2.37 | The role of MAO in MPTP toxicity--a review. ( Gibb, C; Glover, V; Sandler, M, 1986) |
| " Administration in daily dosage of 10 mgs produces an almost complete inhibition of the enzyme." | 2.37 | R-(-)-deprenyl and parkinsonism. ( Yahr, MD, 1987) |
| "Cordycepin has been reported to alleviate cognitive impairments in neurodegenerative diseases." | 1.91 | Cordycepin improved the cognitive function through regulating adenosine A ( Han, YY; Huang, SY; Li, CH; Liu, L; Mai, ZF; Shang, YJ; Su, ZY; Zeng, ZW, 2023) |
| "Causes of dopaminergic neuronal loss in Parkinson's disease (PD) are subject of investigation and the common use of models of acute neurodegeneration induced by neurotoxins 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine, and rotenone contributed to advances in the study of PD." | 1.91 | Protective Effects of Flavonoid Rutin Against Aminochrome Neurotoxicity. ( Costa, ACS; Costa, SL; Cuenca-Bermejo, L; De Araújo, FM; de Fatima Dias Costa, M; de Jesus, LB; Farias, AA; Ferreira, KMS; Frota, AF; Herrero, MT; Menezes-Filho, JA; Munoz, P; Sanches, FS; Santos, CC; Segura-Aguilar, J; Silva, VDA; Soares, EN; Souza, JT, 2023) |
| "Identification of genetic mutations in Parkinson's disease (PD) promulgates the genetic nature of disease susceptibility." | 1.91 | Apoptotic Factors and Mitochondrial Complexes Assist Determination of Strain-Specific Susceptibility of Mice to Parkinsonian Neurotoxin MPTP. ( Alladi, PA; Nambisan, AK; Raju, TR; Sagar, BKC; Vidyadhara, DJ; Yarreiphang, H, 2023) |
| "Methods: To create a cell model of Parkinson's disease, MPTP (2500 μmol/L) was administered to rat adrenal pheochromocytoma cells (PC-12) to produce an MPTP group." | 1.91 | Effect of Eleutheroside E on an MPTP-Induced Parkinson's Disease Cell Model and Its Mechanism. ( Liang, L; Liao, C; Meng, F; Qiu, H; Wu, L; Yao, Y; Zheng, W, 2023) |
| "Morin is a flavonoid that can be isolated from fruits like mulberry." | 1.91 | Morin exhibits a neuroprotective effect in MPTP-induced Parkinson's disease model via TFEB/AMPK-mediated mitophagy. ( Chen, G; Cui, J; Huang, J; Li, D; Ran, S; Wang, Z, 2023) |
| "The effects of FGF21 on Parkinson's disease (PD) and its relationship with gut microbiota have not been elucidated." | 1.91 | Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis. ( Deng, P; Gao, H; Li, C; Wang, W; Wang, X; Yang, C; Zhao, L; Zhu, L, 2023) |
| "In the murine model of early Parkinson's disease, the balance between dopamine and 5-hydroxytryptamine systems varied among brain regions." | 1.91 | Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease. ( He, L; Huang, H; Shi, J; Xie, S; Yang, R; Yang, Y; Ye, S; Zhang, S; Zhang, Y, 2023) |
| "Chlorogenic acid (CGA) is a phenolic compound appearing in coffee, honeysuckle, and eucommia that showed their potential as antioxidants and neuroprotectors." | 1.91 | Neuroprotective effect of chlorogenic acid on Parkinson's disease like symptoms through boosting the autophagy in zebrafish. ( Finiuk, N; Gao, X; Jin, M; Liu, K; Liu, X; Rostyslav, P; Sik, A; Stoika, R; Zhang, B; Zheng, Y, 2023) |
| "Rest tremor is one of the most prominent clinical features of Parkinson's disease (PD)." | 1.91 | Tuned to Tremor: Increased Sensitivity of Cortico-Basal Ganglia Neurons to Tremor Frequency in the MPTP Nonhuman Primate Model of Parkinson's Disease. ( Bergman, H; Eitan, R; Linkovski, O; Mevorach, T; Rahamim, N; Rosin, B; Slovik, M, 2023) |
| "Our primate model of parkinsonism recapitulates important pathologic features in nature PD and provides an unbiased view of the axis of neuronal vulnerability and resistance." | 1.91 | A primate nigrostriatal atlas of neuronal vulnerability and resilience in a model of Parkinson's disease. ( Hao, ZZ; Huang, M; Li, Y; Liu, R; Liu, S; Liu, X; Sang, X; Shao, M; Shen, Y; Tang, L; Xu, C; Xu, N; Yi, W; Yue, F, 2023) |
| "Although the etiology of Parkinson's disease (PD) is poorly understood, studies in animal models revealed loss of dopamine and the dopaminergic neurons harbouring the neurotransmitter to be the principal cause behind this neuro-motor disorder." | 1.72 | Garcinol blocks motor behavioural deficits by providing dopaminergic neuroprotection in MPTP mouse model of Parkinson's disease: involvement of anti-inflammatory response. ( Bhattacharya, P; Borah, A; Chetia Phukan, B; Deb, S; Dutta, A; Mazumder, MK; Paul, R; Saikia, R; Sandhir, R, 2022) |
| "Current stem cell therapies for Parkinson's disease (PD) focus on a neurorestorative approach that aims to repair the CNS during the symptomatic phase." | 1.72 | Reduced dopaminergic neuron degeneration and global transcriptional changes in Parkinson's disease mouse brains engrafted with human neural stems during the early disease stage. ( Boese, AC; Hamblin, MH; Lee, JP; Murad, R; Pereira, MCL; Yin, J, 2022) |
| "Animal models of Parkinson's disease were built according to MPTP administration." | 1.72 | Effect of Different MPTP Administration Intervals on Mouse Models of Parkinson's Disease. ( Ma, Y; Rong, Q, 2022) |
| " Chronic administration of CP690550 (3 and 10 mg/kg, po) for 7 days significantly reversed the behavioural, biochemical and histological alterations induced by MPTP." | 1.72 | Protective Effect of CP690550 in MPTP-Induced Parkinson's Like Behavioural, Biochemical and Histological Alterations in Mice. ( Albekairi, NA; Albekairi, TH; Alharbi, M; Alharbi, OO; Alshammari, A; Singh, S; Yeapuri, P, 2022) |
| "The incidence of Parkinson's disease (PD) has increased tremendously, especially in the aged population and people with metabolic dysfunction; however, its underlying molecular mechanisms remain unclear." | 1.72 | Neuronal SH2B1 attenuates apoptosis in an MPTP mouse model of Parkinson's disease via promoting PLIN4 degradation. ( Dai, Y; Han, X; Hu, G; Hu, J; Hu, Q; Liu, Y; Rui, L; Xu, T; Yi, X, 2022) |
| "In the context of Parkinson's disease (PD), the sensitivity of dopaminergic neurons in the substantia nigra pars compacta to oxidative stress is considered a key factor of PD pathogenesis." | 1.72 | Human IPSC 3D brain model as a tool to study chemical-induced dopaminergic neuronal toxicity. ( Burtscher, J; Harris, G; Hartung, T; Hogberg, HT; Katt, ME; Pamies, D; Searson, PC; Smirnova, L; Wiersma, D; Zhao, L, 2022) |
| "Mangiferin (MGF) is a glucosyl xanthone mainly derived from Mangifera indica L." | 1.72 | Mangiferin, a natural glucoxilxanthone, inhibits mitochondrial dynamin-related protein 1 and relieves aberrant mitophagic proteins in mice model of Parkinson's disease. ( Chen, NH; Feng, ST; Guo, ZY; Wang, XL; Wang, YT; Wang, ZZ; Yan, X; Yuan, YH; Zhang, NN; Zhang, Y, 2022) |
| "Inflammasome involvement in Parkinson's disease (PD) has been intensively investigated." | 1.72 | Microglial AIM2 alleviates antiviral-related neuro-inflammation in mouse models of Parkinson's disease. ( Fan, Y; Hu, YC; Li, S; Liu, Y; Ma, CM; Rui, WJ; Shi, JP; Wang, BW; Yang, L, 2022) |
| "Curcumin (CUR) has been reported to provide neuroprotective effects on neurological disorders and modulate the gut flora in intestinal-related diseases." | 1.72 | Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease. ( Cui, C; Han, Y; Li, G; Li, H; Yu, H; Zhang, B, 2022) |
| "Shikonin plays protective roles in age-associated diseases." | 1.72 | Shikonin ameliorates oxidative stress and neuroinflammation via the Akt/ERK/JNK/NF-κB signalling pathways in a model of Parkinson's disease. ( Du, J; Guo, L; Li, W; Li, Y; Qiu, J; Wang, L; Zhang, T, 2022) |
| "Neurodegenerative diseases such as Parkinson's disease (PD) are known to be related to oxidative stress and neuroinflammation, and thus, modulating neuroinflammation offers a possible means of treating PD-associated pathologies." | 1.72 | Anti-Inflammatory and Neuroprotective Effects of Morin in an MPTP-Induced Parkinson's Disease Model. ( Ahn, J; Chang, SC; Ha, NC; Hong, DG; Kim, J; Lee, H; Lee, J; Lee, M; Lee, S; Yang, S, 2022) |
| " We administered a single dosage of MPTP (200μg/g bw) via intraperitoneal injection (i/p) and assessed the locomotor activity and swimming pattern at 0h, 24h, and 96h post-injection through an open field test." | 1.72 | Characterization of neurobehavioral pattern in a zebrafish 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model: A 96-hour behavioral study. ( Doolaanea, AA; Kumar, J; Mohamed, WMY; Mohd Nasir, MH; Nabeel Ibrahim, W; Othman, N; Razali, K, 2022) |
| "Research has connected Parkinson's disease (PD) with impaired intestinal barrier." | 1.72 | Neuroprotective Effects of Sodium Butyrate and Monomethyl Fumarate Treatment through GPR109A Modulation and Intestinal Barrier Restoration on PD Mice. ( Ding, ST; Jian, YX; Lei, YH; Liu, HD; Liu, MR; Miao, WT; Xu, JY; Xu, RC; Xu, WX; Yan, N, 2022) |
| "However, the mechanisms and treatment of pain in PD have not been well studied." | 1.72 | Dexmedetomidine alleviates pain in MPTP-treated mice by activating the AMPK/mTOR/NF-κB pathways in astrocytes. ( Chen, Y; Cheng, O; Cui, J; Li, C; Li, Y; Zhu, D, 2022) |
| "We first confirmed that synucleinopathies existed in the stomachs of chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/probenecid (MPTP/p)-induced PD mice, as indicated by the significant increase in abnormal aggregated and nitrated α-synuclein in the TH-positive neurons and enteric glial cells (EGCs) of the gastric myenteric plexus." | 1.72 | Gastric Enteric Glial Cells: A New Contributor to the Synucleinopathies in the MPTP-Induced Parkinsonism Mouse. ( Chen, NH; Heng, Y; Li, YY; Wen, L; Yan, JQ; Yuan, YH, 2022) |
| "Epimedin B treatment ameliorated MPTP-induced motor dysfunction and alleviated the decreased contents of DA with its metabolites in the striatum and the loss of tyrosine hydroxylase-immunoreactive (TH-IR) neurons in the substantial nigra pars compacta (SNpc)." | 1.72 | Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target. ( Chen, WF; Dong, XL; Hu, ZF; Zhang, M, 2022) |
| "The main neuropathological feature of Parkinson's disease (PD) is degeneration of dopamine (DA) neurons in the substantia nigra (SN); PD prevalence is higher in men, suggesting a role of sex hormones in neuroprotection." | 1.62 | Effect of sex and gonadectomy on brain MPTP toxicity and response to dutasteride treatment in mice. ( Bourque, M; Coulombe, K; Di Paolo, T; Isenbrandt, A; Lamontagne-Proulx, J; Morissette, M; Soulet, D, 2021) |
| "Heterogenous diseases such as Parkinson's disease (PD) needs an efficient animal model to enhance understanding of the underlying mechanisms and to develop therapeutics." | 1.62 | Impaired mitochondrial functions and energy metabolism in MPTP-induced Parkinson's disease: comparison of mice strains and dose regimens. ( Garg, P; Pathania, A; Sandhir, R, 2021) |
| "Parkinson's disease is the second major neurodegenerative diseases secondarily to Alzheimer's disease." | 1.62 | Effects and potential mechanisms of rapamycin on MPTP-induced acute Parkinson's disease in mice. ( Chen, X; He, Y; Luo, H; Luo, Z; Tian, F; Wang, M; Yin, L; Yu, X; Zhang, G, 2021) |
| "The andrographolide activity was characterized by analyzing its role in different protein quality control mechanisms." | 1.62 | Andrographolide upregulates protein quality control mechanisms in cell and mouse through upregulation of mTORC1 function. ( Dutta, N; Ghosh, S; Majumder, C; Mandal, SC; Nelson, VK; Pal, M; Sareng, HR, 2021) |
| "Depression was induced by a 14-day chronic unpredictable mild stress (CUMS), and PD was induced by 1-day acute injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.62 | Depression Induced by Chronic Unpredictable Mild Stress Increases Susceptibility to Parkinson's Disease in Mice via Neuroinflammation Mediated by P2X7 Receptor. ( Dong, AQ; Hu, H; Li, LX; Liu, CF; Mao, CJ; Ren, C; Wang, F; Zhang, YT, 2021) |
| "Simvastatin has been touted as a potential neuroprotective agent for neurologic disorders such as PD, but the specific underlying mechanism remains unclear." | 1.62 | Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease via Inhibition of A1 Reactive Astrocytes. ( Bu, WG; Du, RW, 2021) |
| "Prucalopride treatment also ameliorated intestinal barrier impairment and increased IL-6 release in PD model mice." | 1.62 | Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier. ( Cui, C; Hong, H; Huang, SB; Jia, XB; Qiao, CM; Shen, YQ; Shi, Y; Wu, J; Yao, L; Zhao, WJ; Zhou, Y, 2021) |
| "Parkinson's disease is the second most common neurodegenerative disease." | 1.62 | The neuroprotective effects of isoquercitrin purified from apple pomace by high-speed countercurrent chromatography in the MPTP acute mouse model of Parkinson's disease. ( Cheng, Y; Hu, Y; Li, H; Liu, C; Liu, J; Qin, X; Wang, W; Wei, Y; Zhang, P, 2021) |
| "(R)-ketamine has greater and longer-lasting antidepressant effects than (S)-ketamine in animal models of depression." | 1.56 | MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling. ( Chang, L; Fujita, A; Fujita, Y; Hashimoto, K; Pu, Y, 2020) |
| "A moving tremor was also observed by visual inspection during this period." | 1.56 | Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious precl ( Ando, K; Hikishima, K; Inoue, R; Inoue, T; Kawai, K; Komaki, Y; Nishime, C; Nishinaka, E; Okano, H; Urano, K, 2020) |
| "Dopaminergic cell loss in Parkinson's disease (PD) leads to NMDAR dysregulation in the cortico-striato-pallidal-thalmo-cortical network and altered plasticity in brain regions important to cognitive function." | 1.56 | NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model. ( Barth, AL; Brotchie, JM; Cearley, CN; Hill, MP; Johnston, TH; Moskal, JR; Schneider, JS, 2020) |
| "Simvastatin can play a positive role in Parkinson's disease." | 1.56 | Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice. ( Fan, H; Huang, J; Lai, X; Liu, A; Qiao, L; Shen, M; Wu, J; Yan, J, 2020) |
| "However, the function of BDNF-AS in Parkinson's disease (PD) remains unknown." | 1.56 | LncRNA BDNF-AS promotes autophagy and apoptosis in MPTP-induced Parkinson's disease via ablating microRNA-125b-5p. ( Cheng, G; Fan, Y; Lu, K; Zhao, X, 2020) |
| " The results indicated that the chronic administration of either DHM or PRE-084 attenuated the Dicer cKO-induced loss of DA neurons and motor impairments, although the two drugs acted through different mechanisms." | 1.56 | Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin. ( Cao, T; Guo, CH; Waddington, JL; Zhen, XC; Zheng, LT, 2020) |
| "The main symptom of Parkinson's disease (PD) is motor dysfunction and remarkably approximately 30-40% of PD patients exhibit cognitive impairments." | 1.56 | Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice. ( Fukunaga, K; Haga, H; Izumi, H; Kawahata, I; Miyachi, H; Shinoda, Y; Yamada, R, 2020) |
| "Clioquinol (CQ) has been shown to have therapeutic benefits in rodent models of neurodegenerative disorders." | 1.56 | Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway. ( Cheng, A; Huang, C; Liu, W; Luo, Q; Shi, L; Shi, R; Xia, Y; Zeng, W; Zhengli, C, 2020) |
| "Of these, the most common is insomnia, the difficulty to initiate and maintain sleep." | 1.56 | Basal ganglia beta oscillations during sleep underlie Parkinsonian insomnia. ( Bergman, H; Deffains, M; Israel, Z; Kaplan, A; Mizrahi-Kliger, AD, 2020) |
| "Evidence suggests that the Parkinson's disease (PD) pathogenesis is strongly associated with bidirectional pathways in the microbiota-gut-brain axis (MGBA), and psychobiotics may inhibit PD progression." | 1.56 | Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson's disease. ( Cheng, YF; Chiou, JJ; Hsieh-Li, HM; Hsu, CC; Huang, CW; Kuo, WC; Liao, JF; Tsai, YC; Wang, S; You, ST, 2020) |
| "Genetic susceptibility is a strong risk factor for PD." | 1.56 | Functional validation of a human GLUD2 variant in a murine model of Parkinson's disease. ( Chen, X; Ding, L; Gao, F; Gong, J; Guo, W; Li, Y; Lin, Y; Pan, X; Peng, G; Sun, X; Wang, S; Xu, P; Xuan, A; Yang, X; Zhang, W; Zhang, X; Zhang, Y; Zhang, Z; Zhu, X, 2020) |
| "In the MPTP-induced mouse models of Parkinson's disease, THSG ameliorated the animal behaviors against MPTP-induced neurotoxicity, which was demonstrated by the pole test and the tail suspension test." | 1.51 | 2,3,5,4'-Tetrahydroxystilbene-2-O-β-d-glucoside attenuates MPP+/MPTP-induced neurotoxicity in vitro and in vivo by restoring the BDNF-TrkB and FGF2-Akt signaling axis and inhibition of apoptosis. ( Gu, RZ; Lan, R; Lang, XY; Li, XX; Liu, QS; Qin, XY; Yu, Y, 2019) |
| " Mice were put on the subacute dosing regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), producing bilateral degeneration of the nigrostriatal pathway consistent with early-stage PD." | 1.51 | Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson's disease mouse model. ( Jackson-Lewis, V; Ji, R; Karakatsani, ME; Konofagou, EE; Murillo, MF; Niimi, Y; Przedborski, S; Smith, M, 2019) |
| "A major hallmark of Parkinson's disease (PD) is the degeneration of dopaminergic neurons in the substantia nigra, and the causative mechanism is thought to be the activation of programmed neuronal death." | 1.51 | miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson's disease. ( Chen, HZ; Cheng, Q; Cui, HL; Hu, YB; Huang, WY; Ren, RJ; Wang, G; Wang, H; Zhang, YF, 2019) |
| "Andrographolide has been found to exert neuroprotective effects in several models of neurological diseases." | 1.51 | Andrographolide alleviates Parkinsonism in MPTP-PD mice via targeting mitochondrial fission mediated by dynamin-related protein 1. ( Fan, T; Gao, J; Geng, J; Guo, W; Jiang, C; Liu, W; Qin, ZH; Sun, Y; Xu, Q, 2019) |
| "Treatment of nimesulide with MPTP further potentiated expressions of p62, ATG-5, beclin-1, LC3 autophagic proteins." | 1.48 | Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson's Disease. ( Mishra, KP; Niranjan, R; Thakur, AK, 2018) |
| "Neuroinflammation is one of the hallmarks of neurodegenerative diseases, such as Parkinson's disease (PD)." | 1.48 | The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor. ( Boyle, AM; Budge, KM; Neal, ML; Richardson, JR; Safadi, FF, 2018) |
| "More than 90% of the cases of Parkinson's disease have unknown etiology." | 1.48 | Targeted deletion of the aquaglyceroporin AQP9 is protective in a mouse model of Parkinson's disease. ( Amiry-Moghaddam, M; Berg, T; Leergaard, TB; MacAulay, N; Mylonakou, MN; Ottersen, OP; Paulsen, RE; Prydz, A; Rahmani, S; Skare, Ø; Skauli, N; Stahl, K; Torp, R, 2018) |
| "The nonhuman primate model of Parkinson's disease emulates the cardinal symptoms of the disease, including tremor, rigidity, bradykinesia, postural instability, freezing and cognitive impairment." | 1.48 | Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease. ( Choudhury, GR; Daadi, MM, 2018) |
| "Patients with Parkinson's disease (PD) often have non-motor symptoms related to gastrointestinal (GI) dysfunction, such as constipation and delayed gastric emptying, which manifest prior to the motor symptoms of PD." | 1.48 | Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease. ( Bai, Q; Gao, J; Jia, Y; Jiang, R; Lai, F; Liu, X; Tang, Y; Xiao, H; Xie, W, 2018) |
| "The pathological alterations of Parkinson's disease (PD) predominantly manifest as a loss of dopaminergic neurons in the substantia nigra, which may be caused by oxidative stress damage." | 1.48 | Proanthocyanidins exert a neuroprotective effect via ROS/JNK signaling in MPTP‑induced Parkinson's disease models in vitro and in vivo. ( Chen, H; He, P; Jiao, J; Li, S; Liu, C; Lv, Y; Mao, X; Xu, J; Xue, X, 2018) |
| "Parkinson's disease is characterized by progressive death of dopaminergic neurons, leading to motor and cognitive dysfunction." | 1.48 | Nicotine promotes neuron survival and partially protects from Parkinson's disease by suppressing SIRT6. ( Bender, CA; Francisco, AB; Glorioso, C; Libert, S; Lugay, FJ; Nicholatos, JW; Salazar, JE; Yeh, T, 2018) |
| "Cognitive impairment often occurs in Parkinson's disease (PD), but the mechanism of onset remains unknown." | 1.46 | Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. ( Ishii, T; Kinoshita, KI; Muroi, Y; Unno, T, 2017) |
| "Treatment with isradipine prevented against MPP+-induced iron influx in the MES23." | 1.46 | Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice. ( Liu, S; Ma, ZG; Wang, QM; Xu, YY, 2017) |
| "A crucial event in the pathogenesis of Parkinson's disease is the death of dopaminergic neurons of the nigrostriatal system, which are responsible for the regulation of motor function." | 1.46 | Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease. ( Khakimova, GR; Kozina, EA; Kucheryanu, VG; Ugrumov, MV, 2017) |
| "Melanoma is strongly tied to red hair/fair skin, a phenotype of loss-of-function polymorphisms in the MC1R (melanocortin 1 receptor) gene." | 1.46 | The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival. ( Cai, W; Chen, H; Chen, X; Fisher, DE; Li, H; Logan, R; Maguire, M; Robinson, K; Schwarzschild, MA; Vanderburg, CR; Wang, Y; Ya, B; Yu, Y; Zuo, F, 2017) |
| "Isobavachalcone is a main component of Chinese herb medicine Psoralea corylifolia, which function includes immunoregulation, anti-oxidation and the regulation of β-amyloid (Aβ42) deposited in hippocampus in Alzheimer's patients." | 1.46 | Isobavachalcone Attenuates MPTP-Induced Parkinson's Disease in Mice by Inhibition of Microglial Activation through NF-κB Pathway. ( Fu, W; Jing, H; Wang, M; Wang, S; Xu, D; Zhang, C, 2017) |
| "Hypercholesterolemia is a known contributor to the pathogenesis of Alzheimer's disease while its role in the occurrence of Parkinson's disease (PD) is only conjecture and far from conclusive." | 1.46 | Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress. ( Borah, A; Choudhury, A; Giri, A; Kumar, S; Paul, R; Sandhir, R, 2017) |
| "Icariin pretreatment could ameliorate the decreased striatum DA content and the loss of TH-IR neurons in the SNpc induced by MPTP." | 1.46 | Neuroprotective properties of icariin in MPTP-induced mouse model of Parkinson's disease: Involvement of PI3K/Akt and MEK/ERK signaling pathways. ( Chen, L; Chen, WF; Chen, XH; Du, ZR; Teng, JJ; Wong, MS; Wu, L; Xu, AL, 2017) |
| " Mice were treated with four intraperitoneal injections for every 2 h with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at the dosage of 14 mg/kg b." | 1.43 | Effect of monocrotophos, an organophosphorus insecticide, on the striatal dopaminergic system in a mouse model of Parkinson's disease. ( Ali, SJ; Rajini, PS, 2016) |
| "Brain bioavailability of drugs developed to address central nervous system diseases is classically documented through cerebrospinal fluid collected in normal animals, i." | 1.43 | Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease. ( Bezard, E; Contamin, H; Li, Q; Thiollier, T; Wu, C; Zhang, J, 2016) |
| "Parkinson's disease is a neurodegenerative disorder characterized by a loss of nigrostriata dopaminergic neurons, which has been thought, at least in part, to result from oxidative stress." | 1.43 | Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system. ( Du, N; Guo, Z; Han, M; Huang, Y; Liu, J; Xu, S, 2016) |
| "Although the initial events of sporadic Parkinson's disease (PD) are not known, consistent evidence supports the hypothesis that the disease results from the combined effect of genetic and environmental risk factors." | 1.43 | Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson's disease. ( Di Meco, A; Lauretti, E; Merali, S; Praticò, D, 2016) |
| "In the MPTP-induced animal model of Parkinson's disease, Coptis chinensis dose-dependently improved motor functions and increased tyrosine hydroxylase-positive neurons in the substantia nigra compared to the MPTP control." | 1.43 | Neuroprotective Effect of Coptis chinensis in MPP[Formula: see text] and MPTP-Induced Parkinson's Disease Models. ( Fei, J; Friedemann, T; Kramer, ER; Schröder, S; Schumacher, U; Wang, W; Ying, Y, 2016) |
| "Paeonol treatment decreased MPTP/p‑induced oxidative stress, as determined by evaluating the activity levels of superoxide dismutase, catalase and glutathione." | 1.43 | Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice. ( Chen, YH; Liu, H; Qu, HD; Shi, X, 2016) |
| "Circuitry models of Parkinson's disease (PD) are based on striatal dopamine loss and aberrant striatal inputs into the basal ganglia network." | 1.43 | Human striatal recordings reveal abnormal discharge of projection neurons in Parkinson's disease. ( DeLong, MR; Gross, RE; Mewes, K; Obeso, JA; Papa, SM; Singh, A, 2016) |
| "Hydrogen sulfide (H2S) has a neuroprotective effect during the neural injury of Parkinson's disease." | 1.43 | Involvement of microRNA-135a-5p in the Protective Effects of Hydrogen Sulfide Against Parkinson's Disease. ( Li, J; Liao, S; Lin, Y; Liu, Y; Quan, H; Yang, Q, 2016) |
| "Phytic acid (PA) is a naturally occurring constituent which exhibits protective action in Parkinson's disease (PD)." | 1.42 | Phytic acid attenuates inflammatory responses and the levels of NF-κB and p-ERK in MPTP-induced Parkinson's disease model of mice. ( Gai, X; Hou, L; Liu, C; Liu, L; Lu, T; Lv, Y; Wang, Y; Xu, P; Zhang, J; Zhang, L; Zhang, Z, 2015) |
| "Lycopene is a carotenoid with unique pharmacological properties and its efficacy on experimental Hunginton's disease and brain ischemia has shown intense neuroprotective effects." | 1.42 | Neuroprotective effect of lycopene against MPTP induced experimental Parkinson's disease in mice. ( Janakiraman, U; Manivasagam, T; Prema, A; Thenmozhi, AJ, 2015) |
| "Geniposide treatment (100mg/kg ip." | 1.42 | Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease. ( Chen, Y; Hölscher, C; Li, L; Zhang, Y, 2015) |
| "As an exemplar, Parkinson's disease (PD) involves multiple perturbed cellular functions, including mitochondrial dysfunction and autophagic dysregulation in preferentially-sensitive dopamine neurons, a selective pathophysiology recapitulated in vitro using the neurotoxin MPP(+)." | 1.42 | Protein-protein interaction networks identify targets which rescue the MPP+ cellular model of Parkinson's disease. ( Jackson, B; Keane, H; Ryan, BJ; Wade-Martins, R; Whitmore, A, 2015) |
| "Piperine (10 mg/kg) was administered orally for 15 days including 8 days of pretreatment." | 1.42 | Neuroprotective effects of piperine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model. ( Chen, YH; Liu, H; Qu, HD; Yang, W, 2015) |
| "Although anti-Parkinson's disease activity of puerarin was reported in both of in vivo and in vitro model, detailed mechanisms are not clarified." | 1.40 | Neuroprotective effects of puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease model in mice. ( Li, Q; Li, X; Wang, X; Wu, S; Zhu, G, 2014) |
| " This effort led to the discovery of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine (PF470, 14) as a highly potent, selective, and orally bioavailable mGluR5 NAM." | 1.40 | Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat ( Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L, 2014) |
| "Morphine has been found to elevate dopamine levels, which indicates a potential therapeutic effect in PD treatment that has not been investigated previously." | 1.40 | Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. ( Hu, X; Huang, B; Li, H; Ma, Y; Rizak, JD; Yan, T; Yang, S, 2014) |
| "In animal models of Parkinson's disease (PD), the serotonergic (5-hydroxytryptamine, 5-HT) system is thought to play an important pathophysiological role in the development and expression of l-3,4-dihydroxyphenylalanine (l-3,4-dihydroxyphenylalanine-DOPA)-induced dyskinesia (LID)." | 1.40 | Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease. ( Bezard, E; Ko, WK; Li, Q, 2014) |
| " Silymarin treatment showed a non-monotonic dose-response curve and only 50 and 100mg/kg doses preserved dopamine levels (62% and 69%, respectively) after MPTP intoxication." | 1.40 | Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease. ( Carrillo-S, C; Chavarría, A; García, E; Pérez-H, J; Pérez-Tamayo, R; Ruiz-Mar, G, 2014) |
| "In an MPTP-treated animal model of Parkinson's disease, MSC administration significantly increased final maturation of late autophagic vacuoles, fusion with lysosomes." | 1.40 | Neuroprotective effects of mesenchymal stem cells through autophagy modulation in a parkinsonian model. ( Kim, HN; Lee, PH; Oh, SH; Park, HJ; Shin, JY, 2014) |
| "c-Abl is activated in the brain of Parkinson's disease (PD) patients and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated mice where it inhibits parkin through tyrosine phosphorylation leading to the accumulation of parkin substrates, and neuronal cell death." | 1.40 | The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. ( Brahmachari, S; Dawson, TM; Dawson, VL; Karuppagounder, SS; Ko, HS; Lee, Y, 2014) |
| "Calpain-p25-mediated increase in cdk5 expression leading to dopaminergic neuronal death has been demonstrated in human PD and MPTP-PD models." | 1.40 | Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins. ( Beiping, H; Dheen, ST; Kanagaraj, N; Tay, SS, 2014) |
| "Guanosine is a pleiotropic molecule affecting multiple cellular processes, including cellular growth, differentiation and survival." | 1.40 | Guanosine exerts neuroprotective effects by reversing mitochondrial dysfunction in a cellular model of Parkinson's disease. ( Chen, W; Dong, YH; Li, DW; Li, GR; Sun, BQ; Tang, MN; Yao, M, 2014) |
| "A goldfish (Carassius auratus) model of Parkinson's disease (PD) was constructed by a single dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) according to previously reported methods." | 1.40 | (1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Kong, L; Li, M; Liu, Q; Lu, Z; Wang, J; Wei, D; Yang, M, 2014) |
| "L-DOPA-induced dyskinesias (LID)s are abnormal involuntary movements limiting the chronic use of L-DOPA, the main pharmacological treatment of Parkinson's disease (PD)." | 1.39 | Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia. ( Di Paolo, T; Morissette, M; Parent, M; Riahi, G; Samadi, P, 2013) |
| "The available scientific data indicate that the pathomechanism of Parkinson's disease (PD) involves the accumulation of endogenous and exogenous toxic substances." | 1.39 | Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice. ( Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013) |
| "The development of dyskinesias following chronic L-DOPA replacement therapy remains a major problem in the long-term treatment of Parkinson's disease." | 1.39 | IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. ( Aron Badin, R; Auguet, M; Bertrand, A; Boulet, S; Brouillet, E; Chabrier, PE; Dollé, F; Gaillard, MC; Guillermier, M; Hantraye, P; Jan, C; Malgorn, C; Savasta, M; Spinnewyn, B; Van Camp, N, 2013) |
| "Neurodegenerative disorders such as Parkinson's disease (PD) often exhibit significant declines in PUFAs." | 1.38 | Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease. ( Agar, A; Balkan, S; Hacioglu, G; Ozsoy, O; Saka-Topcuoglu, E; Seval-Celik, Y; Tanriover, G, 2012) |
| "Neuroinflammation is thought to be one of the major pathological mechanisms responsible for Parkinson's disease (PD), and has been a primary target in the development of treatment for PD." | 1.38 | Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation in vitro and in vivo. ( Ha, SK; Ju, MS; Kim, HG; Kim, SY; Lee, H; Oh, MS, 2012) |
| "The marmoset shows prominent Parkinson's disease (PD) signs due to dopaminergic neural degeneration." | 1.38 | PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease. ( Ando, K; Higuchi, M; Inoue, T; Itoh, T; Minamimoto, T; Nagai, Y; Obayashi, S; Oh-Nishi, A; Suhara, T, 2012) |
| "Parkinson's disease is a neurodegenerative disorder that can, at least partly, be mimicked by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine." | 1.38 | S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. ( Berg, D; Fleckenstein, C; Itohara, S; Lang, JD; Maetzler, W; Martin, HL; Mounsey, RB; Mustafa, S; Sathe, K; Schulte, C; Synofzik, M; Teismann, P; Vukovic, Z, 2012) |
| "Parkinson's disease is characterized by motor deficits caused by loss of midbrain dopaminergic neurons." | 1.37 | Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. ( Andersson, A; Dannaeus, K; Delfani, K; Di Monte, DA; Haegerstrand, A; Häggblad, J; Hill, MP; Isacson, R; Janson Lang, AM; McCormack, AL; Nielsen, E; Palmer, T; Patrone, C; Rönnholm, H; Wikstrom, L; Zachrisson, O; Zhao, M, 2011) |
| "Studies on Parkinson's disease patients and dopamine-depleted animals indicate that dopaminergic neurons in the retina degenerate due to the genetic and environmental factors that cause dopaminergic neuron loss in the substantia nigra." | 1.37 | Minor retinal degeneration in Parkinson's disease. ( Huang, YM; Yin, ZQ, 2011) |
| "Hydrogen sulfide (H(2)S) has been shown to protect neurons." | 1.37 | Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease. ( Ichinose, F; Kakinohana, M; Kaneki, M; Kida, K; Marutani, E; Tokuda, K; Yamada, M, 2011) |
| "In a mouse model of MPTP-induced Parkinson's disease (PD), AQP4-deficient animals show more robust microglial inflammatory responses and more severe loss of dopaminergic neurons (DNs) compared with WT mice." | 1.37 | Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease. ( Chi, Y; Fan, Y; He, L; Hu, G; Kong, H; Li, CJ; Liu, W; Sonoda, L; Su, C; Tripathi, P; Wang, X; Wen, X; Yu, MS; Zhang, C; Zhou, S, 2011) |
| "Parkinson's disease is a neurodegenerative disorder manifesting in debilitating motor symptoms." | 1.37 | Dispersed activity during passive movement in the globus pallidus of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primate. ( Bar-Gad, I; Belelovsky, K; Erez, Y; Tischler, H, 2011) |
| " The current PD drugs provide only symptomatic relief and have limitations in terms of adverse effects and inability to prevent neurodegeneration." | 1.37 | Chronic dietary supplementation with turmeric protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated neurotoxicity in vivo: implications for Parkinson's disease. ( Harish, G; Mythri, RB; Shankaranarayana Rao, BS; Srinivas Bharath, MM; Veena, J, 2011) |
| "The clinical stage of Parkinson's disease begins after this period." | 1.37 | Experimental modeling of preclinical and clinical stages of Parkinson's disease. ( Bocharov, EV; Khaindrava, VG; Klodt, PD; Kozina, EA; Kryzhanovsky, GN; Kucheryanu, VG; Kudrin, VS; Nanaev, AK; Narkevich, VB; Raevskii, KS; Ugrumov, MV, 2011) |
| "Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder of mature and older individuals." | 1.36 | Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. ( Charlton, CG; King, J; Mackey, V; Muthian, G, 2010) |
| "In the mouse Parkinson's disease model, treatment with Yi-Gan San also significantly improved motor functioning and prevented dopaminergic loss related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine challenge." | 1.36 | Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo. ( Cho, KH; Doo, AR; Eun-Kyung, K; Hong, J; Jung, JH; Jung, WS; Kim, SN; Lee, H; Moon, SK; Park, HJ; Park, JY, 2010) |
| "Nrf2-knockout mice showed exacerbated gliosis and dopaminergic nigrostriatal degeneration, as determined by immunohistochemical staining of tyrosine hydroxylase in striatum (STR) and substantia nigra (SN) and by HPLC determination of striatal dopamine and 3,4- dihydroxyphenylacetic acid (DOPAC)." | 1.36 | Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. ( Cuadrado, A; Dulak, J; Fernández-Ruiz, J; García, C; Grochot-Przeczek, A; Innamorato, NG; Jazwa, A; Jozkowicz, A; Rojo, AI; Stachurska, A, 2010) |
| "The tremor is intermittent and does not appear in all human patients." | 1.36 | Computational physiology of the basal ganglia in Parkinson's disease. ( Bergman, H; Elias, S; Heimer, G; Rivlin-Etzion, M, 2010) |
| "The development of Parkinson's disease is accompanied by concurrent activation of caspase-3 and apoptosis of dopaminergic neurons of human patients and rodent models." | 1.36 | Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice. ( Amutuhaire, W; Ichinose, F; Kaneki, M; Kida, K; Yamada, M, 2010) |
| " Furthermore, chronic administration of low doses of the 5-HT(1) agonists in combination was able to prevent development of dyskinesia, and reduce the up-regulation of FosB after daily treatment with l-DOPA in the rat 6-OHDA model." | 1.35 | Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. ( Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C, 2008) |
| "The chronic use of methamphetamine leads to cardiomyopathy and a nigrostriatal dopamine deficiency that partly mimics what occurs in Parkinson's disease." | 1.35 | Methamphetamine fails to alter the noradrenergic integrity of the heart. ( Fornai, F; Paparelli, A; Pasquali, L; Ruffoli, R; Ruggieri, S; Soldani, P, 2008) |
| "In most environmental models of Parkinson's disease (PD), a single neurodegenerative agent is introduced to cause nigrostriatal dopamine depletion." | 1.35 | Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice. ( Barth, TM; Boehm, GW; Byler, SL; Karp, JD; Kohman, RA; Schallert, T; Tarr, AJ, 2009) |
| "Animal models of Parkinson's disease have been widely used for investigating the mechanisms of neurodegenerative process and for discovering alternative strategies for treating the disease." | 1.35 | Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. ( Kurz, MJ; Lau, YS; Pothakos, K, 2009) |
| "The main contributory factors of Parkinson's disease (PD) are aging, genetic factors, and environmental exposure to pesticides and heavy metals." | 1.35 | The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype and nicotine-mediated neuroprotection. ( Nath, C; Patel, DK; Singh, C; Singh, K; Singh, MP; Singh, RK; Singh, S; Singh, VK, 2009) |
| " Here, we show that drinking H(2)-containing water significantly reduced the loss of dopaminergic neurons in PD model mice using both acute and chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.35 | Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. ( Fujita, K; Katafuchi, T; Kido, MA; Nakabeppu, Y; Noda, M; Ohno, M; Sakumi, K; Seike, T; Takaki, A; Tanaka, Y; Yamada, H; Yamaguchi, H; Yamakawa, Y; Yutsudo, N, 2009) |
| "Different Parkinson's disease (PD) animal models reproduce the early phase of the disease, which deny the possible existence of a synergic effect of consecutive insults to the dopaminergic neurons." | 1.35 | Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease. ( Andersen, ML; Andreatini, R; Dombrowski, P; Lima, MM; Reksidler, AB; Tufik, S; Vital, MA; Zanata, SM, 2008) |
| "In reserpine-treated animals, specific delta opioid binding was increased in premotor cortex (+30%), sensorimotor striatum (+20%), and associative striatum (+17%) rostrally, but was not changed in caudal forebrain." | 1.34 | Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. ( Brotchie, JM; Hallett, PJ, 2007) |
| "In the pathogenesis of Parkinson's disease and Huntington's disease excitotoxicity may play an important role." | 1.33 | Effects of mitochondrial toxins on the brain amino acid concentrations. ( Hartai, Z; Juhasz, G; Kekesi, KA; Klivenyi, P; Vecsei, L, 2005) |
| "Mouse model of Parkinson's disease was established by intraperitoneal injection with 1-methl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP)." | 1.33 | [Effects of yinxing pingchan recipe and its components on activity of mitochondrial enzyme complex in brain of mice with Parkinson's disease]. ( Bai, LM; Sun, HM; Zhang, J, 2005) |
| "Although the pathogenesis of Parkinson's disease (PD) remains unknown, it appears that microglial activation is associated with enhanced neurodegeneration in animal models of PD as well as in PD patients." | 1.33 | Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. ( Hong, JS; Kovacs, M; Liu, J; Ma, T; McLaughlin, P; Zhang, J; Zhang, W; Zhou, Y, 2006) |
| "Parkinson's disease is associated with a progressive loss of substantia nigra pars compacta dopaminergic neurons." | 1.33 | Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. ( Garris, BL; Garris, DR; Lau, YS; Novikova, L, 2006) |
| "Current gene therapy models for Parkinson's disease (PD) have adapted two treatment strategies." | 1.33 | Doxycycline-regulated co-expression of GDNF and TH in PC12 cells. ( Li, KR; Niu, DB; Wang, JJ; Wang, K; Wang, XM; Xue, B; Zhang, T, 2006) |
| "The aetiology of idiopathic Parkinson's disease (PD) is poorly defined but environmental aggression may be relevant." | 1.33 | Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. ( Cavada, C; Close, RM; Cuadrado, A; de Sagarra, MR; Fernández-Ruiz, J; Jackson-Lewis, V; Montero, C; Rojo, AI; Salazar, M; Sánchez-González, MA, 2006) |
| "Long-term treatment of Parkinson's disease with levodopa is compromised by the development of motor complications, including on-off fluctuations and involuntary movements termed dyskinesia." | 1.32 | Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. ( Brotchie, JM; Crossman, AR; Duty, S; Fox, SH; Henry, B, 2003) |
| "In sporadic Parkinson's disease, representing the most prevalent movement disorder, oxidative and nitrosative stress are believed to contribute to disease pathogenesis, but the exact molecular basis for protein aggregation remains unclear." | 1.32 | Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. ( Gaston, B; Gu, Z; Lipton, SA; Ma, Y; Masliah, E; Nakamura, T; Palmer, LA; Rockenstein, EM; Shi, ZQ; Uehara, T; Yao, D; Zhang, Z, 2004) |
| "The pathogenic mechanisms underlying idiopathic Parkinson's disease (PD) remain enigmatic." | 1.31 | Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. ( Benkovic, SA; Luster, MI; Matheson, JM; Miller, DB; O'Callaghan, JP; Sriram, K, 2002) |
| "The common marmoset develops motor deficits after MPTP treatment and exhibits dyskinesia after chronic levodopa (L-dopa) dosing and subsequent re-challenge with L-dopa and other dopaminergic agents." | 1.31 | The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. ( Banerji, T; Jackson, MJ; Jenner, P; Pearce, RK; Scheel-Krüger, J; Smith, LA, 2002) |
| "In the advanced stage of Parkinson's disease, abnormal blood pressure responses, such as orthostatic hypotension and abnormal circadian blood pressure rhythm, may occur." | 1.31 | Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. ( Fujiwara, H; Matsuo, H; Nagashima, K; Nishida, H; Nishigaki, K; Noda, T; Takatsu, H; Wada, H; Watanabe, S, 2000) |
| "In animal models of Parkinson's disease, loss of striatal dopamine leads to enhanced excitation of striatal NR2B-containing NMDA receptors." | 1.31 | Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. ( Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Hill, MP; Hille, C; Maneuf, Y; McGuire, S; Nash, JE; Peggs, D, 2000) |
| "It is thought that Parkinson's disease involves apoptosis, and NGF prevents apoptosis in an in vivo model system." | 1.31 | Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease. ( Chiba, H; Shimoke, K, 2001) |
| "Clinical and experimental grafting in Parkinson's disease has shown the need for enhanced survival of dopamine neurons to obtain improved functional recovery." | 1.31 | Evidence for target-specific outgrowth from subpopulations of grafted human dopamine neurons. ( Almqvist, PM; Bygdeman, M; Johansson, S; Strömberg, I; Törnqvist, N, 2001) |
| "Although the cause of Parkinson's disease (PD) is unknown, data suggest roles for environmental factors that may sensitize dopaminergic neurons to age-related dysfunction and death." | 1.31 | Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. ( Cadet, JL; Cutler, RG; Duan, W; Kruman, II; Ladenheim, B; Mattson, MP, 2002) |
| "Murine model of Parkinson's disease uses a quite selective toxic effect of MPTP on nigrostriatal system." | 1.31 | [Treatment of neurodegenerative diseases: new perspectives]. ( Członkowska, A; Kurkowska-Jastrzebska, I, 2001) |
| "Parkinson's disease is characterized by degeneration of dopamine (DA) neurons and their terminals." | 1.30 | SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys. ( Babich, JW; Barrow, SA; Elmaleh, DR; Fischman, AJ; Hanson, RN; Madras, BK; Meltzer, P, 1997) |
| "That thalidomide has activity in this model suggests that an inflammatory process may be involved in the induction of lesions by MPTP in DAergic neurons." | 1.30 | Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. ( Boireau, A; Bordier, F; Dubédat, P; Impérato, A; Pény, C, 1997) |
| "Lisuride was applied to 4 x 5 cm of skin of the abdomen of monkeys." | 1.30 | [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease]. ( Fukuda, T; Irifune, M; Iwata, S; Kaseda, S; Nomoto, M; Osame, M, 1998) |
| " These results are consistent with previous work highlighting the importance of aberrant amine production in neurological disease and demonstrate that treatments that reduce endogenous melatonin bioavailability can ameliorate experimental PD." | 1.30 | A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. ( Armstrong, SM; Willis, GL, 1999) |
| "R-apomorphine is a potent radical scavenger and iron chelator." | 1.30 | Apomorphine protects against MPTP-induced neurotoxicity in mice. ( Berkuzki, T; Grünblatt, E; Mandel, S; Youdim, MB, 1999) |
| "Haloperidol has recently been found to be metabolized to its pyridinium ion (HP+)." | 1.29 | Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. ( Fang, J; Yu, PH; Zuo, D, 1995) |
| " Thrice daily dosing at a 4-h interval with the short-acting agent SKF 82958 maintained the maximal antiparkinsonian response but some shortening in the duration of response was observed after several days." | 1.29 | Dopamine D1 receptor desensitization profile in MPTP-lesioned primates. ( Bédard, PJ; Blanchet, PJ; Britton, DR; Grondin, R; Shiosaki, K, 1996) |
| "Two patients with Parkinson's disease who underwent implantation of fetal mesencephalic tissue into the putamen were serially studied using positron emission tomography and [18F]6-L-fluorodopa ([18F]dopa)." | 1.28 | Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. ( Björklund, A; Bloomfield, PM; Brooks, DJ; Brundin, P; Leenders, KL; Lindvall, O; Marsden, CD; Rehncrona, S; Sawle, GV; Widner, H, 1992) |
| " In addition, we point out that with long-term administration to rodents, deprenyl loses its selectivity as an inhibitor of MAO-B and also inhibits MAO-A." | 1.28 | Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. ( Heikkila, RE; Sieber, BA; Terleckyj, I, 1990) |
| "Although it is known that Parkinson's disease results from a loss of dopaminergic neurons in the substantia nigra, the resulting alterations in activity in the basal ganglia responsible for parkinsonian motor deficits are still poorly characterized." | 1.28 | Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. ( Bergman, H; DeLong, MR; Wichmann, T, 1990) |
| "Idiopathic Parkinson's disease has been postulated to result from exposure to environmental toxins similar to the parkinsonism-causing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)." | 1.28 | Studies on the interactions of MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) with the cytochrome P-450 enzyme system--clues to a possible aetiological factor in Parkinson's disease. ( Das, NP; Lee, EJ; Moochhala, SM; Shahi, GS, 1989) |
| "The hypothesis is that Alzheimer's disease, Parkinson's disease (PD), and motoneurone disease are due to environmental damage to specific regions of the central nervous system and that the damage remains subclinical for several decades but makes those affected especially prone to the consequences of age-related neuronal attrition." | 1.27 | Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotrophic interaction between ageing and environment? ( Calne, DB; Eisen, A; McGeer, E; Spencer, P, 1986) |
| "In idiopathic Parkinson's disease massive cell death occurs in the dopamine-containing substantia nigra." | 1.27 | Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. ( Agid, YA; Graybiel, AM; Hirsch, E, 1988) |
| "Idiopathic Parkinson's disease may derive from the action of an environmental 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-like compound." | 1.27 | (-)Deprenyl in perspective: prophylaxis for Parkinson's disease? ( Sandler, M, 1986) |
| "To simulate an animal model of Parkinson's disease, MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine) was administered to five monkeys." | 1.27 | Autotransplantation of the superior cervical ganglion into the brain. A possible therapy for Parkinson's disease. ( Imai, H; Itakura, T; Kamei, I; Komai, N; Naka, Y; Nakai, K; Nakakita, K, 1988) |
| "Idiopathic Parkinson's disease (PD) has been reported to occur more commonly among non-smokers than among cigarette smokers, for reasons that are unknown." | 1.27 | Monoamine oxidase B, smoking, and Parkinson's disease. ( Perry, TL; Yong, VW, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 91 (9.36) | 18.7374 |
| 1990's | 146 (15.02) | 18.2507 |
| 2000's | 179 (18.42) | 29.6817 |
| 2010's | 311 (32.00) | 24.3611 |
| 2020's | 245 (25.21) | 2.80 |
| Authors | Studies |
|---|---|
| Masilamoni, GJ | 1 |
| Weinkle, A | 1 |
| Papa, SM | 3 |
| Smith, Y | 2 |
| Liu, X | 13 |
| Chen, W | 8 |
| Wang, C | 5 |
| Liu, W | 7 |
| Hayashi, T | 4 |
| Mizuno, K | 3 |
| Hattori, S | 2 |
| Fujisaki, H | 2 |
| Ikejima, T | 2 |
| Bai, X | 1 |
| Zhang, X | 19 |
| Fang, R | 2 |
| Wang, J | 11 |
| Ma, Y | 9 |
| Liu, Z | 6 |
| Dong, H | 5 |
| Li, Q | 13 |
| Ge, J | 1 |
| Yu, M | 5 |
| Fei, J | 5 |
| Sun, R | 1 |
| Huang, F | 5 |
| Isenbrandt, A | 1 |
| Morissette, M | 7 |
| Bourque, M | 5 |
| Lamontagne-Proulx, J | 1 |
| Coulombe, K | 1 |
| Soulet, D | 1 |
| Di Paolo, T | 9 |
| Shan, J | 1 |
| Qu, Y | 2 |
| Wang, S | 6 |
| Wei, Y | 3 |
| Chang, L | 2 |
| Ma, L | 4 |
| Hashimoto, K | 3 |
| Chetia Phukan, B | 1 |
| Dutta, A | 2 |
| Deb, S | 1 |
| Saikia, R | 1 |
| Mazumder, MK | 2 |
| Paul, R | 3 |
| Bhattacharya, P | 2 |
| Sandhir, R | 3 |
| Borah, A | 3 |
| Shamadykova, DV | 1 |
| Panteleev, DY | 1 |
| Kust, NN | 1 |
| Savchenko, EA | 1 |
| Rybalkina, EY | 1 |
| Revishchin, AV | 1 |
| Pavlova, GV | 1 |
| Pathania, A | 1 |
| Garg, P | 1 |
| Seo, MH | 3 |
| Lim, S | 3 |
| Yeo, S | 5 |
| Ahuja, M | 1 |
| Ammal Kaidery, N | 1 |
| Attucks, OC | 1 |
| McDade, E | 1 |
| Hushpulian, DM | 1 |
| Gaisin, A | 1 |
| Gaisina, I | 1 |
| Ahn, YH | 1 |
| Nikulin, S | 1 |
| Poloznikov, A | 1 |
| Gazaryan, I | 1 |
| Yamamoto, M | 2 |
| Matsumoto, M | 1 |
| Igarashi, K | 1 |
| Sharma, SM | 1 |
| Thomas, B | 1 |
| Ribeiro-Carvalho, A | 1 |
| Leal-Rocha, PH | 1 |
| Isnardo-Fernandes, J | 1 |
| Araújo, UC | 1 |
| Abreu-Villaça, Y | 1 |
| Filgueiras, CC | 1 |
| Manhães, AC | 1 |
| Mo, J | 1 |
| Xiong, B | 1 |
| Liao, Q | 1 |
| Chen, Y | 4 |
| Wang, Y | 25 |
| Xing, S | 1 |
| He, S | 1 |
| Lyu, W | 1 |
| Zhang, N | 1 |
| Sun, H | 3 |
| Han, S | 2 |
| Vaidya, B | 2 |
| Kaur, H | 1 |
| Thapak, P | 1 |
| Sharma, SS | 2 |
| Singh, JN | 1 |
| Cui, C | 5 |
| Hong, H | 3 |
| Shi, Y | 3 |
| Zhou, Y | 11 |
| Qiao, CM | 4 |
| Zhao, WJ | 3 |
| Zhao, LP | 2 |
| Wu, J | 8 |
| Quan, W | 2 |
| Niu, GY | 2 |
| Wu, YB | 1 |
| Li, CS | 1 |
| Cheng, L | 4 |
| Hong, Y | 1 |
| Shen, YQ | 4 |
| Liu, N | 2 |
| Bai, L | 1 |
| Lu, Z | 3 |
| Gu, R | 1 |
| Zhao, D | 1 |
| Yan, F | 2 |
| Bai, J | 2 |
| Sun, X | 8 |
| Zhang, C | 4 |
| Tao, H | 1 |
| Yao, S | 1 |
| Wu, X | 4 |
| Cheng, YY | 1 |
| Chen, BY | 1 |
| Bian, GL | 1 |
| Ding, YX | 2 |
| Chen, LW | 2 |
| Ma, X | 1 |
| Hao, J | 1 |
| Li, Y | 14 |
| Cai, X | 1 |
| Zheng, Y | 3 |
| Dongjie, S | 1 |
| Rajendran, RS | 1 |
| Xia, Q | 1 |
| She, G | 1 |
| Tu, P | 1 |
| Zhang, Y | 38 |
| Liu, K | 3 |
| Yang, Y | 6 |
| Zhang, S | 8 |
| Guan, J | 1 |
| Jiang, Y | 2 |
| Zhang, J | 22 |
| Luo, L | 1 |
| Sun, C | 1 |
| Tremblay, MÈ | 1 |
| Sun, CP | 1 |
| Zhou, JJ | 1 |
| Yu, ZL | 1 |
| Huo, XK | 1 |
| Morisseau, C | 1 |
| Hammock, BD | 2 |
| Ma, XC | 1 |
| Zhu, Z | 2 |
| Liu, LF | 1 |
| Su, CF | 1 |
| Liu, J | 12 |
| Tong, BC | 1 |
| Iyaswamy, A | 1 |
| Krishnamoorthi, S | 1 |
| Sreenivasmurthy, SG | 1 |
| Guan, XJ | 1 |
| Kan, YX | 1 |
| Xie, WJ | 1 |
| Zhao, CL | 1 |
| Cheung, KH | 1 |
| Lu, JH | 1 |
| Tan, JQ | 1 |
| Zhang, HJ | 1 |
| Song, JX | 1 |
| Li, M | 5 |
| Pereira, MCL | 1 |
| Boese, AC | 1 |
| Murad, R | 1 |
| Yin, J | 1 |
| Hamblin, MH | 1 |
| Lee, JP | 1 |
| Zuo, T | 1 |
| Xie, M | 1 |
| Yan, M | 1 |
| Zhang, Z | 21 |
| Tian, T | 1 |
| Zhu, Y | 2 |
| Wang, L | 14 |
| Sun, Y | 4 |
| Rong, Q | 1 |
| Ren, Q | 2 |
| Jiang, X | 3 |
| Paudel, YN | 1 |
| Gao, X | 4 |
| Gao, D | 1 |
| Zhang, P | 4 |
| Sheng, W | 1 |
| Shang, X | 1 |
| Jin, M | 4 |
| Alshammari, A | 1 |
| Alharbi, M | 1 |
| Albekairi, NA | 1 |
| Albekairi, TH | 1 |
| Alharbi, OO | 1 |
| Yeapuri, P | 1 |
| Singh, S | 4 |
| Han, X | 3 |
| Liu, Y | 13 |
| Dai, Y | 2 |
| Xu, T | 1 |
| Hu, Q | 2 |
| Yi, X | 1 |
| Rui, L | 1 |
| Hu, G | 7 |
| Hu, J | 2 |
| Pamies, D | 1 |
| Wiersma, D | 1 |
| Katt, ME | 1 |
| Zhao, L | 4 |
| Burtscher, J | 1 |
| Harris, G | 1 |
| Smirnova, L | 1 |
| Searson, PC | 1 |
| Hartung, T | 1 |
| Hogberg, HT | 1 |
| Peng, H | 1 |
| Yu, S | 3 |
| Yin, Y | 1 |
| Zhou, J | 3 |
| Kim, A | 3 |
| Pavlova, E | 3 |
| Kolacheva, A | 2 |
| Bogdanov, V | 3 |
| Dilmukhametova, L | 1 |
| Blokhin, V | 2 |
| Valuev, L | 1 |
| Valuev, I | 1 |
| Gorshkova, M | 1 |
| Ugrumov, M | 4 |
| Lin, CY | 2 |
| Tseng, HC | 1 |
| Chu, YR | 1 |
| Wu, CL | 1 |
| Zhang, PH | 2 |
| Tsai, HJ | 1 |
| Park, JE | 3 |
| Leem, YH | 3 |
| Park, JS | 3 |
| Kim, DY | 5 |
| Kang, JL | 1 |
| Kim, HS | 3 |
| Wang, M | 7 |
| Zhao, Y | 2 |
| Gao, Y | 11 |
| Yang, G | 2 |
| Lim, HS | 3 |
| Park, G | 3 |
| Tran, KKN | 1 |
| Wong, VHY | 1 |
| Lim, JKH | 1 |
| Shahandeh, A | 1 |
| Hoang, A | 1 |
| Finkelstein, DI | 6 |
| Bui, BV | 1 |
| Nguyen, CTO | 1 |
| Wang, B | 3 |
| Lu, J | 1 |
| Xia, W | 1 |
| Lillethorup, TP | 1 |
| Noer, O | 1 |
| Alstrup, AKO | 1 |
| Real, CC | 1 |
| Stokholm, K | 1 |
| Thomsen, MB | 1 |
| Zaer, H | 1 |
| Orlowski, D | 1 |
| Mikkelsen, TW | 1 |
| Glud, AN | 1 |
| Nielsen, EHT | 1 |
| Schacht, AC | 1 |
| Winterdahl, M | 1 |
| Brooks, DJ | 2 |
| Sørensen, JCH | 1 |
| Landau, AM | 1 |
| Su, Y | 2 |
| Li, H | 12 |
| Ma, J | 5 |
| Yuan, Y | 3 |
| Shi, M | 3 |
| Zhao, Z | 3 |
| Holscher, C | 5 |
| Dong, L | 2 |
| Luo, X | 2 |
| Kang, SS | 1 |
| Wu, Z | 1 |
| Edgington-Mitchell, L | 1 |
| Ye, K | 2 |
| Phukan, BC | 1 |
| Roy, R | 1 |
| Choudhury, A | 2 |
| Kumar, D | 1 |
| Nath, J | 1 |
| Kumar, S | 3 |
| Xue, J | 4 |
| Qi, Y | 3 |
| Tang, X | 3 |
| Dong, X | 1 |
| He, X | 6 |
| Yang, L | 9 |
| Xu, Y | 2 |
| Kou, L | 1 |
| Chi, X | 1 |
| Han, C | 1 |
| Wan, F | 1 |
| Yin, S | 1 |
| Zhou, Q | 2 |
| Zou, W | 1 |
| Xiong, N | 1 |
| Huang, J | 5 |
| Xia, Y | 4 |
| Wang, T | 2 |
| Wang, SM | 1 |
| Wang, Q | 4 |
| Ye, LY | 1 |
| Chen, SX | 1 |
| Tao, L | 1 |
| Yang, ZS | 1 |
| Xu, B | 1 |
| Wang, X | 16 |
| Xu, Z | 2 |
| Quan, J | 1 |
| Wu, LK | 1 |
| Agarwal, S | 1 |
| Kuo, CH | 1 |
| Kung, YL | 1 |
| Day, CH | 1 |
| Lin, PY | 1 |
| Lin, SZ | 1 |
| Hsieh, DJ | 1 |
| Huang, CY | 1 |
| Chiang, CY | 1 |
| Wang, XL | 1 |
| Feng, ST | 1 |
| Wang, YT | 1 |
| Zhang, NN | 1 |
| Guo, ZY | 2 |
| Yan, X | 1 |
| Yuan, YH | 3 |
| Wang, ZZ | 1 |
| Chen, NH | 3 |
| Hu, N | 1 |
| Li, S | 11 |
| Narmashiri, A | 1 |
| Abbaszadeh, M | 1 |
| Ghazizadeh, A | 1 |
| Yu, Z | 3 |
| Qin, G | 1 |
| Ge, Z | 1 |
| Li, W | 2 |
| Jiao, L | 1 |
| Su, LY | 3 |
| Liu, Q | 4 |
| Luo, R | 2 |
| Qiao, X | 1 |
| Xie, T | 1 |
| Yang, LX | 2 |
| Chen, C | 4 |
| Yao, YG | 2 |
| Zhang, K | 2 |
| Liu, P | 2 |
| Yuan, L | 1 |
| Geng, Z | 1 |
| Li, B | 3 |
| Zhang, B | 6 |
| Wu, Y | 6 |
| Liu, H | 4 |
| Sheng, H | 1 |
| Chen, Z | 3 |
| Xun, D | 1 |
| Wu, H | 6 |
| Xiao, S | 1 |
| Bi, Y | 1 |
| Duperrier, S | 1 |
| Bortolozzi, A | 1 |
| Sgambato, V | 1 |
| Rui, WJ | 1 |
| Fan, Y | 4 |
| Hu, YC | 1 |
| Ma, CM | 1 |
| Wang, BW | 1 |
| Shi, JP | 1 |
| Zhang, W | 9 |
| Chen, Q | 1 |
| Ding, W | 2 |
| D'Amico, R | 2 |
| Impellizzeri, D | 3 |
| Genovese, T | 1 |
| Fusco, R | 1 |
| Peritore, AF | 2 |
| Crupi, R | 3 |
| Interdonato, L | 1 |
| Franco, G | 1 |
| Marino, Y | 1 |
| Arangia, A | 1 |
| Gugliandolo, E | 2 |
| Cuzzocrea, S | 5 |
| Di Paola, R | 2 |
| Siracusa, R | 4 |
| Cordaro, M | 3 |
| Cheng, Q | 2 |
| Fang, J | 2 |
| Ding, H | 3 |
| Meng, J | 1 |
| Fang, X | 1 |
| Ma, C | 1 |
| Alosaimi, F | 1 |
| Temel, Y | 1 |
| Hescham, S | 1 |
| Witzig, VS | 1 |
| Almasabi, F | 1 |
| Tan, SKH | 1 |
| Jahanshahi, A | 1 |
| Zhao, G | 4 |
| Cao, Y | 1 |
| Jia, M | 1 |
| Yuan, S | 4 |
| Feng, J | 1 |
| Han, Y | 1 |
| Yu, H | 2 |
| Li, G | 3 |
| Bi, F | 1 |
| Xiong, J | 1 |
| Yang, C | 4 |
| Li, X | 11 |
| Chen, G | 2 |
| Guo, W | 3 |
| Tian, W | 1 |
| Guo, L | 1 |
| Qiu, J | 1 |
| Du, J | 2 |
| Zhang, T | 4 |
| Kim, YM | 1 |
| Choi, SY | 5 |
| Hwang, O | 5 |
| Lee, JY | 1 |
| Zhou, L | 3 |
| An, J | 1 |
| Zheng, X | 1 |
| Han, D | 1 |
| Lin, ZH | 1 |
| Xue, NJ | 1 |
| Zheng, R | 2 |
| Yan, YQ | 1 |
| Wang, ZX | 1 |
| Li, YL | 1 |
| Ying, CZ | 1 |
| Song, Z | 1 |
| Tian, J | 1 |
| Pu, JL | 1 |
| Zhang, BR | 1 |
| He, D | 2 |
| Li, J | 5 |
| Wang, H | 7 |
| Ye, B | 2 |
| He, Y | 5 |
| Li, Z | 4 |
| Fu, S | 2 |
| Liu, D | 2 |
| Hong, DG | 2 |
| Lee, S | 4 |
| Kim, J | 6 |
| Yang, S | 4 |
| Lee, M | 1 |
| Ahn, J | 1 |
| Lee, H | 9 |
| Chang, SC | 2 |
| Ha, NC | 1 |
| Lee, J | 4 |
| Guo, Y | 1 |
| Huang, H | 2 |
| Xu, J | 5 |
| Jiang, C | 2 |
| Chang, N | 1 |
| Ge, Q | 2 |
| Wang, G | 6 |
| Zhao, X | 2 |
| Huang, M | 2 |
| Bargues-Carot, A | 1 |
| Riaz, Z | 1 |
| Wickham, H | 1 |
| Zenitsky, G | 1 |
| Jin, H | 3 |
| Anantharam, V | 3 |
| Kanthasamy, A | 4 |
| Kanthasamy, AG | 2 |
| Kang, Z | 1 |
| Cai, L | 1 |
| Ding, J | 5 |
| Lu, M | 4 |
| Santoro, M | 2 |
| Fadda, P | 1 |
| Klephan, KJ | 1 |
| Hull, C | 1 |
| Teismann, P | 7 |
| Platt, B | 1 |
| Riedel, G | 3 |
| Razali, K | 1 |
| Mohd Nasir, MH | 1 |
| Othman, N | 1 |
| Doolaanea, AA | 1 |
| Kumar, J | 2 |
| Nabeel Ibrahim, W | 1 |
| Mohamed, WMY | 1 |
| Qiao, C | 2 |
| Dang, T | 1 |
| Zhou, YZ | 1 |
| Zhao, R | 1 |
| Huang, L | 5 |
| Cheng, S | 1 |
| Zou, Z | 1 |
| Tian, X | 2 |
| Guan, Q | 1 |
| Mu, K | 1 |
| Xie, J | 6 |
| Ye, Q | 2 |
| Lin, S | 1 |
| Yang, X | 4 |
| Chen, S | 10 |
| Wu, N | 1 |
| Xu, RC | 1 |
| Miao, WT | 1 |
| Xu, JY | 1 |
| Xu, WX | 1 |
| Liu, MR | 1 |
| Ding, ST | 1 |
| Jian, YX | 1 |
| Lei, YH | 1 |
| Yan, N | 1 |
| Liu, HD | 1 |
| Davin, A | 1 |
| Chabardès, S | 1 |
| Belaid, H | 1 |
| Fagret, D | 1 |
| Djaileb, L | 1 |
| Dauvilliers, Y | 1 |
| David, O | 1 |
| Torres-Martinez, N | 1 |
| Piallat, B | 1 |
| Zolotarev, YA | 1 |
| Shram, SI | 1 |
| Dadayan, AK | 1 |
| Dolotov, OV | 1 |
| Markov, DD | 1 |
| Nagaev, IY | 1 |
| Kudrin, VS | 2 |
| Narkevich, VB | 2 |
| Sokolov, OY | 1 |
| Kost, NV | 1 |
| Li, C | 2 |
| Zhu, D | 1 |
| Cheng, O | 1 |
| Cui, J | 2 |
| Ding, Y | 1 |
| Zhou, M | 1 |
| Ma, R | 2 |
| Deng, J | 3 |
| Hao, WZ | 1 |
| Zhang, JC | 1 |
| Ho, CT | 1 |
| Huang, JQ | 1 |
| Shen, J | 1 |
| Zha, Q | 1 |
| Yang, QH | 1 |
| Zhou, YQ | 1 |
| Liang, X | 1 |
| Chen, YJ | 1 |
| Qi, GX | 1 |
| Zhang, XJ | 2 |
| Yao, WB | 1 |
| Gao, XD | 1 |
| Heng, Y | 2 |
| Li, YY | 1 |
| Wen, L | 2 |
| Yan, JQ | 1 |
| Li, T | 3 |
| Chu, C | 2 |
| Yu, L | 2 |
| Zhai, Q | 2 |
| Zhao, J | 5 |
| Zhang, H | 5 |
| Tian, F | 3 |
| Chang, Q | 2 |
| Zheng, J | 2 |
| Li, D | 5 |
| Wu, S | 2 |
| Yang, H | 6 |
| Ojha, U | 2 |
| Khanal, S | 2 |
| Park, PH | 2 |
| Hong, JT | 4 |
| Choi, DY | 5 |
| Wan, J | 3 |
| Tan, J | 3 |
| Yi, S | 3 |
| Huang, K | 3 |
| Chang, D | 3 |
| Ishola, IO | 4 |
| Oloyo, AK | 3 |
| Olubodun-Obadun, TG | 4 |
| Godswill, OD | 3 |
| Omilabu, SA | 3 |
| Adeyemi, OO | 4 |
| Zhang, M | 7 |
| Hu, ZF | 3 |
| Dong, XL | 3 |
| Chen, WF | 5 |
| Jiang, Z | 3 |
| Yin, X | 3 |
| Li, F | 3 |
| Han, G | 4 |
| Gao, Z | 3 |
| Wang, Z | 10 |
| Pan, S | 3 |
| Wei, H | 3 |
| Kong, Y | 3 |
| Cui, X | 3 |
| Zhu, X | 3 |
| Mao, Y | 2 |
| Cao, F | 2 |
| Presti-Silva, SM | 2 |
| Herlinger, AL | 2 |
| Martins-Silva, C | 2 |
| Pires, RGW | 2 |
| Ibarra-Gutiérrez, MT | 1 |
| Serrano-García, N | 1 |
| Orozco-Ibarra, M | 1 |
| Shi, L | 3 |
| Jia, L | 1 |
| Xiu, M | 1 |
| Sun, T | 3 |
| Chen, L | 6 |
| Liu, R | 2 |
| Liu, QS | 3 |
| Cheng, Y | 4 |
| Bannikova, A | 1 |
| Huang, SY | 1 |
| Su, ZY | 1 |
| Han, YY | 1 |
| Liu, L | 4 |
| Shang, YJ | 1 |
| Mai, ZF | 1 |
| Zeng, ZW | 1 |
| Li, CH | 1 |
| Lv, J | 1 |
| Zhu, J | 4 |
| Wang, P | 1 |
| Liu, T | 1 |
| Yuan, J | 1 |
| Yin, H | 1 |
| Lan, Y | 1 |
| Sun, Q | 2 |
| Ding, G | 1 |
| Zhou, C | 2 |
| Oduola-Akande, MD | 1 |
| Akande, AJ | 1 |
| Aktas, B | 1 |
| Kartik, S | 2 |
| Pal, R | 2 |
| Chaudhary, MJ | 2 |
| Nath, R | 2 |
| Kumar, M | 2 |
| Binwal, M | 1 |
| Bawankule, DU | 1 |
| De Araújo, FM | 1 |
| Frota, AF | 1 |
| de Jesus, LB | 1 |
| Cuenca-Bermejo, L | 1 |
| Ferreira, KMS | 1 |
| Santos, CC | 1 |
| Soares, EN | 1 |
| Souza, JT | 1 |
| Sanches, FS | 1 |
| Costa, ACS | 1 |
| Farias, AA | 1 |
| de Fatima Dias Costa, M | 1 |
| Munoz, P | 1 |
| Menezes-Filho, JA | 1 |
| Segura-Aguilar, J | 1 |
| Costa, SL | 1 |
| Herrero, MT | 6 |
| Silva, VDA | 1 |
| Lee, YR | 2 |
| Moon, GH | 1 |
| Shim, D | 1 |
| Kim, JC | 1 |
| Lee, KJ | 1 |
| Chung, KH | 1 |
| An, JH | 1 |
| Chiu, YJ | 1 |
| Lin, CH | 1 |
| Yang, PN | 1 |
| Lo, YS | 1 |
| Chen, YC | 1 |
| Chen, CM | 1 |
| Wu, YR | 1 |
| Yao, CF | 1 |
| Chang, KH | 1 |
| Lee-Chen, GJ | 1 |
| Tiwari, PC | 1 |
| Chen, YH | 4 |
| Kuo, YY | 1 |
| You, YQ | 1 |
| Lin, YT | 1 |
| Chen, PC | 2 |
| Briñez-Gallego, P | 1 |
| da Costa Silva, DG | 1 |
| Cordeiro, MF | 1 |
| Horn, AP | 1 |
| Hort, MA | 1 |
| Bai, Q | 3 |
| Wen, Q | 1 |
| Han, L | 2 |
| Wang, K | 4 |
| Ren, XL | 1 |
| Zhang, MD | 1 |
| Wu, KN | 1 |
| Chu, ZW | 1 |
| Liu, SS | 1 |
| Jiang, XX | 1 |
| Zhu, JH | 3 |
| Wu, HM | 1 |
| Xue, Z | 1 |
| Zhu, L | 3 |
| Zhuo, L | 2 |
| Liao, W | 1 |
| García-Fernández, MD | 1 |
| Larrea, A | 1 |
| Fernández, R | 1 |
| Rodríguez-Puertas, R | 1 |
| Astigarraga, E | 1 |
| Manuel, I | 1 |
| Barreda-Gómez, G | 1 |
| Fukunaga, K | 2 |
| Cheng, A | 2 |
| Arimura, N | 1 |
| Yoshino, H | 2 |
| Sasaki, T | 1 |
| Kawahata, I | 2 |
| Shen, C | 1 |
| Tong, J | 2 |
| Zhou, R | 1 |
| Yildirim, S | 1 |
| Oylumlu, E | 1 |
| Ozkan, A | 1 |
| Sinen, O | 1 |
| Bulbul, M | 1 |
| Goksu, ET | 1 |
| Ertosun, MG | 1 |
| Tanriover, G | 2 |
| Jiang, W | 1 |
| Rong, Z | 1 |
| Sun, L | 2 |
| Yarreiphang, H | 1 |
| Vidyadhara, DJ | 1 |
| Nambisan, AK | 1 |
| Raju, TR | 1 |
| Sagar, BKC | 1 |
| Alladi, PA | 1 |
| Guo, S | 1 |
| Yao, Y | 1 |
| Liao, C | 1 |
| Qiu, H | 1 |
| Liang, L | 3 |
| Zheng, W | 1 |
| Wu, L | 3 |
| Meng, F | 1 |
| Tang, C | 1 |
| Liu, M | 4 |
| Zhou, Z | 1 |
| Xiang, J | 1 |
| Ran, S | 1 |
| Ohno, Y | 1 |
| Okita, E | 1 |
| Kawai-Uchida, M | 1 |
| Shoukei, Y | 1 |
| Soshiroda, K | 1 |
| Kanda, T | 1 |
| Uchida, S | 1 |
| Guo, M | 1 |
| Lanza, M | 1 |
| Cucinotta, L | 1 |
| Casili, G | 2 |
| Filippone, A | 2 |
| Basilotta, R | 1 |
| Capra, AP | 1 |
| Campolo, M | 2 |
| Paterniti, I | 2 |
| Esposito, E | 2 |
| Meng, HW | 1 |
| Shen, ZB | 1 |
| Meng, XS | 1 |
| Yin, ZQ | 2 |
| Wang, XR | 1 |
| Zou, TF | 1 |
| Liu, ZG | 1 |
| Wang, TX | 1 |
| Chen, YL | 1 |
| Yang, XX | 1 |
| Li, QS | 1 |
| Duan, YJ | 1 |
| Pu, Z | 1 |
| Liu, S | 3 |
| Guo, Z | 2 |
| Yan, J | 3 |
| Tang, Y | 3 |
| Xiao, H | 3 |
| Gao, J | 4 |
| Wang, W | 3 |
| Deng, P | 1 |
| Gao, H | 1 |
| Xu, FH | 1 |
| Qiu, YZ | 1 |
| Yang, FH | 1 |
| Ji, MM | 1 |
| Liu, KC | 1 |
| Zhang, SS | 1 |
| Pan, B | 1 |
| Niu, B | 1 |
| Xia, C | 1 |
| Gupta, P | 1 |
| Laha, JK | 1 |
| Roy, I | 1 |
| Atiq, A | 1 |
| Lee, HJ | 1 |
| Khan, A | 1 |
| Kang, MH | 1 |
| Rehman, IU | 1 |
| Ahmad, R | 1 |
| Tahir, M | 1 |
| Ali, J | 1 |
| Choe, K | 1 |
| Kim, MO | 1 |
| Duan, Y | 2 |
| Sekar, S | 3 |
| Miranzadeh Mahabadi, H | 1 |
| Buettner, B | 1 |
| Taghibiglou, C | 1 |
| Yang, R | 2 |
| Ye, S | 1 |
| Xie, S | 1 |
| He, L | 2 |
| Shi, J | 1 |
| Bok, E | 1 |
| Park, GH | 1 |
| Geng, X | 1 |
| Zou, Y | 1 |
| Qi, R | 1 |
| Zhong, L | 1 |
| Menshchikova, EB | 1 |
| Khrapova, MV | 1 |
| Kozhin, PM | 1 |
| Chechushkov, AV | 1 |
| Serykh, AE | 1 |
| Romakh, LP | 1 |
| Kandalintseva, NV | 1 |
| Pan, T | 1 |
| Xiao, Q | 3 |
| Fan, HJ | 1 |
| Xu, L | 3 |
| Qin, SC | 1 |
| Jin, XM | 1 |
| Xiao, BG | 2 |
| Ma, CG | 2 |
| Chai, Z | 1 |
| Fujimori, H | 1 |
| Ohba, T | 1 |
| Nakamura, S | 2 |
| Shimazawa, M | 1 |
| Hara, H | 1 |
| Ren, Z | 1 |
| Xiu, S | 1 |
| Yang, N | 1 |
| Chan, P | 1 |
| Rostyslav, P | 1 |
| Finiuk, N | 1 |
| Sik, A | 1 |
| Stoika, R | 1 |
| Guo, X | 1 |
| Sheng, X | 1 |
| Zheng, L | 1 |
| Usenko, T | 1 |
| Bezrukova, A | 1 |
| Rudenok, MM | 2 |
| Basharova, K | 1 |
| Shadrina, MI | 2 |
| Slominsky, PA | 2 |
| Zakharova, E | 1 |
| Pchelina, S | 1 |
| Lian, C | 1 |
| Pan, L | 1 |
| Lai, W | 1 |
| Zhang, F | 1 |
| Peng, L | 1 |
| Zhou, S | 2 |
| Zhang, G | 2 |
| Tan, Z | 1 |
| Heo, EJ | 1 |
| Lee, Y | 7 |
| Hyung Seo, M | 1 |
| Cui, M | 2 |
| Huang, B | 2 |
| Meka, ST | 1 |
| Bojja, SL | 1 |
| Kumar, G | 1 |
| Birangal, SR | 1 |
| Rao, CM | 1 |
| Rahamim, N | 1 |
| Slovik, M | 1 |
| Mevorach, T | 1 |
| Linkovski, O | 1 |
| Bergman, H | 6 |
| Rosin, B | 1 |
| Eitan, R | 1 |
| Park, M | 1 |
| Ha, J | 1 |
| Choi, HS | 1 |
| Kim, BS | 2 |
| Jeong, YK | 1 |
| Li, HY | 1 |
| Liu, DS | 1 |
| Li, LB | 1 |
| Zhang, YB | 1 |
| Dong, HY | 1 |
| Rong, H | 1 |
| Zhang, JY | 1 |
| Wang, JP | 1 |
| Luo, N | 1 |
| Tang, L | 1 |
| Xu, N | 1 |
| Yi, W | 2 |
| Sang, X | 2 |
| Shao, M | 1 |
| Hao, ZZ | 1 |
| Shen, Y | 4 |
| Yue, F | 2 |
| Xu, C | 1 |
| Li, N | 1 |
| Huang, Y | 4 |
| Soltys, D | 1 |
| Fujita, A | 1 |
| Fujita, Y | 1 |
| Pu, Y | 1 |
| Cui, W | 1 |
| Zhan, Y | 1 |
| Shao, X | 1 |
| Fu, W | 2 |
| Xiao, D | 1 |
| Qin, X | 2 |
| Lin, Y | 3 |
| Balke, D | 1 |
| Tatenhorst, L | 1 |
| Dambeck, V | 1 |
| Ribas, VT | 1 |
| Vahsen, BF | 1 |
| Michel, U | 1 |
| Bähr, M | 4 |
| Lingor, P | 2 |
| Datta, I | 1 |
| Mekha, SR | 1 |
| Kaushal, A | 1 |
| Ganapathy, K | 1 |
| Razdan, R | 1 |
| Yu, Y | 4 |
| Lang, XY | 1 |
| Li, XX | 1 |
| Gu, RZ | 1 |
| Lan, R | 1 |
| Qin, XY | 1 |
| Mei, M | 1 |
| Zhao, F | 1 |
| Lin, QS | 1 |
| Chen, P | 1 |
| Wang, WX | 1 |
| Lin, CC | 1 |
| Yu, LH | 1 |
| Lin, YX | 1 |
| Xu, YF | 1 |
| Kang, DZ | 1 |
| Ando, K | 3 |
| Inoue, T | 3 |
| Hikishima, K | 2 |
| Komaki, Y | 2 |
| Kawai, K | 2 |
| Inoue, R | 1 |
| Nishime, C | 1 |
| Nishinaka, E | 1 |
| Urano, K | 1 |
| Okano, H | 2 |
| Xue, B | 2 |
| Xiao, W | 1 |
| Tian, H | 1 |
| Edwards Iii, G | 1 |
| Gamez, N | 1 |
| Armijo, E | 1 |
| Kramm, C | 1 |
| Morales, R | 1 |
| Taylor-Presse, K | 1 |
| Schulz, PE | 1 |
| Soto, C | 1 |
| Moreno-Gonzalez, I | 1 |
| Mishra, A | 1 |
| Tiwari, V | 1 |
| Shukla, S | 1 |
| Wang, F | 4 |
| Dong, K | 1 |
| Sun, YJ | 1 |
| Liu, CF | 3 |
| Xing, MJ | 1 |
| Cheng, X | 1 |
| Wei, S | 1 |
| Zheng, JW | 1 |
| Zhao, XF | 1 |
| Wang, XM | 2 |
| Fu, J | 1 |
| Song, HF | 1 |
| Monje, MHG | 1 |
| Blesa, J | 1 |
| García-Cabezas, MÁ | 1 |
| Obeso, JA | 11 |
| Cavada, C | 2 |
| Ji, R | 1 |
| Smith, M | 2 |
| Niimi, Y | 1 |
| Karakatsani, ME | 1 |
| Murillo, MF | 1 |
| Jackson-Lewis, V | 12 |
| Przedborski, S | 12 |
| Konofagou, EE | 1 |
| Wu, XF | 1 |
| Duan, LX | 1 |
| Gao, XL | 1 |
| Guo, ML | 1 |
| Wang, DM | 1 |
| Barth, AL | 1 |
| Schneider, JS | 4 |
| Johnston, TH | 3 |
| Hill, MP | 3 |
| Brotchie, JM | 6 |
| Moskal, JR | 1 |
| Cearley, CN | 1 |
| Huang, R | 1 |
| Lin, L | 1 |
| Jin, L | 1 |
| Zhu, R | 2 |
| Liu, A | 1 |
| Fan, H | 1 |
| Qiao, L | 1 |
| Shen, M | 1 |
| Lai, X | 1 |
| Barilar, JO | 1 |
| Knezovic, A | 1 |
| Perhoc, AB | 1 |
| Homolak, J | 1 |
| Riederer, P | 7 |
| Salkovic-Petrisic, M | 1 |
| Seo, J | 1 |
| Park, J | 6 |
| Kim, K | 1 |
| Won, J | 1 |
| Yeo, HG | 1 |
| Jin, YB | 1 |
| Koo, BS | 1 |
| Lim, KS | 2 |
| Jeong, KJ | 1 |
| Kang, P | 1 |
| Lee, HY | 1 |
| Choi, WS | 1 |
| Baek, SH | 1 |
| Jeon, CY | 1 |
| Hong, JJ | 1 |
| Huh, JW | 1 |
| Kim, YH | 2 |
| Park, SJ | 1 |
| Kim, SU | 1 |
| Lee, DS | 2 |
| Lee, SR | 1 |
| Marchetti, B | 6 |
| Tirolo, C | 6 |
| L'Episcopo, F | 6 |
| Caniglia, S | 6 |
| Testa, N | 6 |
| Smith, JA | 1 |
| Pluchino, S | 3 |
| Serapide, MF | 3 |
| Lu, K | 1 |
| Cheng, G | 1 |
| Guo, CH | 1 |
| Cao, T | 2 |
| Zheng, LT | 1 |
| Waddington, JL | 1 |
| Zhen, XC | 2 |
| Haga, H | 1 |
| Yamada, R | 1 |
| Izumi, H | 1 |
| Shinoda, Y | 1 |
| Miyachi, H | 1 |
| Massaquoi, MS | 1 |
| Liguore, WA | 1 |
| Churchill, MJ | 1 |
| Moore, C | 2 |
| Melrose, HL | 1 |
| Meshul, CK | 2 |
| Moreau, C | 2 |
| Rolland, AS | 1 |
| Pioli, E | 1 |
| Odou, P | 1 |
| Barthelemy, C | 1 |
| Lannoy, D | 1 |
| Demailly, A | 1 |
| Carta, N | 1 |
| Deramecourt, V | 1 |
| Auger, F | 2 |
| Kuchcinski, G | 1 |
| Laloux, C | 3 |
| Defebvre, L | 2 |
| Bordet, R | 2 |
| Duce, J | 1 |
| Devedjian, JC | 3 |
| Bezard, E | 13 |
| Fisichella, M | 1 |
| Devos, D | 3 |
| Togashi, K | 2 |
| Hasegawa, M | 2 |
| Nagai, J | 2 |
| Kotaka, K | 1 |
| Yazawa, A | 1 |
| Takahashi, M | 1 |
| Masukawa, D | 2 |
| Goshima, Y | 2 |
| Hensley, K | 2 |
| Ohshima, T | 2 |
| Liu, WW | 1 |
| Wei, SZ | 1 |
| Huang, GD | 1 |
| Liu, LB | 1 |
| Gu, C | 1 |
| Wang, XH | 1 |
| Xia, ST | 1 |
| Xie, AM | 1 |
| Hu, LF | 1 |
| Mann, E | 1 |
| Jackson, M | 1 |
| Lincoln, L | 2 |
| Fisher, R | 2 |
| Rose, S | 3 |
| Duty, S | 2 |
| Javed, H | 2 |
| Thangavel, R | 1 |
| Selvakumar, GP | 2 |
| Dubova, I | 1 |
| Schwartz, N | 1 |
| Ahmed, ME | 1 |
| Zaheer, S | 1 |
| Kempuraj, D | 1 |
| Iyer, S | 1 |
| Zaheer, A | 1 |
| Khan, MM | 2 |
| Kong, F | 1 |
| Ding, Q | 1 |
| Cai, Y | 2 |
| Hao, Y | 1 |
| Tang, B | 1 |
| Zhu, M | 2 |
| Gong, D | 1 |
| Yu, R | 1 |
| Lin, Z | 2 |
| Ouyang, Z | 1 |
| Huang, X | 1 |
| Reglodi, D | 1 |
| Vaudry, D | 1 |
| Jia, E | 1 |
| Ouyang, T | 1 |
| Pan, M | 1 |
| Bai, Y | 2 |
| Huang, C | 1 |
| Luo, Q | 1 |
| Zeng, W | 1 |
| Shi, R | 1 |
| Zhengli, C | 1 |
| Ji, YJ | 1 |
| Wang, HL | 1 |
| Yin, BL | 1 |
| Ren, XY | 1 |
| Imai, Y | 1 |
| Singh, SS | 1 |
| Rai, SN | 2 |
| Birla, H | 1 |
| Zahra, W | 1 |
| Rathore, AS | 1 |
| Dilnashin, H | 1 |
| Singh, R | 1 |
| Singh, SP | 4 |
| Mizrahi-Kliger, AD | 1 |
| Kaplan, A | 1 |
| Israel, Z | 3 |
| Deffains, M | 2 |
| Travagli, RA | 1 |
| Browning, KN | 1 |
| Camilleri, M | 1 |
| Liao, JF | 1 |
| Cheng, YF | 1 |
| You, ST | 1 |
| Kuo, WC | 1 |
| Huang, CW | 1 |
| Chiou, JJ | 1 |
| Hsu, CC | 1 |
| Hsieh-Li, HM | 1 |
| Tsai, YC | 1 |
| Moon, BC | 2 |
| Choi, G | 1 |
| Dong, M | 2 |
| Wang, CC | 1 |
| Shi, HH | 1 |
| Yanagita, T | 1 |
| Xue, CH | 1 |
| Zhang, TT | 1 |
| Wang, YM | 1 |
| Beaudry, F | 1 |
| Huot, P | 3 |
| Huan, F | 1 |
| Xie, X | 1 |
| Yu, G | 1 |
| Jiang, L | 1 |
| Gao, R | 1 |
| Xie, L | 2 |
| Qian, C | 2 |
| Ye, Y | 1 |
| Mao, H | 1 |
| Cai, LJ | 1 |
| Tu, L | 1 |
| Huang, XM | 1 |
| Qiu, N | 1 |
| Xie, GH | 1 |
| Liao, JX | 1 |
| Du, W | 1 |
| Zhang, YY | 1 |
| Tian, JY | 1 |
| Yang, W | 2 |
| Hao, W | 1 |
| Meng, Z | 1 |
| Ding, S | 1 |
| Huang, W | 2 |
| Yang, J | 2 |
| Gu, X | 1 |
| Wi, R | 1 |
| Chung, YC | 3 |
| Jin, BK | 3 |
| Gong, J | 2 |
| Ding, L | 2 |
| Pan, X | 1 |
| Chen, X | 5 |
| Peng, G | 1 |
| Gao, F | 1 |
| Xuan, A | 1 |
| Xu, P | 4 |
| Jeon, H | 1 |
| Kim, HY | 2 |
| Bae, CH | 1 |
| Kim, S | 2 |
| Park, H | 1 |
| Chang, KA | 1 |
| Song, SY | 1 |
| Kim, IS | 3 |
| Koppula, S | 2 |
| Park, JY | 3 |
| Kim, BW | 1 |
| Yoon, SH | 1 |
| Choi, DK | 5 |
| Lin, J | 1 |
| Zhang, Q | 1 |
| Gao, WQ | 1 |
| Xu, H | 4 |
| Ardah, MT | 2 |
| Bharathan, G | 1 |
| Kitada, T | 2 |
| Haque, ME | 4 |
| Thadathil, N | 1 |
| Xiao, J | 1 |
| Hori, R | 1 |
| Alway, SE | 1 |
| Yue, D | 1 |
| Zeng, C | 1 |
| Okyere, SK | 1 |
| Hu, Y | 2 |
| Ding, ZX | 1 |
| Wu, WJ | 1 |
| Lu, CW | 1 |
| Wang, SE | 1 |
| Lin, CL | 1 |
| Wu, CH | 1 |
| Mustapha, M | 1 |
| Mat Taib, CN | 1 |
| Zhang, HQ | 1 |
| Wang, JY | 1 |
| Li, ZF | 1 |
| Cui, L | 1 |
| Huang, SS | 1 |
| Zhu, LB | 1 |
| Fan, HH | 1 |
| Hao, L | 1 |
| Shao, S | 1 |
| Dionísio, PA | 1 |
| Amaral, JD | 1 |
| Rodrigues, CMP | 2 |
| Yin, L | 1 |
| Luo, Z | 1 |
| Yu, X | 2 |
| Luo, H | 1 |
| Dutta, N | 1 |
| Ghosh, S | 2 |
| Nelson, VK | 1 |
| Sareng, HR | 1 |
| Majumder, C | 1 |
| Mandal, SC | 1 |
| Pal, M | 1 |
| Suh, YJ | 1 |
| Ishigami, A | 1 |
| Kim, H | 3 |
| Hur, JS | 1 |
| Ren, C | 1 |
| Li, LX | 1 |
| Dong, AQ | 1 |
| Zhang, YT | 1 |
| Hu, H | 1 |
| Mao, CJ | 1 |
| Du, RW | 1 |
| Bu, WG | 1 |
| Zhang, DD | 1 |
| Zhang, CY | 1 |
| Zhang, YX | 2 |
| Cui, HP | 1 |
| Jia, H | 1 |
| Zhou, H | 2 |
| Meng, L | 1 |
| Xia, X | 1 |
| Zhou, W | 1 |
| Pang, N | 1 |
| Bian, T | 1 |
| Yuan, T | 1 |
| Niu, L | 1 |
| Zheng, H | 2 |
| Jia, XB | 2 |
| Huang, SB | 1 |
| Yao, L | 2 |
| McQuade, RM | 1 |
| Singleton, LM | 1 |
| Constable, R | 1 |
| Di Natale, M | 1 |
| Ringuet, MT | 1 |
| Berger, JP | 1 |
| Kauhausen, J | 1 |
| Parish, CL | 1 |
| Furness, JB | 1 |
| Diwakarla, S | 1 |
| Hou, Y | 1 |
| Liu, C | 4 |
| Ge, S | 1 |
| Azam, S | 1 |
| Akther, M | 1 |
| Cho, DY | 1 |
| Nodel, M | 1 |
| Pavlenko, T | 1 |
| Chesnokova, N | 1 |
| Maegawa, H | 1 |
| Niwa, H | 1 |
| Kim, JS | 1 |
| Ang, MJ | 1 |
| Kim, SH | 2 |
| Moon, CJ | 1 |
| Seong, B | 1 |
| Jang, YJ | 1 |
| Kim, C | 1 |
| Lv, M | 1 |
| Xue, G | 2 |
| Cheng, H | 1 |
| Meng, P | 1 |
| Lian, X | 1 |
| Deng, R | 1 |
| Jia, JJ | 1 |
| Sun, B | 1 |
| Zhou, X | 1 |
| Chang, E | 1 |
| Choi, YJ | 2 |
| Kim, DW | 4 |
| Shin, MJ | 3 |
| Yeo, HJ | 1 |
| Yeo, EJ | 2 |
| Lee, LR | 1 |
| Song, Y | 1 |
| Kim, DS | 4 |
| Han, KH | 3 |
| Lee, KW | 1 |
| Park, JK | 1 |
| Eum, WS | 4 |
| Zheng, S | 1 |
| Tang, J | 1 |
| Houser, MC | 1 |
| Caudle, WM | 1 |
| Chang, J | 1 |
| Kannarkat, GT | 1 |
| Kelly, SD | 1 |
| Oliver, D | 1 |
| Joers, V | 1 |
| Shannon, KM | 1 |
| Keshavarzian, A | 1 |
| Tansey, MG | 1 |
| Heo, G | 1 |
| Lee, KM | 1 |
| Kim, AH | 1 |
| Chung, KW | 1 |
| Im, E | 1 |
| Chung, HY | 1 |
| Spathis, AD | 1 |
| Asvos, X | 1 |
| Ziavra, D | 1 |
| Karampelas, T | 1 |
| Topouzis, S | 1 |
| Cournia, Z | 1 |
| Qing, X | 1 |
| Alexakos, P | 1 |
| Smits, LM | 1 |
| Dalla, C | 1 |
| Rideout, HJ | 1 |
| Schwamborn, JC | 1 |
| Tamvakopoulos, C | 1 |
| Fokas, D | 1 |
| Vassilatis, DK | 1 |
| Bulteau, AL | 1 |
| Mena, NP | 1 |
| Auchère, F | 1 |
| Lee, I | 1 |
| Prigent, A | 2 |
| Lobsiger, CS | 1 |
| Camadro, JM | 1 |
| Hirsch, EC | 9 |
| Gnanasegaran, N | 1 |
| Govindasamy, V | 1 |
| Simon, C | 1 |
| Gan, QF | 1 |
| Vincent-Chong, VK | 1 |
| Mani, V | 1 |
| Krishnan Selvarajan, K | 1 |
| Subramaniam, V | 1 |
| Musa, S | 1 |
| Abu Kasim, NH | 1 |
| Ahn, S | 1 |
| Song, TJ | 1 |
| Park, SU | 1 |
| Jeon, S | 2 |
| Oh, JY | 1 |
| Jang, J | 1 |
| Hong, S | 2 |
| Song, MA | 1 |
| Shin, HS | 1 |
| Jung, YR | 1 |
| Park, HJ | 8 |
| Kinoshita, KI | 1 |
| Muroi, Y | 1 |
| Unno, T | 1 |
| Ishii, T | 1 |
| Mingazov, ER | 1 |
| Khakimova, GR | 2 |
| Kozina, EA | 3 |
| Medvedev, AE | 1 |
| Buneeva, OA | 1 |
| Bazyan, AS | 1 |
| Ugrumov, MV | 3 |
| Gotsbacher, MP | 1 |
| Telfer, TJ | 1 |
| Witting, PK | 1 |
| Double, KL | 1 |
| Codd, R | 1 |
| Du, ZR | 2 |
| Xu, AL | 2 |
| Yan, Z | 1 |
| Xiao, HH | 1 |
| Wong, MS | 2 |
| Yao, XS | 1 |
| Bhatnagar, M | 1 |
| Goel, I | 1 |
| Roy, T | 1 |
| Shukla, SD | 1 |
| Khurana, S | 1 |
| Wang, QM | 1 |
| Xu, YY | 1 |
| Ma, ZG | 1 |
| Koo, JH | 1 |
| Jang, YC | 1 |
| Hwang, DJ | 1 |
| Um, HS | 1 |
| Lee, NH | 1 |
| Jung, JH | 2 |
| Cho, JY | 1 |
| Yuan, Z | 1 |
| Feng, P | 1 |
| Ji, C | 2 |
| Chou, ML | 1 |
| Wu, JW | 1 |
| Gouel, F | 1 |
| Jonneaux, A | 1 |
| Timmerman, K | 1 |
| Renn, TY | 1 |
| Chang, HM | 1 |
| Lin, LT | 1 |
| Burnouf, T | 1 |
| Modo, M | 1 |
| Crum, WR | 1 |
| Gerwig, M | 1 |
| Vernon, AC | 1 |
| Patel, P | 1 |
| Jackson, MJ | 3 |
| Jenner, P | 14 |
| Iravani, MM | 2 |
| Napolitano, F | 1 |
| Booth Warren, E | 1 |
| Migliarini, S | 1 |
| Punzo, D | 1 |
| Errico, F | 1 |
| Thiolat, ML | 1 |
| Vescovi, AL | 1 |
| Calabresi, P | 1 |
| Morelli, M | 3 |
| Konradi, C | 1 |
| Pasqualetti, M | 1 |
| Usiello, A | 1 |
| Lin, JG | 1 |
| Chen, CJ | 1 |
| Yang, HB | 1 |
| Hung, SY | 1 |
| Kikuchi, T | 1 |
| Morizane, A | 2 |
| Doi, D | 1 |
| Magotani, H | 1 |
| Onoe, H | 1 |
| Mizuma, H | 1 |
| Takara, S | 1 |
| Takahashi, R | 2 |
| Inoue, H | 1 |
| Morita, S | 1 |
| Okita, K | 1 |
| Nakagawa, M | 1 |
| Parmar, M | 1 |
| Takahashi, J | 3 |
| Tunje, R | 1 |
| Ye, YL | 1 |
| Sonauddin, A | 1 |
| Hansraj, B | 1 |
| Ngawang, S | 1 |
| Shivani, S | 1 |
| Liu, RP | 1 |
| Zhang, R | 1 |
| Andersen, AH | 1 |
| Hardy, PA | 1 |
| Forman, E | 1 |
| Evans, A | 1 |
| Ai, Y | 1 |
| Yue, J | 1 |
| Yue, G | 1 |
| Gash, DM | 3 |
| Grondin, R | 4 |
| Klemann, CJHM | 1 |
| Xicoy, H | 1 |
| Poelmans, G | 1 |
| Bloem, BR | 2 |
| Martens, GJM | 1 |
| Visser, JE | 1 |
| Singh, B | 2 |
| Pandey, S | 3 |
| Yadav, SK | 3 |
| Verma, R | 2 |
| Mahdi, AA | 2 |
| Wen, Z | 1 |
| Tang, P | 1 |
| Tu, N | 1 |
| Wu, G | 1 |
| Kusuda, Y | 1 |
| Takemura, A | 1 |
| Nakano, M | 1 |
| Ishihara, A | 1 |
| Yeon, SK | 1 |
| Choi, JW | 2 |
| Park, JH | 1 |
| Kim, HJ | 1 |
| Shin, SJ | 1 |
| Jang, BK | 2 |
| Bahn, YS | 1 |
| Lee, YS | 1 |
| Pae, AN | 1 |
| Park, KD | 2 |
| Luo, S | 1 |
| Gu, Q | 1 |
| Zhou, T | 1 |
| Liang, Z | 1 |
| Abbate, V | 1 |
| Hider, R | 1 |
| Lees, A | 1 |
| Alieva, AK | 1 |
| Zyrin, VS | 1 |
| Kolacheva, AA | 1 |
| Shulskaya, MV | 1 |
| Ugryumov, MV | 1 |
| Mani, S | 1 |
| Barathidasan, R | 1 |
| Manivasagam, T | 2 |
| Thenmozhi, AJ | 2 |
| Sevanan, M | 1 |
| Chidambaram, SB | 2 |
| Essa, MM | 1 |
| Guillemin, GJ | 1 |
| Sakharkar, MK | 1 |
| Bagga, P | 1 |
| Pickup, S | 1 |
| Crescenzi, R | 1 |
| Martinez, D | 1 |
| Borthakur, A | 1 |
| D'Aquilla, K | 1 |
| Singh, A | 3 |
| Verma, G | 1 |
| Detre, JA | 1 |
| Greenberg, J | 1 |
| Hariharan, H | 1 |
| Reddy, R | 1 |
| Iannielli, A | 1 |
| Bido, S | 2 |
| Folladori, L | 1 |
| Segnali, A | 1 |
| Cancellieri, C | 1 |
| Maresca, A | 1 |
| Massimino, L | 1 |
| Rubio, A | 1 |
| Morabito, G | 1 |
| Caporali, L | 1 |
| Tagliavini, F | 1 |
| Musumeci, O | 1 |
| Gregato, G | 1 |
| Carelli, V | 1 |
| Tiranti, V | 1 |
| Broccoli, V | 1 |
| Motyl, J | 1 |
| Przykaza, Ł | 1 |
| Boguszewski, PM | 1 |
| Kosson, P | 1 |
| Strosznajder, JB | 1 |
| Niranjan, R | 1 |
| Mishra, KP | 1 |
| Thakur, AK | 1 |
| Neal, ML | 1 |
| Boyle, AM | 1 |
| Budge, KM | 1 |
| Safadi, FF | 1 |
| Richardson, JR | 1 |
| Evangelista, M | 1 |
| Ge, G | 1 |
| Guderyon, MJ | 1 |
| He, Z | 1 |
| Clark, RA | 3 |
| Stahl, K | 1 |
| Rahmani, S | 1 |
| Prydz, A | 1 |
| Skauli, N | 1 |
| MacAulay, N | 1 |
| Mylonakou, MN | 1 |
| Torp, R | 1 |
| Skare, Ø | 1 |
| Berg, T | 1 |
| Leergaard, TB | 1 |
| Paulsen, RE | 1 |
| Ottersen, OP | 1 |
| Amiry-Moghaddam, M | 1 |
| Peruzzotti-Jametti, L | 1 |
| Balzarotti, B | 1 |
| Feng, S | 2 |
| Nie, K | 2 |
| Gan, R | 1 |
| Rosa, AI | 1 |
| Duarte-Silva, S | 1 |
| Silva-Fernandes, A | 1 |
| Nunes, MJ | 1 |
| Carvalho, AN | 2 |
| Rodrigues, E | 2 |
| Gama, MJ | 2 |
| Maciel, P | 1 |
| Castro-Caldas, M | 2 |
| Wu, KC | 1 |
| Liou, HH | 1 |
| Lee, CY | 1 |
| Lin, CJ | 1 |
| Ma, M | 1 |
| Nonaka, R | 1 |
| Yamaguchi, A | 1 |
| Ishikawa, KI | 1 |
| Kobayashi, K | 1 |
| Murayama, S | 1 |
| Hwang, SH | 1 |
| Saiki, S | 1 |
| Akamatsu, W | 1 |
| Hattori, N | 2 |
| Lee, E | 1 |
| Hwang, I | 1 |
| Park, S | 2 |
| Hwang, B | 1 |
| Cho, Y | 2 |
| Son, J | 1 |
| Yu, JW | 2 |
| Xue, L | 1 |
| Tong, Q | 2 |
| Yuan, X | 2 |
| Yuan, C | 1 |
| Joniec-Maciejak, I | 1 |
| Wawer, A | 1 |
| Turzyńska, D | 1 |
| Sobolewska, A | 1 |
| Maciejak, P | 1 |
| Szyndler, J | 1 |
| Mirowska-Guzel, D | 1 |
| Płaźnik, A | 1 |
| Kang, YC | 1 |
| Son, M | 1 |
| Kang, S | 1 |
| Im, S | 1 |
| Piao, Y | 2 |
| Song, MY | 1 |
| Park, KS | 1 |
| Pak, YK | 2 |
| Nigmatullina, R | 1 |
| Zalyalova, Z | 1 |
| Soshnikova, N | 1 |
| Krasnov, A | 1 |
| Vorobyeva, N | 1 |
| Georgieva, S | 1 |
| Kudrin, V | 1 |
| Narkevich, V | 1 |
| Choudhury, GR | 1 |
| Daadi, MM | 2 |
| Jang, Y | 1 |
| Kwon, I | 1 |
| Song, W | 1 |
| Cosio-Lima, LM | 1 |
| Taylor, S | 1 |
| Lai, F | 1 |
| Jiang, R | 1 |
| Xie, W | 1 |
| Jia, Y | 1 |
| Ansari, JA | 1 |
| Hamadjida, A | 1 |
| Frouni, I | 1 |
| Kwan, C | 1 |
| Sui, D | 1 |
| Chen, H | 2 |
| Lv, Y | 2 |
| He, P | 1 |
| Jiao, J | 1 |
| Mao, X | 1 |
| Xue, X | 1 |
| Su, J | 1 |
| Huang, P | 1 |
| Qin, M | 1 |
| Lu, Q | 1 |
| Liu, F | 1 |
| Wu, R | 1 |
| Lee, SB | 1 |
| Kim, HT | 1 |
| Yang, HO | 2 |
| Jang, W | 1 |
| Tonouchi, A | 1 |
| Nicholatos, JW | 1 |
| Francisco, AB | 1 |
| Bender, CA | 1 |
| Yeh, T | 1 |
| Lugay, FJ | 1 |
| Salazar, JE | 1 |
| Glorioso, C | 1 |
| Libert, S | 1 |
| Zhu, YL | 1 |
| Sun, MF | 1 |
| Cheng, K | 1 |
| Xu, YD | 1 |
| Zhou, ZL | 1 |
| Yang, XS | 1 |
| Dou, F | 1 |
| Chu, X | 1 |
| Lu, G | 2 |
| Pupyshev, AB | 1 |
| Tikhonova, MA | 1 |
| Akopyan, AA | 1 |
| Tenditnik, MV | 1 |
| Dubrovina, NI | 1 |
| Korolenko, TA | 1 |
| Xu, LL | 1 |
| Wu, YF | 1 |
| Li, CC | 1 |
| Dai, Z | 1 |
| You, QD | 1 |
| Jiang, ZY | 1 |
| Di, B | 1 |
| Gratuze, M | 1 |
| Josset, N | 1 |
| Petry, FR | 1 |
| Pflieger, M | 1 |
| Eyoum Jong, L | 1 |
| Truchetti, G | 1 |
| Poitras, I | 1 |
| Julien, J | 1 |
| Bezeau, F | 1 |
| Morin, F | 1 |
| Samadi, P | 2 |
| Cicchetti, F | 2 |
| Bretzner, F | 1 |
| Planel, E | 1 |
| Jiang, PE | 1 |
| Lang, QH | 1 |
| Yu, QY | 1 |
| Tang, XY | 1 |
| Liu, QQ | 1 |
| Li, XY | 1 |
| Feng, XZ | 1 |
| Kim, KI | 1 |
| Jia, K | 1 |
| Dou, S | 1 |
| Chen, J | 3 |
| Cheng, B | 1 |
| Darabi, MA | 1 |
| Tu, G | 1 |
| Ying, L | 1 |
| Xiao, B | 1 |
| Xing, M | 1 |
| Zhang, L | 5 |
| Tang, H | 1 |
| Gao, L | 1 |
| Huang, Z | 1 |
| Chattopadhyay, M | 1 |
| Chowdhury, AR | 1 |
| Feng, T | 1 |
| Assenmacher, CA | 1 |
| Radaelli, E | 1 |
| Guengerich, FP | 1 |
| Avadhani, NG | 1 |
| Sun, F | 1 |
| Deng, Y | 1 |
| Manzoor, R | 1 |
| Ma, H | 1 |
| Sampath, C | 1 |
| Kalpana, R | 1 |
| Ansah, T | 1 |
| Charlton, C | 2 |
| Hale, A | 1 |
| Channon, KM | 1 |
| Srinivasan, S | 1 |
| Gangula, PR | 1 |
| Müller-Nedebock, AC | 1 |
| Brennan, RR | 1 |
| Venter, M | 1 |
| Pienaar, IS | 1 |
| van der Westhuizen, FH | 1 |
| Elson, JL | 1 |
| Ross, OA | 1 |
| Bardien, S | 1 |
| Hu, ZL | 1 |
| Ding, JH | 2 |
| Du, RH | 1 |
| Song, J | 1 |
| Fan, K | 1 |
| Qi, M | 1 |
| Hu, YB | 1 |
| Zhang, YF | 1 |
| Ren, RJ | 1 |
| Cui, HL | 1 |
| Huang, WY | 1 |
| Chen, HZ | 1 |
| Geng, J | 1 |
| Fan, T | 1 |
| Qin, ZH | 1 |
| Xu, Q | 1 |
| Steidinger, TU | 1 |
| Slone, SR | 1 |
| Standaert, DG | 1 |
| Yacoubian, TA | 1 |
| Ayton, S | 1 |
| Lei, P | 1 |
| Duce, JA | 1 |
| Wong, BX | 1 |
| Sedjahtera, A | 1 |
| Adlard, PA | 3 |
| Bush, AI | 2 |
| Zhu, G | 1 |
| Wakeman, DR | 1 |
| Weiss, S | 1 |
| Sladek, JR | 6 |
| Elsworth, JD | 7 |
| Bauereis, B | 1 |
| Leranth, C | 1 |
| Hurley, PJ | 1 |
| Roth, RH | 6 |
| Redmond, DE | 7 |
| González, H | 1 |
| Contreras, F | 1 |
| Prado, C | 1 |
| Elgueta, D | 1 |
| Franz, D | 1 |
| Bernales, S | 1 |
| Pacheco, R | 1 |
| Quiroga-Varela, A | 1 |
| Walters, JR | 1 |
| Brazhnik, E | 1 |
| Marin, C | 1 |
| Imam, SZ | 2 |
| Trickler, W | 1 |
| Kimura, S | 1 |
| Binienda, ZK | 1 |
| Paule, MG | 1 |
| Slikker, W | 1 |
| Ali, SF | 1 |
| Ghosh, A | 3 |
| Saminathan, H | 1 |
| Sondarva, G | 1 |
| Harischandra, DS | 2 |
| Qian, Z | 1 |
| Rana, A | 2 |
| Fifel, K | 2 |
| Dkhissi-Benyahya, O | 1 |
| Cooper, HM | 2 |
| Mundiñano, IC | 1 |
| Hernandez, M | 1 |
| Dicaudo, C | 1 |
| Ordoñez, C | 1 |
| Marcilla, I | 2 |
| Tuñon, MT | 1 |
| Luquin, MR | 6 |
| Alvarez-Fischer, D | 2 |
| Noelker, C | 1 |
| Grünewald, A | 1 |
| Vulinović, F | 1 |
| Guerreiro, S | 1 |
| Fuchs, J | 1 |
| Lu, L | 1 |
| Lombès, A | 1 |
| Oertel, WH | 3 |
| Michel, PP | 3 |
| Hartmann, A | 3 |
| Zhao, Q | 1 |
| Cai, D | 1 |
| Hao, D | 1 |
| Purushothuman, S | 1 |
| Nandasena, C | 1 |
| Peoples, CL | 1 |
| El Massri, N | 2 |
| Johnstone, DM | 2 |
| Mitrofanis, J | 5 |
| Stone, J | 3 |
| Zachrisson, O | 1 |
| Zhao, M | 2 |
| Andersson, A | 1 |
| Dannaeus, K | 1 |
| Häggblad, J | 1 |
| Isacson, R | 1 |
| Nielsen, E | 1 |
| Patrone, C | 1 |
| Rönnholm, H | 1 |
| Wikstrom, L | 1 |
| Delfani, K | 2 |
| McCormack, AL | 1 |
| Palmer, T | 1 |
| Di Monte, DA | 3 |
| Janson Lang, AM | 1 |
| Haegerstrand, A | 1 |
| Riahi, G | 1 |
| Parent, M | 2 |
| Zhelev, Z | 1 |
| Bakalova, R | 1 |
| Aoki, I | 1 |
| Lazarova, D | 1 |
| Saga, T | 1 |
| Guo, B | 1 |
| Xu, D | 2 |
| Duan, H | 1 |
| Lee, SM | 1 |
| Prakash, J | 1 |
| Chouhan, S | 1 |
| Westfall, S | 1 |
| Verma, M | 1 |
| Singh, TD | 1 |
| Balan, G | 1 |
| Barreiro, G | 1 |
| Boscoe, BP | 1 |
| Chenard, LK | 1 |
| Cianfrogna, J | 1 |
| Claffey, MM | 1 |
| Coffman, KJ | 1 |
| Drozda, SE | 1 |
| Dunetz, JR | 1 |
| Fonseca, KR | 1 |
| Galatsis, P | 1 |
| Grimwood, S | 1 |
| Lazzaro, JT | 1 |
| Mancuso, JY | 1 |
| Miller, EL | 1 |
| Reese, MR | 1 |
| Rogers, BN | 1 |
| Sakurada, I | 1 |
| Skaddan, M | 1 |
| Smith, DL | 1 |
| Stepan, AF | 1 |
| Trapa, P | 1 |
| Tuttle, JB | 1 |
| Verhoest, PR | 1 |
| Walker, DP | 1 |
| Wright, AS | 1 |
| Zaleska, MM | 1 |
| Zasadny, K | 1 |
| Shaffer, CL | 1 |
| Porras, G | 1 |
| De Deurwaerdere, P | 1 |
| Marti, M | 2 |
| Morgenstern, R | 1 |
| Sohr, R | 1 |
| Morari, M | 2 |
| Meissner, WG | 1 |
| Chou, VP | 2 |
| Ko, N | 1 |
| Holman, TR | 1 |
| Manning-Boğ, AB | 3 |
| Willis, GL | 2 |
| Armstrong, SM | 2 |
| Youn, JK | 1 |
| Kim, ST | 3 |
| Park, SY | 1 |
| Lee, HR | 1 |
| Cho, SW | 2 |
| Hwang, HS | 2 |
| Yan, T | 1 |
| Rizak, JD | 1 |
| Hu, X | 1 |
| Plangár, I | 1 |
| Zádori, D | 1 |
| Szalárdy, L | 1 |
| Vécsei, L | 2 |
| Klivényi, P | 2 |
| Ko, WK | 1 |
| Pérez-H, J | 1 |
| Carrillo-S, C | 1 |
| García, E | 1 |
| Ruiz-Mar, G | 1 |
| Pérez-Tamayo, R | 1 |
| Chavarría, A | 1 |
| Shin, JY | 2 |
| Kim, HN | 2 |
| Oh, SH | 2 |
| Lee, PH | 3 |
| Bové, J | 1 |
| Martínez-Vicente, M | 1 |
| Dehay, B | 1 |
| Perier, C | 4 |
| Recasens, A | 1 |
| Bombrun, A | 1 |
| Antonsson, B | 1 |
| Vila, M | 9 |
| Rekha, KR | 1 |
| Sikorska, M | 1 |
| Lanthier, P | 1 |
| Miller, H | 1 |
| Beyers, M | 1 |
| Sodja, C | 1 |
| Zurakowski, B | 1 |
| Gangaraju, S | 1 |
| Sandhu, JK | 1 |
| Karuppagounder, SS | 1 |
| Brahmachari, S | 2 |
| Dawson, VL | 2 |
| Dawson, TM | 2 |
| Ko, HS | 1 |
| Kanagaraj, N | 1 |
| Beiping, H | 1 |
| Dheen, ST | 1 |
| Tay, SS | 1 |
| Feng, G | 1 |
| Bao, Q | 1 |
| Jiang, J | 2 |
| Parsanejad, M | 1 |
| Qu, D | 1 |
| Irrcher, I | 1 |
| Rousseaux, MW | 1 |
| Aleyasin, H | 1 |
| Kamkar, F | 1 |
| Callaghan, S | 3 |
| Slack, RS | 4 |
| Mak, TW | 1 |
| Figeys, D | 1 |
| Park, DS | 5 |
| Johnston, TM | 1 |
| Fox, SH | 5 |
| Li, DW | 1 |
| Yao, M | 1 |
| Dong, YH | 1 |
| Tang, MN | 1 |
| Li, GR | 1 |
| Sun, BQ | 1 |
| Wei, Z | 3 |
| Sun, N | 1 |
| Mao, T | 1 |
| Yun, HM | 1 |
| Oh, KW | 2 |
| Ali, SJ | 1 |
| Rajini, PS | 1 |
| Wei, D | 1 |
| Yang, M | 1 |
| Kong, L | 1 |
| Wolff, EF | 1 |
| Mutlu, L | 1 |
| Massasa, EE | 1 |
| Eugene Redmond, D | 1 |
| Taylor, HS | 1 |
| Lee, JA | 1 |
| Kim, JH | 1 |
| Woo, SY | 1 |
| Son, HJ | 2 |
| Han, SH | 1 |
| Kim, DJ | 1 |
| Eom, SA | 1 |
| Ahn, EH | 2 |
| Chung, SY | 1 |
| Sohn, EJ | 1 |
| Jo, HS | 1 |
| Jeon, SJ | 1 |
| Kwon, HY | 1 |
| Rappold, PM | 1 |
| Grima, JC | 1 |
| Fan, RZ | 1 |
| de Mesy-Bentley, KL | 1 |
| Zhuang, X | 1 |
| Bowers, WJ | 1 |
| Tieu, K | 6 |
| Poulin, JF | 1 |
| Zou, J | 1 |
| Drouin-Ouellet, J | 1 |
| Kim, KY | 1 |
| Awatramani, RB | 1 |
| Peritore, C | 1 |
| Ginsberg, J | 1 |
| Shih, J | 1 |
| Arun, S | 1 |
| Donmez, G | 1 |
| Yano, R | 2 |
| Itoh, T | 2 |
| Yamada, M | 5 |
| Momoshima, S | 1 |
| Okano, HJ | 1 |
| Wales, P | 1 |
| Quinti, L | 1 |
| Zuo, F | 2 |
| Moniot, S | 2 |
| Herisson, F | 1 |
| Rauf, NA | 1 |
| Silverman, RB | 1 |
| Ayata, C | 1 |
| Maxwell, MM | 1 |
| Steegborn, C | 2 |
| Schwarzschild, MA | 2 |
| Outeiro, TF | 2 |
| Kazantsev, AG | 1 |
| Stojkovska, I | 1 |
| Wagner, BM | 1 |
| Morrison, BE | 1 |
| Takahashi-Niki, K | 1 |
| Inafune, A | 1 |
| Michitani, N | 1 |
| Hatakeyama, Y | 1 |
| Suzuki, K | 1 |
| Sasaki, M | 1 |
| Kitamura, Y | 3 |
| Niki, T | 1 |
| Iguchi-Ariga, SM | 1 |
| Ariga, H | 1 |
| Pan, J | 3 |
| Xiong, R | 1 |
| Kang, WY | 1 |
| Zhao, ZB | 1 |
| Chen, SD | 2 |
| Urs, NM | 1 |
| Peterson, SM | 1 |
| Daigle, TL | 1 |
| Bass, CE | 2 |
| Gainetdinov, RR | 2 |
| Caron, MG | 2 |
| Lu, XL | 1 |
| Lin, YH | 1 |
| Wu, Q | 1 |
| Su, FJ | 1 |
| Ye, CH | 1 |
| He, BX | 1 |
| Huang, FW | 1 |
| Pei, Z | 1 |
| Yao, XL | 1 |
| Hou, L | 1 |
| Gai, X | 1 |
| Lu, T | 1 |
| Lu, C | 1 |
| Hu, R | 1 |
| Li, K | 2 |
| Wang, YQ | 1 |
| Wang, MY | 1 |
| Fu, XR | 1 |
| Gao, GF | 1 |
| Fan, YM | 1 |
| Duan, XL | 1 |
| Zhao, BL | 1 |
| Chang, YZ | 1 |
| Shi, ZH | 1 |
| Prema, A | 1 |
| Janakiraman, U | 1 |
| Lim, CS | 1 |
| Seo, H | 1 |
| Park, CA | 1 |
| Zhuo, M | 1 |
| Kaang, BK | 1 |
| Lee, K | 1 |
| Guo, H | 2 |
| Shi, F | 2 |
| Yu, B | 1 |
| Hu, L | 1 |
| Wang, XQ | 1 |
| Qiu, YH | 1 |
| Peng, YP | 1 |
| Lv, E | 1 |
| Gong, X | 1 |
| Jia, J | 1 |
| Ray, A | 1 |
| Sehgal, N | 1 |
| Karunakaran, S | 2 |
| Rangarajan, G | 1 |
| Ravindranath, V | 2 |
| Mounsey, RB | 2 |
| Mustafa, S | 2 |
| Robinson, L | 1 |
| Ross, RA | 1 |
| Pertwee, RG | 1 |
| Choi, JS | 3 |
| Bae, WY | 1 |
| Park, C | 2 |
| Jeong, JW | 3 |
| Lv, L | 1 |
| Feng, YM | 1 |
| Li, GD | 1 |
| Zhou, HJ | 1 |
| Lei, XG | 1 |
| Li, JL | 1 |
| Hu, XT | 1 |
| Xu, X | 1 |
| Song, N | 2 |
| Wang, R | 1 |
| Jiang, H | 2 |
| Binukumar, BK | 1 |
| Shukla, V | 1 |
| Amin, ND | 1 |
| Grant, P | 1 |
| Bhaskar, M | 1 |
| Skuntz, S | 1 |
| Steiner, J | 1 |
| Pant, HC | 1 |
| Li, L | 1 |
| Schildknecht, S | 1 |
| Pape, R | 1 |
| Meiser, J | 1 |
| Karreman, C | 1 |
| Strittmatter, T | 1 |
| Odermatt, M | 1 |
| Cirri, E | 1 |
| Friemel, A | 1 |
| Ringwald, M | 1 |
| Pasquarelli, N | 1 |
| Ferger, B | 3 |
| Brunner, T | 1 |
| Marx, A | 1 |
| Möller, HM | 1 |
| Hiller, K | 1 |
| Leist, M | 1 |
| Filali, M | 1 |
| Lalonde, R | 1 |
| Dovero, S | 2 |
| Gross, C | 2 |
| Bae, N | 1 |
| Oh, MS | 6 |
| Keane, H | 1 |
| Ryan, BJ | 1 |
| Jackson, B | 1 |
| Whitmore, A | 1 |
| Wade-Martins, R | 1 |
| Qu, HD | 2 |
| Singh, D | 1 |
| Menon, SA | 1 |
| Al-Mansoori, KM | 1 |
| Al-Wandi, A | 1 |
| Majbour, NK | 1 |
| Varghese, S | 1 |
| Vaikath, NN | 1 |
| Azzouz, M | 1 |
| El-Agnaf, OM | 1 |
| Mandal, S | 1 |
| Mandal, SD | 1 |
| Chuttani, K | 1 |
| Sawant, KK | 1 |
| Subudhi, BB | 1 |
| Zhang, QS | 2 |
| Mu, Z | 1 |
| Hu, JF | 1 |
| Yang, B | 2 |
| Fang, F | 1 |
| Thiollier, T | 1 |
| Wu, C | 1 |
| Contamin, H | 1 |
| Xu, S | 1 |
| Du, N | 1 |
| Han, M | 1 |
| Mitra, S | 1 |
| Ghosh, N | 1 |
| Sinha, P | 1 |
| Chakrabarti, N | 1 |
| Bhattacharyya, A | 1 |
| Hwang, CJ | 1 |
| Jung, YY | 1 |
| Lee, YJ | 1 |
| Yun, JS | 1 |
| Han, SB | 1 |
| Oh, S | 1 |
| Park, MH | 1 |
| Lauretti, E | 1 |
| Di Meco, A | 1 |
| Merali, S | 1 |
| Praticò, D | 1 |
| Maetzler, W | 2 |
| Stathakos, P | 1 |
| Martin, HL | 2 |
| Hobert, MA | 1 |
| Rattay, TW | 1 |
| Gasser, T | 1 |
| Forrester, JV | 1 |
| Berg, D | 3 |
| Tracey, KJ | 1 |
| Quek, CY | 1 |
| Hung, LW | 1 |
| Sharples, RA | 1 |
| Sherratt, NA | 1 |
| Barnham, KJ | 1 |
| Hill, AF | 1 |
| Ren, YD | 1 |
| Jing, YE | 1 |
| Zhang, SX | 1 |
| Lu, F | 2 |
| Liu, SM | 2 |
| Miville-Godbout, E | 1 |
| Al-Sweidi, S | 1 |
| Smith, T | 1 |
| Mochizuki, A | 1 |
| Senanayake, V | 1 |
| Jayasinghe, D | 1 |
| Goodenowe, D | 1 |
| Chao, PC | 1 |
| Lee, HL | 1 |
| Yin, MC | 2 |
| Franke, SK | 1 |
| van Kesteren, RE | 1 |
| Hofman, S | 1 |
| Wubben, JA | 1 |
| Smit, AB | 2 |
| Philippens, IH | 2 |
| Hopes, L | 1 |
| Grolez, G | 1 |
| Lopes, R | 1 |
| Ryckewaert, G | 1 |
| Carrière, N | 1 |
| Petrault, M | 1 |
| Jissendi, P | 1 |
| Delmaire, C | 1 |
| Morin, N | 1 |
| Grégoire, L | 2 |
| Rajput, A | 1 |
| Rajput, AH | 1 |
| Kumar, AS | 1 |
| Jagadeeshan, S | 1 |
| Subramanian, A | 1 |
| Surabhi, RP | 1 |
| Singhal, M | 1 |
| Bhoopalan, H | 1 |
| Pitani, RS | 1 |
| Duvuru, P | 1 |
| Venkatraman, G | 1 |
| Rayala, SK | 1 |
| Kucheryanu, VG | 2 |
| Cataldi, S | 1 |
| Codini, M | 1 |
| Hunot, S | 5 |
| Légeron, FP | 1 |
| Ferri, I | 1 |
| Siccu, P | 1 |
| Sidoni, A | 1 |
| Ambesi-Impiombato, FS | 1 |
| Beccari, T | 1 |
| Curcio, F | 1 |
| Albi, E | 1 |
| Giacoppo, S | 1 |
| Rajan, TS | 1 |
| De Nicola, GR | 1 |
| Iori, R | 1 |
| Rollin, P | 1 |
| Bramanti, P | 1 |
| Mazzon, E | 1 |
| Zhang, LX | 1 |
| Sun, XY | 1 |
| Ren, ZX | 1 |
| Zhao, YF | 1 |
| Moro, C | 1 |
| Darlot, F | 1 |
| Torres, N | 1 |
| Chabrol, C | 1 |
| Agay, D | 1 |
| Auboiroux, V | 1 |
| Benabid, AL | 5 |
| Friedemann, T | 1 |
| Ying, Y | 1 |
| Kramer, ER | 1 |
| Schumacher, U | 1 |
| Schröder, S | 1 |
| Wang, ZH | 1 |
| Zhang, JL | 1 |
| Duan, YL | 1 |
| Li, GF | 1 |
| Zheng, DL | 1 |
| Shi, X | 1 |
| Mewes, K | 1 |
| Gross, RE | 1 |
| DeLong, MR | 3 |
| Hain, EG | 1 |
| Klein, C | 1 |
| Munder, T | 1 |
| Braun, J | 1 |
| Riek, K | 1 |
| Mueller, S | 1 |
| Sack, I | 1 |
| Steiner, B | 1 |
| Iskhakova, L | 1 |
| Katabi, S | 1 |
| Haber, SN | 3 |
| Li, YH | 1 |
| Xi, JY | 1 |
| Yu, WB | 1 |
| Liu, JC | 1 |
| Song, LJ | 1 |
| Feng, L | 1 |
| Yan, YP | 1 |
| Zhang, GX | 1 |
| Xiao-Feng, L | 1 |
| Wen-Ting, Z | 1 |
| Yuan-Yuan, X | 1 |
| Chong-Fa, L | 1 |
| Jin-Jun, R | 1 |
| Wen-Ya, W | 1 |
| Sampaio, TB | 1 |
| Marcondes Sari, MH | 1 |
| Pesarico, AP | 1 |
| Nogueira, CW | 1 |
| Yu, C | 1 |
| Kim, E | 1 |
| Gu, PS | 1 |
| Moon, M | 1 |
| Choi, JG | 2 |
| Jiang, M | 1 |
| Yun, Q | 1 |
| Niu, G | 1 |
| Komnig, D | 1 |
| Imgrund, S | 1 |
| Reich, A | 1 |
| Gründer, S | 1 |
| Falkenburger, BH | 3 |
| Liao, S | 1 |
| Quan, H | 1 |
| Yang, Q | 1 |
| Shadfar, S | 1 |
| Kim, YG | 1 |
| Katila, N | 1 |
| Neupane, S | 1 |
| Bhurtel, S | 1 |
| Srivastav, S | 1 |
| Jeong, GS | 1 |
| Kim, KS | 1 |
| Zhao, TT | 1 |
| Shin, KS | 1 |
| Cho, YJ | 1 |
| Lee, KE | 1 |
| Lee, MK | 1 |
| Cai, W | 1 |
| Maguire, M | 1 |
| Ya, B | 1 |
| Logan, R | 1 |
| Robinson, K | 1 |
| Vanderburg, CR | 1 |
| Fisher, DE | 1 |
| Jing, H | 1 |
| Viveros-Paredes, JM | 1 |
| Gonzalez-Castañeda, RE | 1 |
| Escalante-Castañeda, A | 1 |
| Tejeda-Martínez, AR | 1 |
| Castañeda-Achutiguí, F | 1 |
| Flores-Soto, ME | 1 |
| Shen, XL | 1 |
| Du, XX | 1 |
| Xie, JX | 1 |
| Meng, X | 1 |
| Tong, H | 1 |
| Qu, S | 2 |
| Giri, A | 1 |
| Lei, M | 1 |
| Chen, XH | 1 |
| Teng, JJ | 1 |
| de Oliveira, RM | 1 |
| Vicente Miranda, H | 1 |
| Francelle, L | 1 |
| Pinho, R | 1 |
| Szegö, ÉM | 1 |
| Martinho, R | 1 |
| Munari, F | 1 |
| Lázaro, DF | 1 |
| Guerreiro, P | 1 |
| Fonseca-Ornelas, L | 1 |
| Marijanovic, Z | 1 |
| Antas, P | 1 |
| Gerhardt, E | 1 |
| Enguita, FJ | 1 |
| Fauvet, B | 1 |
| Penque, D | 1 |
| Pais, TF | 1 |
| Becker, S | 1 |
| Kügler, S | 1 |
| Lashuel, HA | 1 |
| Zweckstetter, M | 1 |
| Weng, CC | 1 |
| Chen, ZA | 1 |
| Chao, KT | 1 |
| Ee, TW | 1 |
| Lin, KJ | 3 |
| Chan, MH | 1 |
| Hsiao, IT | 1 |
| Yen, TC | 2 |
| Kung, MP | 1 |
| Hsu, CH | 1 |
| Wey, SP | 2 |
| Langston, JW | 18 |
| Castro-Hernández, J | 1 |
| Al Sweidi, S | 1 |
| Callier, S | 1 |
| Natale, G | 1 |
| Pasquali, L | 2 |
| Ruggieri, S | 2 |
| Paparelli, A | 2 |
| Fornai, F | 2 |
| Meredith, GE | 3 |
| Totterdell, S | 2 |
| Potashkin, JA | 1 |
| Surmeier, DJ | 2 |
| Kim, YJ | 2 |
| Moon, W | 3 |
| Chae, Y | 3 |
| Kang, M | 1 |
| Chung, MY | 1 |
| Hong, MS | 1 |
| Chung, JH | 1 |
| Joh, TH | 3 |
| Muñoz, A | 1 |
| Gardoni, F | 1 |
| Marcello, E | 1 |
| Qin, C | 1 |
| Carlsson, T | 1 |
| Kirik, D | 2 |
| Di Luca, M | 1 |
| Björklund, A | 2 |
| Carta, M | 1 |
| Wang, YY | 2 |
| Wang, QD | 1 |
| Yuan, ZY | 1 |
| Zhang, ZX | 1 |
| Gu, P | 1 |
| Wang, MW | 1 |
| Samantaray, S | 2 |
| Butler, JT | 1 |
| Ray, SK | 1 |
| Banik, NL | 1 |
| Ruffoli, R | 1 |
| Soldani, P | 1 |
| Saeed, U | 1 |
| Mishra, M | 1 |
| Valli, RK | 1 |
| Joshi, SD | 1 |
| Meka, DP | 1 |
| Seth, P | 1 |
| Byler, SL | 1 |
| Boehm, GW | 1 |
| Karp, JD | 1 |
| Kohman, RA | 1 |
| Tarr, AJ | 1 |
| Schallert, T | 1 |
| Barth, TM | 1 |
| Boehmler, W | 1 |
| Petko, J | 1 |
| Woll, M | 1 |
| Frey, C | 1 |
| Thisse, B | 1 |
| Thisse, C | 1 |
| Canfield, VA | 1 |
| Levenson, R | 1 |
| Takagi, Y | 2 |
| Saiki, H | 2 |
| Vázquez-Claverie, M | 1 |
| Garrido-Gil, P | 1 |
| San Sebastián, W | 1 |
| Belzunegui, S | 1 |
| Izal-Azcárate, A | 1 |
| López, B | 1 |
| Pothakos, K | 2 |
| Kurz, MJ | 2 |
| Lau, YS | 5 |
| Perry, T | 1 |
| Kindy, MS | 1 |
| Harvey, BK | 1 |
| Tweedie, D | 1 |
| Holloway, HW | 1 |
| Powers, K | 1 |
| Shen, H | 1 |
| Egan, JM | 1 |
| Sambamurti, K | 1 |
| Brossi, A | 1 |
| Lahiri, DK | 1 |
| Mattson, MP | 3 |
| Hoffer, BJ | 2 |
| Greig, NH | 1 |
| Vargas, MR | 1 |
| Pani, AK | 1 |
| Smeyne, RJ | 2 |
| Johnson, DA | 1 |
| Kan, YW | 1 |
| Johnson, JA | 1 |
| Yokoyama, H | 2 |
| Kuroiwa, H | 1 |
| Kato, H | 1 |
| Araki, T | 2 |
| Eberling, JL | 1 |
| Kells, AP | 2 |
| Pivirotto, P | 4 |
| Beyer, J | 2 |
| Bringas, J | 3 |
| Federoff, HJ | 4 |
| Forsayeth, J | 2 |
| Bankiewicz, KS | 4 |
| Santiago, M | 1 |
| Hernández-Romero, MC | 1 |
| Machado, A | 1 |
| Cano, J | 1 |
| Zheng, XW | 1 |
| Qin, GW | 1 |
| Gai, Y | 1 |
| Jiang, ZH | 1 |
| Guo, LH | 1 |
| Shan, S | 1 |
| Hong-Min, T | 1 |
| Yi, F | 1 |
| Jun-Peng, G | 1 |
| Yan-Hong, T | 1 |
| Yun-Ke, Y | 1 |
| Wen-Wei, L | 1 |
| Xiang-Yu, W | 1 |
| Jun, M | 1 |
| Guo-Hua, W | 1 |
| Ya-Ling, H | 1 |
| Hua-Wei, L | 1 |
| Ding-Fang, C | 1 |
| Verhave, PS | 1 |
| Vanwersch, RA | 1 |
| van Helden, HP | 1 |
| Kasture, S | 1 |
| Pontis, S | 2 |
| Pinna, A | 2 |
| Schintu, N | 2 |
| Spina, L | 1 |
| Longoni, R | 1 |
| Simola, N | 2 |
| Ballero, M | 1 |
| Marazziti, D | 1 |
| Di Pietro, C | 1 |
| Golini, E | 1 |
| Mandillo, S | 1 |
| Matteoni, R | 1 |
| Tocchini-Valentini, GP | 1 |
| Dluzen, DE | 2 |
| Sheng, CY | 1 |
| Hong, Z | 1 |
| Yang, HQ | 1 |
| Ding, JQ | 1 |
| Simon, A | 1 |
| Kirkham, M | 1 |
| Calingasan, NY | 1 |
| Wille, EJ | 1 |
| Cormier, K | 2 |
| Smith, K | 2 |
| Ferrante, RJ | 2 |
| Beal, MF | 9 |
| Singh, K | 2 |
| Patel, DK | 1 |
| Singh, C | 1 |
| Nath, C | 1 |
| Singh, VK | 1 |
| Singh, RK | 1 |
| Singh, MP | 2 |
| Winnik, B | 1 |
| Barr, DB | 1 |
| Thiruchelvam, M | 1 |
| Montesano, MA | 1 |
| Richfield, EK | 2 |
| Buckley, B | 1 |
| Fukumitsu, N | 1 |
| Suzuki, M | 1 |
| Fukuda, T | 2 |
| Kiyono, Y | 1 |
| Barber-Singh, J | 1 |
| Seo, BB | 2 |
| Nakamaru-Ogiso, E | 2 |
| Matsuno-Yagi, A | 2 |
| Yagi, T | 2 |
| Su, X | 1 |
| Huang, EJ | 1 |
| Lee, HS | 1 |
| Hadaczek, P | 2 |
| Penticuff, J | 1 |
| Eberling, J | 1 |
| Lee, DW | 1 |
| Rajagopalan, S | 2 |
| Siddiq, A | 1 |
| Gwiazda, R | 1 |
| Ratan, RR | 1 |
| Andersen, JK | 2 |
| Prediger, RD | 2 |
| Rial, D | 1 |
| Medeiros, R | 1 |
| Figueiredo, CP | 1 |
| Doty, RL | 2 |
| Takahashi, RN | 1 |
| Selvaraj, S | 1 |
| Watt, JA | 1 |
| Singh, BB | 1 |
| Vautier, S | 1 |
| Milane, A | 1 |
| Fernandez, C | 1 |
| Chacun, H | 1 |
| Lacomblez, L | 1 |
| Farinotti, R | 1 |
| Fujita, K | 1 |
| Seike, T | 1 |
| Yutsudo, N | 1 |
| Ohno, M | 1 |
| Yamada, H | 1 |
| Yamaguchi, H | 1 |
| Sakumi, K | 1 |
| Yamakawa, Y | 1 |
| Kido, MA | 1 |
| Takaki, A | 1 |
| Katafuchi, T | 1 |
| Tanaka, Y | 1 |
| Nakabeppu, Y | 1 |
| Noda, M | 1 |
| Ono, S | 1 |
| Hirai, K | 1 |
| Tokuda, E | 1 |
| Kalivendi, SV | 1 |
| Yedlapudi, D | 1 |
| Hillard, CJ | 1 |
| Kalyanaraman, B | 1 |
| Roy, A | 2 |
| Matras, J | 1 |
| Gendelman, HE | 2 |
| Pahan, K | 2 |
| Shaw, VE | 1 |
| Spana, S | 1 |
| Ashkan, K | 3 |
| Baker, GE | 1 |
| Matusch, A | 1 |
| Depboylu, C | 2 |
| Palm, C | 1 |
| Wu, B | 1 |
| Höglinger, GU | 2 |
| Schäfer, MK | 1 |
| Becker, JS | 1 |
| Tronci, E | 1 |
| Volpini, R | 1 |
| Cristalli, G | 1 |
| Qian, J | 1 |
| Kawamata, J | 1 |
| Takeuchi, H | 1 |
| Doo, AR | 3 |
| Kim, SN | 3 |
| Yin, CS | 1 |
| Park, HK | 1 |
| Sun, S | 2 |
| Shu, D | 1 |
| He, J | 1 |
| Villalba, RM | 1 |
| Raju, DV | 1 |
| Malagelada, C | 1 |
| Jin, ZH | 1 |
| Greene, LA | 1 |
| Singhal, NK | 1 |
| Sharma, A | 1 |
| Parmar, D | 1 |
| Lee, MS | 1 |
| McCollum, M | 1 |
| Ma, Z | 1 |
| Cohen, E | 1 |
| Leon, R | 1 |
| Tao, R | 1 |
| Wu, JY | 1 |
| Maharaj, D | 1 |
| Wei, J | 1 |
| Gorton, LM | 1 |
| Vuckovic, MG | 1 |
| Vertelkina, N | 1 |
| Petzinger, GM | 3 |
| Jakowec, MW | 3 |
| Wood, RI | 1 |
| Camins, A | 1 |
| Pizarro, JG | 1 |
| Alvira, D | 1 |
| Gutierrez-Cuesta, J | 1 |
| de la Torre, AV | 1 |
| Folch, J | 1 |
| Sureda, FX | 1 |
| Verdaguer, E | 1 |
| Junyent, F | 1 |
| Jordán, J | 1 |
| Ferrer, I | 1 |
| Pallàs, M | 1 |
| Bazzu, G | 1 |
| Calia, G | 1 |
| Puggioni, G | 1 |
| Spissu, Y | 1 |
| Rocchitta, G | 3 |
| Debetto, P | 1 |
| Grigoletto, J | 1 |
| Zusso, M | 1 |
| Migheli, R | 1 |
| Serra, PA | 4 |
| Desole, MS | 3 |
| Miele, E | 3 |
| Biju, K | 1 |
| Roberts, JL | 1 |
| Morgan, WW | 1 |
| Muthian, G | 2 |
| Mackey, V | 2 |
| King, J | 1 |
| Charlton, CG | 1 |
| Al-Jarrah, M | 2 |
| Jamous, M | 1 |
| Al Zailaey, K | 1 |
| Bweir, SO | 1 |
| Ariza, D | 1 |
| Lima, MM | 2 |
| Moreira, CG | 1 |
| Dombrowski, PA | 1 |
| Avila, TV | 1 |
| Allemand, A | 1 |
| Mendes, DA | 1 |
| Da Cunha, C | 2 |
| Vital, MA | 2 |
| Kim, HG | 4 |
| Ju, MS | 2 |
| Kim, DH | 1 |
| Hong, J | 2 |
| Cho, SH | 1 |
| Cho, KH | 2 |
| Park, W | 1 |
| Lee, EH | 2 |
| Kim, SY | 4 |
| Eun-Kyung, K | 1 |
| Moon, SK | 1 |
| Jung, WS | 1 |
| Innamorato, NG | 1 |
| Jazwa, A | 1 |
| Rojo, AI | 2 |
| García, C | 1 |
| Fernández-Ruiz, J | 2 |
| Grochot-Przeczek, A | 1 |
| Stachurska, A | 1 |
| Jozkowicz, A | 1 |
| Dulak, J | 1 |
| Cuadrado, A | 2 |
| Rivlin-Etzion, M | 1 |
| Elias, S | 1 |
| Heimer, G | 1 |
| Akazawa, YO | 1 |
| Saito, Y | 1 |
| Hamakubo, T | 1 |
| Masuo, Y | 1 |
| Yoshida, Y | 1 |
| Nishio, K | 1 |
| Shichiri, M | 1 |
| Miyasaka, T | 1 |
| Iwanari, H | 1 |
| Mochizuki, Y | 1 |
| Kodama, T | 1 |
| Noguchi, N | 1 |
| Niki, E | 1 |
| Khaindrava, VG | 2 |
| Ershov, PV | 1 |
| Antsiperov, VE | 1 |
| Obukhov, IuV | 1 |
| Nanaev, AK | 2 |
| Ugriumov, MV | 1 |
| Rylander, D | 1 |
| O'Sullivan, SS | 1 |
| Lees, AJ | 1 |
| Descarries, L | 1 |
| Cenci, MA | 1 |
| Tsai, SJ | 1 |
| Kuo, WW | 1 |
| Liu, WH | 1 |
| Huang, YM | 1 |
| Kida, K | 2 |
| Amutuhaire, W | 1 |
| Ichinose, F | 2 |
| Kaneki, M | 2 |
| Tokuda, K | 1 |
| Marutani, E | 1 |
| Kakinohana, M | 1 |
| Impagnatiello, F | 1 |
| Morale, MC | 4 |
| Ho, G | 1 |
| Santaniello, S | 2 |
| Gale, JT | 2 |
| Montgomery, EB | 2 |
| Sarma, SV | 2 |
| Kim, MC | 1 |
| Yang, WM | 1 |
| Huh, Y | 1 |
| Rieker, C | 1 |
| Engblom, D | 1 |
| Kreiner, G | 1 |
| Domanskyi, A | 2 |
| Schober, A | 2 |
| Stotz, S | 1 |
| Neumann, M | 2 |
| Grummt, I | 1 |
| Schütz, G | 2 |
| Parlato, R | 2 |
| Zimin, IA | 1 |
| Kapitsa, IG | 1 |
| Voronina, TA | 1 |
| Kovalev, GI | 1 |
| Chi, Y | 1 |
| Wen, X | 1 |
| Kong, H | 1 |
| Sonoda, L | 1 |
| Tripathi, P | 1 |
| Li, CJ | 1 |
| Yu, MS | 1 |
| Su, C | 1 |
| Erez, Y | 1 |
| Tischler, H | 1 |
| Belelovsky, K | 1 |
| Bar-Gad, I | 1 |
| Aguiar, AS | 1 |
| Moreira, EL | 1 |
| Matheus, FC | 1 |
| Castro, AA | 1 |
| Walz, R | 1 |
| De Bem, AF | 1 |
| Latini, A | 1 |
| Tasca, CI | 1 |
| Farina, M | 1 |
| Raisman-Vozari, R | 1 |
| Mythri, RB | 1 |
| Veena, J | 1 |
| Harish, G | 1 |
| Shankaranarayana Rao, BS | 1 |
| Srinivas Bharath, MM | 1 |
| Ardashov, OV | 1 |
| Pavlova, AV | 1 |
| Il'ina, IV | 1 |
| Morozova, EA | 1 |
| Korchagina, DV | 1 |
| Karpova, EV | 1 |
| Volcho, KP | 1 |
| Tolstikova, TG | 1 |
| Salakhutdinov, NF | 1 |
| Jiao, XY | 1 |
| Duan, L | 1 |
| Yu, J | 1 |
| Lee, MJ | 1 |
| Lee, BH | 1 |
| Han, HS | 1 |
| Geissler, C | 1 |
| Vinnikov, IA | 1 |
| Alter, H | 1 |
| Vogt, MA | 1 |
| Gass, P | 1 |
| Huh, SH | 1 |
| Jin, MY | 1 |
| Yoon, NS | 1 |
| Hong, JY | 1 |
| Kim, YS | 2 |
| Hong, JK | 1 |
| Pu, XP | 1 |
| King, JM | 1 |
| Vezoli, J | 1 |
| Leviel, V | 1 |
| Dehay, C | 1 |
| Kennedy, H | 1 |
| Gronfier, C | 1 |
| Procyk, E | 1 |
| Shchepinov, MS | 1 |
| Pollock, E | 1 |
| Cantor, CR | 1 |
| Molinari, RJ | 1 |
| Mudò, G | 1 |
| Mäkelä, J | 1 |
| Di Liberto, V | 1 |
| Tselykh, TV | 1 |
| Olivieri, M | 1 |
| Piepponen, P | 1 |
| Eriksson, O | 1 |
| Mälkiä, A | 1 |
| Bonomo, A | 1 |
| Kairisalo, M | 1 |
| Aguirre, JA | 1 |
| Korhonen, L | 1 |
| Belluardo, N | 1 |
| Lindholm, D | 1 |
| Tremblay, L | 2 |
| Xilouri, M | 1 |
| Kyratzi, E | 1 |
| Pitychoutis, PM | 1 |
| Papadopoulou-Daifoti, Z | 1 |
| Maniati, M | 1 |
| Ulusoy, A | 1 |
| Wada, K | 1 |
| Stefanis, L | 1 |
| Bae, H | 2 |
| Shim, I | 1 |
| Lee, JM | 1 |
| Hwang, DS | 1 |
| Lee, CH | 1 |
| Goldberg, NR | 1 |
| Fields, V | 1 |
| Pflibsen, L | 1 |
| Salvatore, MF | 1 |
| Soreq, L | 1 |
| Ben-Shaul, Y | 1 |
| Soreq, H | 1 |
| Klodt, PD | 1 |
| Bocharov, EV | 1 |
| Kryzhanovsky, GN | 1 |
| Raevskii, KS | 1 |
| Blandini, F | 1 |
| Armentero, MT | 1 |
| Deleidi, M | 1 |
| Tian, L | 1 |
| Karimi, M | 1 |
| Loftin, SK | 1 |
| Brown, CA | 1 |
| Xia, H | 1 |
| Mach, RH | 1 |
| Perlmutter, JS | 1 |
| Lee, JD | 1 |
| Huang, CH | 1 |
| Yang, ST | 1 |
| Chu, YH | 1 |
| Shieh, YY | 1 |
| Chen, JW | 1 |
| Li, XZ | 1 |
| Huo, Y | 1 |
| Frank, T | 1 |
| Klinker, F | 1 |
| Laage, R | 1 |
| Lühder, F | 1 |
| Göricke, B | 1 |
| Schneider, A | 1 |
| Neurath, H | 1 |
| Desel, H | 1 |
| Liebetanz, D | 1 |
| Weishaupt, JH | 3 |
| Tasaki, Y | 2 |
| Yamamoto, J | 1 |
| Omura, T | 1 |
| Sakaguchi, T | 1 |
| Kimura, N | 1 |
| Ohtaki, K | 1 |
| Ono, T | 1 |
| Suno, M | 1 |
| Asari, M | 1 |
| Ohkubo, T | 1 |
| Noda, T | 2 |
| Awaya, T | 1 |
| Shimizu, K | 1 |
| Matsubara, K | 2 |
| Koprich, JB | 1 |
| Aman, A | 1 |
| Sheline, CT | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Hacioglu, G | 1 |
| Seval-Celik, Y | 1 |
| Ozsoy, O | 1 |
| Saka-Topcuoglu, E | 1 |
| Balkan, S | 1 |
| Agar, A | 1 |
| Marxreiter, F | 1 |
| Regensburger, M | 1 |
| Winkler, J | 1 |
| Henderson, CJ | 1 |
| Wolf, CR | 1 |
| Rodrigues, CM | 1 |
| Grueter, BA | 1 |
| Malenka, RC | 1 |
| Steinberg, GK | 1 |
| Cho, KI | 1 |
| Searle, K | 1 |
| Webb, M | 1 |
| Yi, H | 1 |
| Ferreira, PA | 1 |
| Ha, SK | 1 |
| Yuan, HH | 1 |
| Chen, RJ | 1 |
| Zhu, YH | 1 |
| Peng, CL | 1 |
| Zhu, XR | 1 |
| Chung, ES | 1 |
| Lee, G | 1 |
| De Jesús-Cortés, H | 1 |
| Drawbridge, J | 1 |
| Estill, SJ | 1 |
| Huntington, P | 1 |
| Tran, S | 1 |
| Britt, J | 1 |
| Tesla, R | 1 |
| Morlock, L | 1 |
| Naidoo, J | 1 |
| Melito, LM | 1 |
| Williams, NS | 1 |
| Ready, JM | 1 |
| McKnight, SL | 1 |
| Pieper, AA | 1 |
| Obayashi, S | 1 |
| Nagai, Y | 1 |
| Oh-Nishi, A | 1 |
| Minamimoto, T | 1 |
| Higuchi, M | 1 |
| Suhara, T | 1 |
| Morganti, JM | 1 |
| Nash, KR | 1 |
| Grimmig, BA | 1 |
| Ranjit, S | 1 |
| Small, B | 1 |
| Bickford, PC | 1 |
| Gemma, C | 1 |
| Kim, JJ | 1 |
| Kim, MK | 1 |
| Oh, NH | 1 |
| Park, PJ | 1 |
| Shin, YK | 1 |
| Kim, IH | 1 |
| Kang, TB | 1 |
| Lee, KH | 2 |
| Clark, J | 1 |
| Silvaggi, JM | 1 |
| Kiselak, T | 1 |
| Zheng, K | 1 |
| Clore, EL | 1 |
| Simon, DK | 1 |
| Sathe, K | 1 |
| Lang, JD | 1 |
| Fleckenstein, C | 1 |
| Schulte, C | 1 |
| Synofzik, M | 1 |
| Vukovic, Z | 1 |
| Itohara, S | 1 |
| Kim, YN | 1 |
| Kim, HR | 1 |
| Woo, SJ | 1 |
| Kim, SM | 1 |
| Carta, AR | 1 |
| Carboni, E | 1 |
| Spiga, S | 1 |
| Aron Badin, R | 1 |
| Spinnewyn, B | 1 |
| Gaillard, MC | 1 |
| Jan, C | 2 |
| Malgorn, C | 1 |
| Van Camp, N | 1 |
| Dollé, F | 1 |
| Guillermier, M | 1 |
| Boulet, S | 1 |
| Bertrand, A | 1 |
| Savasta, M | 1 |
| Auguet, M | 1 |
| Brouillet, E | 2 |
| Chabrier, PE | 1 |
| Hantraye, P | 4 |
| Hare, DJ | 1 |
| Doble, PA | 1 |
| Luk, KC | 1 |
| Rymar, VV | 1 |
| van den Munckhof, P | 1 |
| Nicolau, S | 1 |
| Steriade, C | 1 |
| Bifsha, P | 1 |
| Drouin, J | 1 |
| Sadikot, AF | 1 |
| Sun, HM | 2 |
| Gao, YS | 1 |
| Wu, HX | 1 |
| Gong, XG | 1 |
| Hwang, JJ | 1 |
| Liao, MH | 1 |
| Pan, WH | 1 |
| Chen, JC | 1 |
| Ting, G | 1 |
| Sriram, K | 1 |
| Matheson, JM | 1 |
| Benkovic, SA | 1 |
| Miller, DB | 1 |
| Luster, MI | 1 |
| O'Callaghan, JP | 1 |
| Pearce, RK | 2 |
| Smith, LA | 2 |
| Banerji, T | 1 |
| Scheel-Krüger, J | 1 |
| Dong, Z | 2 |
| Feldon, J | 1 |
| Büeler, H | 2 |
| Dauer, W | 1 |
| Kholodilov, N | 1 |
| Trillat, AC | 1 |
| Goodchild, R | 1 |
| Larsen, KE | 1 |
| Staal, R | 1 |
| Schmitz, Y | 1 |
| Yuan, CA | 1 |
| Rocha, M | 1 |
| Hersch, S | 1 |
| Sulzer, D | 1 |
| Burke, R | 1 |
| Hen, R | 1 |
| Petroske, E | 1 |
| Santa Cruz, K | 1 |
| Callison, RC | 1 |
| Lavasani, M | 1 |
| Korlipara, LV | 1 |
| Schapira, AH | 3 |
| Miller, JW | 1 |
| Orr, CF | 1 |
| Rowe, DB | 1 |
| Halliday, GM | 1 |
| Sugama, S | 2 |
| Cho, BP | 2 |
| DeGiorgio, LA | 1 |
| Lorenzl, S | 2 |
| Albers, DS | 1 |
| Volpe, BT | 1 |
| Eberhardt, O | 1 |
| Schulz, JB | 3 |
| Kunikowska, G | 2 |
| Cole, GM | 1 |
| Kaur, D | 1 |
| Yantiri, F | 1 |
| Mo, JQ | 1 |
| Boonplueang, R | 1 |
| Viswanath, V | 1 |
| Jacobs, R | 1 |
| DiMonte, D | 1 |
| Volitaskis, I | 1 |
| Ellerby, L | 1 |
| Cherny, RA | 1 |
| Broussolle, E | 1 |
| Thobois, S | 1 |
| Wu, DC | 3 |
| Naini, A | 2 |
| Murray, TK | 1 |
| Whalley, K | 1 |
| Robinson, CS | 1 |
| Ward, MA | 1 |
| Hicks, CA | 1 |
| Lodge, D | 1 |
| Vandergriff, JL | 1 |
| Baumbarger, P | 1 |
| Siuda, E | 1 |
| Gates, M | 1 |
| Ogden, AM | 1 |
| Skolnick, P | 1 |
| Zimmerman, DM | 1 |
| Nisenbaum, ES | 1 |
| Bleakman, D | 1 |
| O'Neill, MJ | 1 |
| Crocker, SJ | 2 |
| Smith, PD | 2 |
| Lamba, WR | 1 |
| Hayley, SP | 1 |
| Grimm, E | 1 |
| Callaghan, SM | 1 |
| Melloni, E | 1 |
| Robertson, GS | 1 |
| Anisman, H | 2 |
| Merali, Z | 1 |
| Momma, S | 1 |
| Carlen, M | 1 |
| Cassidy, RM | 1 |
| Johansson, CB | 1 |
| Brismar, H | 1 |
| Shupliakov, O | 1 |
| Frisen, J | 1 |
| Janson, AM | 1 |
| Asanuma, M | 1 |
| Miyazaki, I | 1 |
| Tsuji, T | 1 |
| Ogawa, N | 2 |
| Tsang, F | 1 |
| Soong, TW | 1 |
| Ischiropoulos, H | 1 |
| Youdim, MB | 6 |
| Höglinger, G | 1 |
| Rousselet, E | 1 |
| Breidert, T | 1 |
| Parain, K | 1 |
| Feger, J | 1 |
| Ruberg, M | 5 |
| Cohen-Salmon, C | 1 |
| Launay, JM | 1 |
| Tong, E | 1 |
| Caspersen, C | 1 |
| Yan, SD | 1 |
| Ramasamy, R | 1 |
| Henry, B | 2 |
| Crossman, AR | 5 |
| Jordan-Sciutto, KL | 1 |
| Hayley, S | 1 |
| Mount, MP | 1 |
| O'Hare, MJ | 1 |
| Bélanger, N | 1 |
| Hadj Tahar, A | 1 |
| Bédard, PJ | 3 |
| Zang, LY | 1 |
| Misra, HP | 1 |
| Meissner, W | 2 |
| Gross, CE | 4 |
| Harnack, D | 1 |
| Bioulac, B | 4 |
| Benazzouz, A | 2 |
| Yao, D | 1 |
| Gu, Z | 1 |
| Nakamura, T | 1 |
| Shi, ZQ | 1 |
| Gaston, B | 1 |
| Palmer, LA | 1 |
| Rockenstein, EM | 1 |
| Masliah, E | 1 |
| Uehara, T | 1 |
| Lipton, SA | 1 |
| Linazasoro, G | 2 |
| Chalimoniuk, M | 1 |
| Langfort, J | 1 |
| Lukacova, N | 1 |
| Marsala, J | 1 |
| Wallace, BA | 2 |
| Wolfer, DP | 1 |
| Lipp, HP | 1 |
| Maswood, N | 1 |
| Young, J | 1 |
| Tilmont, E | 1 |
| Gerhardt, GA | 2 |
| Roth, GS | 1 |
| Mattison, J | 1 |
| Lane, MA | 1 |
| Carson, RE | 1 |
| Cohen, RM | 1 |
| Mouton, PR | 1 |
| Quigley, C | 1 |
| Ingram, DK | 1 |
| Finch, CE | 1 |
| Kishi, Y | 1 |
| Fukuda, H | 2 |
| Okamoto, Y | 1 |
| Koyanagi, M | 1 |
| Ideguchi, M | 1 |
| Hayashi, H | 1 |
| Imazato, T | 1 |
| Kawasaki, H | 1 |
| Suemori, H | 1 |
| Omachi, S | 1 |
| Iida, H | 1 |
| Itoh, N | 1 |
| Nakatsuji, N | 1 |
| Sasai, Y | 1 |
| Hashimoto, N | 1 |
| Williams, AC | 3 |
| Ramsden, DB | 2 |
| Haobam, R | 1 |
| Sindhu, KM | 1 |
| Chandra, G | 1 |
| Mohanakumar, KP | 2 |
| Pennathur, S | 2 |
| Vonsattel, JP | 1 |
| Heinecke, JW | 2 |
| Leblois, A | 1 |
| Hansel, D | 1 |
| Boraud, T | 3 |
| Fitzpatrick, E | 1 |
| Shen, HY | 1 |
| He, JC | 1 |
| Huang, QY | 1 |
| Chen, JF | 1 |
| Mela, F | 1 |
| Fantin, M | 1 |
| Zucchini, S | 1 |
| Brown, JM | 1 |
| Witta, J | 1 |
| Di Benedetto, M | 1 |
| Buzas, B | 1 |
| Reinscheid, RK | 1 |
| Salvadori, S | 1 |
| Guerrini, R | 1 |
| Romualdi, P | 1 |
| Candeletti, S | 1 |
| Simonato, M | 1 |
| Cox, BM | 1 |
| Miller, RM | 1 |
| Miklossy, J | 1 |
| Doudet, DD | 1 |
| Schwab, C | 1 |
| McGeer, EG | 3 |
| McGeer, PL | 2 |
| Gennuso, F | 2 |
| Giaquinta, G | 1 |
| Kekesi, KA | 1 |
| Hartai, Z | 1 |
| Juhasz, G | 1 |
| Choi, HJ | 1 |
| Lee, SY | 1 |
| No, H | 1 |
| Kim, SW | 1 |
| Bai, LM | 1 |
| Cioni, S | 1 |
| Mazzarino, MC | 1 |
| McLaughlin, P | 1 |
| Ma, T | 1 |
| Hong, JS | 3 |
| Kovacs, M | 1 |
| Gomez-Ramirez, J | 1 |
| Visanji, NP | 1 |
| Novikova, L | 2 |
| Garris, BL | 1 |
| Garris, DR | 1 |
| Flotte, TR | 1 |
| Kohutnicka, M | 1 |
| Krauze, MT | 1 |
| Cunningham, J | 1 |
| Bankiewicz, K | 2 |
| Wang, JJ | 1 |
| Niu, DB | 1 |
| Li, KR | 1 |
| Kooncumchoo, P | 1 |
| Sharma, S | 1 |
| Porter, J | 1 |
| Govitrapong, P | 1 |
| Ebadi, M | 1 |
| Dietz, GP | 2 |
| Valbuena, PC | 1 |
| Dietz, B | 2 |
| Meuer, K | 2 |
| Müeller, P | 1 |
| Knaryan, VH | 1 |
| Varghese, M | 1 |
| Srinivasan, A | 2 |
| Galoyan, AA | 1 |
| Carvey, PM | 1 |
| Punati, A | 1 |
| Newman, MB | 1 |
| Soderstrom, K | 1 |
| O'Malley, J | 1 |
| Steece-Collier, K | 2 |
| Kordower, JH | 5 |
| von Bohlen Und Halbach, O | 1 |
| He, XJ | 1 |
| Nakayama, H | 1 |
| Yamauchi, H | 1 |
| Ueno, M | 1 |
| Uetsuka, K | 1 |
| Doi, K | 1 |
| Takano, K | 1 |
| Tabata, Y | 1 |
| Kitao, Y | 1 |
| Murakami, R | 1 |
| Suzuki, H | 1 |
| Iinuma, M | 1 |
| Yoneda, Y | 1 |
| Ogawa, S | 1 |
| Hori, O | 1 |
| Gal, S | 1 |
| Fridkin, M | 1 |
| Amit, T | 1 |
| Montero, C | 1 |
| Salazar, M | 1 |
| Close, RM | 1 |
| Sánchez-González, MA | 1 |
| de Sagarra, MR | 1 |
| Hallett, PJ | 1 |
| Khan, SZ | 1 |
| Choi, DH | 1 |
| Block, ML | 1 |
| Browne, SE | 1 |
| Shin, EJ | 1 |
| Pang, H | 1 |
| Wie, MB | 1 |
| Kim, WK | 1 |
| Kim, SJ | 1 |
| Huang, WH | 1 |
| Kim, HC | 1 |
| Witt, SN | 1 |
| Flower, TR | 1 |
| Kim, JM | 2 |
| Jeon, YJ | 1 |
| Oh, JH | 1 |
| Jeong, SY | 1 |
| Song, IS | 1 |
| Kim, NS | 1 |
| Ferro, MM | 1 |
| Angelucci, ME | 1 |
| Anselmo-Franci, JA | 1 |
| Canteras, NS | 1 |
| Breunig, JJ | 1 |
| Rouaux, C | 1 |
| Boutillier, AL | 1 |
| Degregori, J | 1 |
| Rakic, P | 1 |
| Chan, CS | 1 |
| Guzman, JN | 1 |
| Ilijic, E | 1 |
| Mercer, JN | 1 |
| Rick, C | 1 |
| Tkatch, T | 1 |
| Khandhar, SM | 1 |
| Marks, WJ | 1 |
| Cao, X | 1 |
| Hadcock, JR | 1 |
| Iredale, PA | 1 |
| Griffith, DA | 1 |
| Menniti, FS | 1 |
| Factor, S | 1 |
| Greenamyre, JT | 2 |
| Bogaerts, V | 1 |
| Theuns, J | 1 |
| van Broeckhoven, C | 1 |
| Emborg, ME | 3 |
| Wang, YS | 1 |
| Zhou, JP | 1 |
| Wei, ZF | 1 |
| Tian, QY | 1 |
| Zhou, HX | 1 |
| Smirnova, IV | 1 |
| Stehno-Bittel, L | 1 |
| Iwata, S | 2 |
| Nomoto, M | 2 |
| Miyata, A | 1 |
| Reksidler, AB | 1 |
| Dombrowski, P | 1 |
| Andersen, ML | 1 |
| Zanata, SM | 1 |
| Andreatini, R | 1 |
| Tufik, S | 1 |
| Mocchetti, I | 1 |
| Bachis, A | 1 |
| Nosheny, RL | 1 |
| Tanda, G | 1 |
| Stockhausen, KV | 1 |
| Valbuena, P | 1 |
| Opazo, F | 1 |
| Mufson, EJ | 1 |
| Hartley, DM | 1 |
| Mosley, RL | 1 |
| Stack, EC | 1 |
| Ferro, JL | 1 |
| Del Signore, SJ | 1 |
| Goodrich, S | 1 |
| Matson, S | 1 |
| Hunt, BB | 1 |
| Matson, WR | 1 |
| Ryu, H | 1 |
| Thomas, KJ | 1 |
| D'Souza, C | 1 |
| Fraser, P | 1 |
| Cookson, MR | 1 |
| Tandon, A | 1 |
| Miller, RL | 1 |
| James-Kracke, M | 1 |
| Sun, GY | 1 |
| Sun, AY | 1 |
| Rajeswari, A | 1 |
| Sabesan, M | 1 |
| Burns, RS | 3 |
| Chiueh, CC | 1 |
| Markey, SP | 2 |
| Ebert, MH | 2 |
| Jacobowitz, DM | 2 |
| Kopin, IJ | 4 |
| Bannon, MJ | 1 |
| Goedert, M | 1 |
| Williams, B | 1 |
| Parsons, B | 2 |
| Rainbow, TC | 2 |
| Sahgal, A | 1 |
| Andrews, JS | 1 |
| Biggins, JA | 1 |
| Candy, JM | 1 |
| Edwardson, JA | 1 |
| Keith, AB | 1 |
| Turner, JD | 1 |
| Wright, C | 1 |
| Lang, AE | 1 |
| Blair, RD | 1 |
| Kolata, G | 1 |
| Lewin, R | 5 |
| Forno, LS | 2 |
| Rebert, CS | 1 |
| Irwin, I | 4 |
| Tatton, WG | 1 |
| Eastman, MJ | 1 |
| Bedingham, W | 1 |
| Verrier, MC | 1 |
| Bruce, IC | 1 |
| Ballard, P | 1 |
| Huang, CC | 1 |
| Gnanalingham, KK | 1 |
| Milkowski, NA | 1 |
| Hunter, AJ | 1 |
| Marsden, CD | 10 |
| Singer, TP | 3 |
| Ramsay, RR | 2 |
| Ackrell, BA | 1 |
| Mizuno, Y | 5 |
| Ikebe, S | 1 |
| Nakagawa-Hattori, Y | 2 |
| Mochizuki, H | 2 |
| Tanaka, M | 1 |
| Ozawa, T | 1 |
| McNaught, KS | 1 |
| Altomare, C | 1 |
| Cellamare, S | 1 |
| Carotti, A | 1 |
| Thull, U | 1 |
| Carrupt, PA | 1 |
| Testa, B | 2 |
| Laguna, J | 3 |
| Guillén, J | 2 |
| Martínez-Lage, JM | 2 |
| Sawle, GV | 2 |
| Myers, R | 1 |
| Liptrot, J | 1 |
| Holdup, D | 1 |
| Phillipson, O | 1 |
| Lange, KW | 3 |
| Rausch, WD | 1 |
| Gsell, W | 1 |
| Naumann, M | 1 |
| Oestreicher, E | 1 |
| Edwards, RH | 1 |
| Tipton, KF | 2 |
| Carlsson, A | 2 |
| Pollak, P | 1 |
| Limousin, P | 1 |
| Gervason, CL | 1 |
| Jeanneau-Nicolle, E | 1 |
| Isacson, O | 3 |
| Itakura, T | 2 |
| Nakai, M | 1 |
| Nakao, N | 1 |
| Ooiwa, Y | 1 |
| Uematsu, Y | 1 |
| Komai, N | 2 |
| Diederich, NJ | 1 |
| Goetz, CG | 1 |
| Jiménez-Jiménez, FJ | 1 |
| Molina, JA | 1 |
| Morano, A | 1 |
| Mandel, RJ | 1 |
| Sofroniew, MV | 1 |
| Rinne, JO | 1 |
| Naoi, M | 6 |
| Maruyama, W | 3 |
| Poirier, J | 1 |
| Thiffault, C | 1 |
| Mash, DC | 2 |
| Sanchez-Ramos, J | 2 |
| Weiner, WJ | 2 |
| Niwa, T | 3 |
| Takeda, N | 3 |
| Yoshizumi, H | 3 |
| Tatematsu, A | 3 |
| Yoshida, M | 2 |
| Dostert, P | 3 |
| Nagatsu, T | 9 |
| Sandler, M | 6 |
| Glover, V | 4 |
| Clow, A | 1 |
| Jarman, J | 1 |
| Dietz, V | 1 |
| Bodis-Wollner, I | 2 |
| Tagliati, M | 1 |
| Wichmann, T | 2 |
| Plunkett, RJ | 1 |
| Oldfield, EH | 2 |
| Kupsch, A | 1 |
| Kean, A | 1 |
| DiStefano, L | 1 |
| Shinotoh, H | 1 |
| Calne, DB | 4 |
| Beckley, DJ | 1 |
| van Vugt, JP | 1 |
| van Dijk, JG | 1 |
| Remler, MP | 1 |
| Roos, RA | 1 |
| Zuo, D | 1 |
| Yu, PH | 1 |
| Faucheux, BA | 3 |
| Villares, J | 2 |
| Levy, R | 2 |
| Javoy-Agid, F | 3 |
| Hauw, JJ | 2 |
| Agid, Y | 8 |
| Wu, RF | 1 |
| Ichikawa, Y | 1 |
| Coleman, T | 1 |
| Ellis, SW | 1 |
| Martin, IJ | 1 |
| Lennard, MS | 1 |
| Tucker, GT | 1 |
| Ovadia, A | 1 |
| Cass, WA | 1 |
| Yi, A | 1 |
| Simmerman, L | 1 |
| Russell, D | 1 |
| Martin, D | 1 |
| Lapchak, PA | 1 |
| Collins, F | 1 |
| Snyder, SH | 3 |
| Reichmann, H | 1 |
| Janetzky, B | 1 |
| Blanchet, PJ | 1 |
| Shiosaki, K | 1 |
| Britton, DR | 1 |
| Guridi, J | 3 |
| Hirsch, E | 3 |
| Fischman, AJ | 1 |
| Babich, JW | 1 |
| Elmaleh, DR | 2 |
| Barrow, SA | 1 |
| Meltzer, P | 1 |
| Hanson, RN | 1 |
| Madras, BK | 1 |
| Fuhr, P | 1 |
| Steiner, JP | 1 |
| Hamilton, GS | 1 |
| Ross, DT | 1 |
| Valentine, HL | 1 |
| Connolly, MA | 1 |
| Liang, S | 1 |
| Ramsey, C | 1 |
| Li, JH | 1 |
| Howorth, P | 1 |
| Soni, R | 1 |
| Fuller, M | 1 |
| Sauer, H | 1 |
| Nowotnik, AC | 1 |
| Suzdak, PD | 1 |
| Doudet, DJ | 1 |
| Chan, GL | 1 |
| Holden, JE | 2 |
| Morrison, KS | 1 |
| Wyatt, RJ | 1 |
| Ruth, TJ | 1 |
| Barrio, JR | 2 |
| Huang, SC | 2 |
| Phelps, ME | 2 |
| Kojima, H | 1 |
| Abiru, Y | 1 |
| Sakajiri, K | 1 |
| Watabe, K | 1 |
| Ohishi, N | 1 |
| Takamori, M | 1 |
| Hatanaka, H | 1 |
| Yagi, K | 1 |
| Bringas, JR | 1 |
| McLaughlin, W | 1 |
| Hundal, R | 1 |
| Nagy, D | 1 |
| Boireau, A | 1 |
| Bordier, F | 1 |
| Dubédat, P | 1 |
| Pény, C | 1 |
| Impérato, A | 2 |
| Lan, J | 1 |
| Jiang, DH | 1 |
| Selley, ML | 1 |
| Gao, ZG | 1 |
| Cui, WY | 1 |
| Zhang, HT | 1 |
| Liu, CG | 1 |
| During, MJ | 1 |
| Samulski, RJ | 1 |
| Kaplitt, MG | 1 |
| Leone, P | 1 |
| Xiao, X | 1 |
| Freese, A | 1 |
| Taylor, JR | 3 |
| O'Malley, KL | 1 |
| Pautot, V | 1 |
| Macaigne, C | 1 |
| Chariot, P | 1 |
| Goulet, M | 1 |
| Blanchet, P | 1 |
| Lévesque, D | 1 |
| Irifune, M | 1 |
| Kaseda, S | 1 |
| Osame, M | 1 |
| Kakimura, J | 1 |
| Taniguchi, T | 2 |
| Faucheux, B | 1 |
| Duyckaerts, C | 1 |
| Deleu, D | 1 |
| Abe, T | 2 |
| Tohgi, H | 2 |
| Leonardi, ET | 1 |
| Mytilineou, C | 1 |
| Brownell, AL | 1 |
| Jenkins, BG | 1 |
| Shults, CW | 1 |
| Haas, RH | 1 |
| Lonser, RR | 1 |
| Corthésy, ME | 1 |
| Morrison, PF | 1 |
| Gogate, N | 1 |
| Grünblatt, E | 3 |
| Mandel, S | 3 |
| Berkuzki, T | 1 |
| Tanji, H | 1 |
| Fujihara, K | 1 |
| Nagasawa, H | 1 |
| Itoyama, Y | 1 |
| Tolwani, RJ | 1 |
| Green, S | 1 |
| Waggie, K | 1 |
| Han, J | 1 |
| Cheng, FC | 1 |
| Yang, Z | 1 |
| Dryhurst, G | 1 |
| Hashimoto, T | 1 |
| Izawa, Y | 1 |
| Kato, T | 1 |
| Moriizumi, T | 1 |
| Brefel, C | 1 |
| Tison, F | 1 |
| Peyro-Saint-Paul, H | 1 |
| Ladure, P | 1 |
| Rascol, O | 1 |
| LaVoie, MJ | 1 |
| Hastings, TG | 1 |
| Fredriksson, A | 1 |
| Palomo, T | 1 |
| Archer, T | 1 |
| Friedrich, MJ | 1 |
| Takatsu, H | 1 |
| Nishida, H | 1 |
| Matsuo, H | 1 |
| Watanabe, S | 1 |
| Nagashima, K | 1 |
| Wada, H | 1 |
| Nishigaki, K | 1 |
| Fujiwara, H | 1 |
| Muriel, MP | 1 |
| Vyas, S | 1 |
| Mouatt-Prigent, A | 2 |
| Turmel, H | 1 |
| Evan, GI | 1 |
| Schroeder, JA | 1 |
| McGrew, DM | 1 |
| Ramos, E | 1 |
| Nash, JE | 1 |
| Peggs, D | 1 |
| McGuire, S | 1 |
| Maneuf, Y | 1 |
| Hille, C | 1 |
| MacKenzie, G | 1 |
| Peng, TI | 1 |
| Stephans, SE | 1 |
| Bloch, J | 1 |
| Ma, SY | 2 |
| Chu, Y | 2 |
| Leventhal, L | 2 |
| McBride, J | 1 |
| Chen, EY | 1 |
| Palfi, S | 2 |
| Roitberg, BZ | 1 |
| Brown, WD | 1 |
| Pyzalski, R | 1 |
| Taylor, MD | 1 |
| Carvey, P | 1 |
| Ling, Z | 1 |
| Trono, D | 1 |
| Déglon, N | 2 |
| Aebischer, P | 3 |
| François, C | 1 |
| Tandé, D | 1 |
| Yelnik, J | 1 |
| Gassen, M | 1 |
| Gross, A | 1 |
| Foley, P | 1 |
| Shimohama, S | 1 |
| Akaike, A | 1 |
| Yang, MC | 1 |
| McLean, AJ | 1 |
| Rivory, LP | 1 |
| Le Couteur, DG | 1 |
| Costa, S | 1 |
| Shimoke, K | 1 |
| Chiba, H | 1 |
| Vukosavic, S | 1 |
| Djaldetti, R | 1 |
| Liberatore, G | 1 |
| Offen, D | 1 |
| Korsmeyer, SJ | 1 |
| Troadec, JD | 1 |
| Kikly, K | 1 |
| Costantini, LC | 1 |
| Cole, D | 1 |
| Chaturvedi, P | 1 |
| Wang, CY | 1 |
| O'Brien, JS | 1 |
| Rathke-Hartlieb, S | 1 |
| Kahle, PJ | 1 |
| Ozmen, L | 1 |
| Haid, S | 1 |
| Okochi, M | 1 |
| Haass, C | 1 |
| Adams, JD | 1 |
| Chang, ML | 1 |
| Klaidman, L | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Maor, G | 1 |
| Strömberg, I | 2 |
| Törnqvist, N | 1 |
| Johansson, S | 1 |
| Bygdeman, M | 1 |
| Almqvist, PM | 1 |
| Hayakawa, H | 1 |
| Migita, M | 1 |
| Shibata, M | 1 |
| Tanaka, R | 1 |
| Suzuki, A | 1 |
| Shimo-Nakanishi, Y | 1 |
| Urabe, T | 1 |
| Tamayose, K | 1 |
| Shimada, T | 1 |
| Miura, M | 1 |
| Schmidt, N | 1 |
| Boyce, S | 5 |
| Rupniak, NM | 1 |
| Steventon, MJ | 1 |
| Iversen, SD | 1 |
| Duan, W | 1 |
| Ladenheim, B | 1 |
| Cutler, RG | 1 |
| Kruman, II | 1 |
| Cadet, JL | 2 |
| Obinu, MC | 1 |
| Reibaud, M | 1 |
| Blanchard, V | 1 |
| Moussaoui, S | 1 |
| Muramatsu, S | 1 |
| Fujimoto, K | 1 |
| Ikeguchi, K | 1 |
| Shizuma, N | 1 |
| Kawasaki, K | 1 |
| Ono, F | 1 |
| Mizukami, H | 1 |
| Kume, A | 1 |
| Matsumura, M | 1 |
| Nagatsu, I | 1 |
| Urano, F | 1 |
| Ichinose, H | 1 |
| Terao, K | 1 |
| Nakano, I | 1 |
| Ozawa, K | 1 |
| Członkowska, A | 1 |
| Kurkowska-Jastrzebska, I | 1 |
| Thiruchelvam, MJ | 1 |
| Cory-Slechta, DA | 1 |
| Wuertzer, C | 1 |
| Emborg, M | 1 |
| Bakay, R | 1 |
| Wesemann, W | 1 |
| DeLanney, LE | 2 |
| Di Monte, D | 1 |
| Ellis, JE | 1 |
| Byrd, LD | 2 |
| Bakay, RA | 2 |
| Kondo, T | 1 |
| Pifl, C | 1 |
| Nanoff, C | 1 |
| Schingnitz, G | 1 |
| Schütz, W | 1 |
| Hornykiewicz, O | 2 |
| Nakahara, D | 1 |
| Takahashi, A | 1 |
| Fahn, S | 1 |
| Bringmann, G | 1 |
| Friedrich, H | 1 |
| Feineis, D | 1 |
| Mann, VM | 1 |
| Cooper, JM | 1 |
| Krige, D | 1 |
| Jenner, PJ | 1 |
| Felten, DL | 3 |
| Felten, SY | 3 |
| Date, I | 3 |
| Clemens, JA | 1 |
| Ikeda, H | 1 |
| Markey, CJ | 1 |
| Bloomfield, PM | 1 |
| Brundin, P | 1 |
| Leenders, KL | 1 |
| Lindvall, O | 2 |
| Rehncrona, S | 1 |
| Widner, H | 1 |
| Page, RD | 1 |
| Wessel, K | 1 |
| Szelenyi, I | 1 |
| Mitchell, IJ | 1 |
| Sambrook, MA | 3 |
| Tetrud, J | 1 |
| Guttman, M | 1 |
| Fibiger, HC | 1 |
| Jakubovic, A | 1 |
| Notter, MF | 1 |
| Russ, H | 1 |
| Mihatsch, W | 1 |
| Gerlach, M | 1 |
| Przuntek, H | 1 |
| Hikosaka, O | 1 |
| Chacón, JN | 1 |
| Truscott, TG | 1 |
| Taylor, R | 1 |
| Shahi, GS | 2 |
| Das, NP | 2 |
| Moochhala, SM | 2 |
| Collier, TJ | 4 |
| Tanner, CM | 3 |
| Kofman, OS | 1 |
| Prell, GD | 1 |
| Khandelwal, JK | 1 |
| Blandina, P | 1 |
| Morrishow, AM | 1 |
| Green, JP | 1 |
| Pablo, J | 1 |
| Buck, BE | 1 |
| Takahashi, S | 1 |
| Makino, Y | 1 |
| Ohta, S | 1 |
| Hirobe, M | 1 |
| Gupta, M | 1 |
| Schwarz, J | 1 |
| Chen, XL | 1 |
| Roisen, FJ | 1 |
| Devlin, AJ | 1 |
| Bhatti, AR | 1 |
| Melega, WP | 1 |
| Yu, DC | 1 |
| Hoffman, JM | 1 |
| Satyamurthy, N | 1 |
| Mazziotta, JC | 1 |
| Heikkila, RE | 2 |
| Terleckyj, I | 1 |
| Sieber, BA | 1 |
| Landau, WM | 1 |
| Golbe, LI | 2 |
| Fazzini, E | 1 |
| Durso, R | 1 |
| Davoudi, H | 1 |
| Szabo, GK | 1 |
| Albert, ML | 1 |
| Sturman, SG | 1 |
| Steventon, GB | 1 |
| Waring, RH | 1 |
| Robertson, RG | 1 |
| Clarke, CA | 1 |
| Watts, RL | 1 |
| Herring, CJ | 1 |
| Sweeney, KM | 1 |
| Colbassani, HJ | 1 |
| Mandir, A | 1 |
| Iuvone, PM | 1 |
| Duvoisin, RC | 1 |
| Sandyk, R | 1 |
| Iacono, RP | 1 |
| Tetrud, JW | 3 |
| Temlett, JA | 1 |
| Quinn, NP | 1 |
| Jenner, PG | 2 |
| Pourcher, E | 1 |
| Bonnet, AM | 1 |
| Markstein, R | 1 |
| Lataste, X | 1 |
| LeWitt, PA | 1 |
| Pakkenberg, H | 1 |
| Collins, MA | 1 |
| Neafsey, EJ | 1 |
| Ueki, A | 1 |
| Willoughby, J | 2 |
| Stibbe, K | 1 |
| Stern, GM | 1 |
| Sayre, LM | 1 |
| Lee, EJ | 1 |
| Hornsby, PJ | 1 |
| Bocchetta, A | 1 |
| Corsini, GU | 1 |
| Fellman, JH | 1 |
| Nutt, JN | 1 |
| Uhl, GR | 1 |
| Javitch, JA | 1 |
| Ohkubo, S | 1 |
| Hiraro, T | 1 |
| Oka, K | 1 |
| Naylor, R | 1 |
| Costall, B | 1 |
| Eisen, A | 1 |
| McGeer, E | 1 |
| Spencer, P | 1 |
| Clarke, CE | 1 |
| Kito, S | 1 |
| Miyoshi, R | 1 |
| Nitta, K | 1 |
| Matsubayashi, H | 1 |
| Yamamura, Y | 1 |
| Tahara, E | 1 |
| Deutch, AY | 2 |
| Graybiel, AM | 1 |
| Agid, YA | 1 |
| Cohen, G | 1 |
| Olson, L | 1 |
| Backlund, EO | 1 |
| Gerhardt, G | 1 |
| Hoffer, B | 1 |
| Rose, G | 1 |
| Seiger, A | 1 |
| Jankovic, J | 1 |
| D'Amato, RJ | 1 |
| Lipman, ZP | 1 |
| Narabayashi, H | 1 |
| Gibb, C | 2 |
| Stern, G | 1 |
| Boyes, BE | 1 |
| Cumming, P | 1 |
| Martin, WR | 1 |
| Finberg, JP | 1 |
| Perry, TL | 2 |
| Jones, K | 1 |
| Hansen, S | 1 |
| Wall, RA | 1 |
| Yahr, MD | 1 |
| Kamei, I | 1 |
| Nakai, K | 1 |
| Naka, Y | 1 |
| Nakakita, K | 1 |
| Imai, H | 1 |
| Sheng, JG | 1 |
| Xu, DL | 1 |
| Yu, HZ | 1 |
| Sonsalla, PK | 2 |
| Hara, K | 1 |
| Fukuyama, H | 1 |
| Kameyama, M | 1 |
| Hirai, S | 1 |
| Stoessl, AJ | 1 |
| Lindquist, NG | 2 |
| Larsson, BS | 2 |
| Lydén-Sokolowski, A | 2 |
| Jonsson, G | 1 |
| Sundström, E | 1 |
| Hunskår, S | 1 |
| Fruncillo, RJ | 1 |
| Lieberman, AN | 1 |
| Yong, VW | 1 |
| Friedman, J | 1 |
| Livni, E | 1 |
| Spellman, JP | 1 |
| Correia, JA | 1 |
| Alpert, NM | 1 |
| Brownell, GL | 1 |
| Strauss, HW | 1 |
| Schlagmann, C | 1 |
| Remien, J | 1 |
| Youngster, SK | 1 |
| Ricaurte, GA | 1 |
| Battistin, L | 1 |
| Rigo, A | 1 |
| Bracco, F | 1 |
| Dam, M | 1 |
| Pizzolato, G | 1 |
| Sershen, H | 1 |
| Hashim, A | 1 |
| Lajtha, A | 1 |
| Fonne-Pfister, R | 1 |
| Bargetzi, MJ | 1 |
| Meyer, UA | 1 |
| Mizukawa, K | 1 |
| Sora, YH | 1 |
| Sora, I | 1 |
| Eaker, EY | 1 |
| Bixler, GB | 1 |
| Dunn, AJ | 1 |
| Moreshead, WV | 1 |
| Mathias, JR | 1 |
| Ballard, PA | 1 |
| Reznikoff, G | 1 |
| Manaker, S | 1 |
| Rhodes, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Center, Open, Single Dosing, Dose-escalation, Phase 1/2a Study to Evaluate the Safety and Exploratory Efficacy of Embryonic Stem Cell-derived A9 Dopamine Progenitor Cell (A9-DPC) Therapy in Patients With Parkinson's Disease[NCT05887466] | Phase 1/Phase 2 | 12 participants (Anticipated) | Interventional | 2023-05-09 | Recruiting | ||
| Clinical Trial for Near Infrared Endoventricular Illumination for Neuroprotection in Very Early Cases of Parkinson's Disease (Ev-NIRT)[NCT04261569] | 14 participants (Anticipated) | Interventional | 2020-12-14 | Recruiting | |||
| Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease[NCT02200887] | 48 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| Role of Carnosine in Combination With Vitamin B Complex in Preventing the Progression of Diabetic Neuropathy in Type 2 Diabetes Patients[NCT05422352] | 60 participants (Actual) | Interventional | 2021-01-14 | Completed | |||
| A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)[NCT03840005] | Phase 2 | 31 participants (Actual) | Interventional | 2018-12-18 | Completed | ||
| [NCT01502384] | 100 participants (Anticipated) | Observational | 2012-01-31 | Not yet recruiting | |||
| A Randomized, Double-blind, Placebo-controlled Trial of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease[NCT04506073] | Phase 2 | 45 participants (Actual) | Interventional | 2020-11-09 | Completed | ||
| A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease[NCT00909545] | Phase 2 | 99 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Leukine (Sargramostim) for Parkinson's Disease[NCT01882010] | Phase 1 | 37 participants (Actual) | Interventional | 2013-09-01 | Completed | ||
| PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Dopamine Transporter Ligand [18F]FECNT[NCT00083629] | Phase 1 | 30 participants | Interventional | 2004-05-31 | Completed | ||
| Dual Frequency, Dual Region Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease[NCT04650932] | 10 participants (Anticipated) | Interventional | 2022-10-22 | Recruiting | |||
| NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease[NCT00001929] | Phase 2 | 20 participants | Interventional | 1999-03-31 | Completed | ||
| Can Subthreshold Transcranial Magnetic Stimulation (rTMS) to Motor Cortex and/or to Supplementary Motor Area (SMA) Improve Performance of Complex Motor Sequences in Parkinson's Disease?[NCT00001665] | 12 participants | Observational | 1997-01-31 | Completed | |||
| Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease[NCT00921128] | Phase 1 | 0 participants (Actual) | Interventional | 2009-06-02 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Musculoskeletal and Connective Tissue Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Isradipine CR 5mg/Day | 0 |
| Isradipine CR 10mg/Day | 2 |
| Isradipine CR 20mg/Day | 3 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 2 |
| Isradipine CR 10mg/Day | 3 |
| Isradipine CR 20mg/Day | 4 |
Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 3 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 1 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 1 |
| Isradipine CR 10mg/Day | 2 |
| Isradipine CR 20mg/Day | 1 |
Nervous system disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 7 |
| Isradipine CR 5mg/Day | 5 |
| Isradipine CR 10mg/Day | 6 |
| Isradipine CR 20mg/Day | 6 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 1 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 1 |
General Disorders and Administration Site Conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 1 |
| Isradipine CR 10mg/Day | 3 |
| Isradipine CR 20mg/Day | 3 |
Nervous System disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 3 |
| Isradipine CR 10mg/Day | 6 |
| Isradipine CR 20mg/Day | 4 |
Vascular Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Isradipine CR 5mg/Day | 1 |
| Isradipine CR 10mg/Day | 2 |
| Isradipine CR 20mg/Day | 2 |
Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 3 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 1 |
Infections and infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 4 |
| Isradipine CR 10mg/Day | 7 |
| Isradipine CR 20mg/Day | 4 |
Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 2 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 2 |
General disorders and administration site conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Isradipine CR 5mg/Day | 4 |
| Isradipine CR 10mg/Day | 10 |
| Isradipine CR 20mg/Day | 16 |
Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 3 |
| Isradipine CR 5mg/Day | 2 |
| Isradipine CR 10mg/Day | 1 |
| Isradipine CR 20mg/Day | 0 |
Nervous System Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Isradipine CR 5mg/Day | 3 |
| Isradipine CR 10mg/Day | 2 |
| Isradipine CR 20mg/Day | 0 |
Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Isradipine CR 5mg/Day | 2 |
| Isradipine CR 10mg/Day | 5 |
| Isradipine CR 20mg/Day | 0 |
The outcome is defined as change in ADL subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part II) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part II: Activities of Daily Living in the week prior to the designated visit, consisting of 13 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part II score represents the sum of these 13 questions. A greater increase in score indicates a greater increase in disability. A total of 52 points are possible. 52 represents the worst (total) disability), 0--no disability (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 2.60 |
| Isradipine CR 5mg/Day | 3.20 |
| Isradipine CR 10mg/Day | 2.09 |
| Isradipine CR 20mg/Day | 1.86 |
The Beck Depression Inventory (BDI) is a validated self-reported 21-item depression scale that was tested and validated as a reliable instrument for screening for depression in PD. The outcome is defined as change in BDI-II between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total BDI score represents the sum of these 21-items. A higher change in score indicates a greater increase in disability. Total score of 0-13 is considered minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.52 |
| Isradipine CR 5mg/Day | 1.99 |
| Isradipine CR 10mg/Day | 0.11 |
| Isradipine CR 20mg/Day | 1.50 |
The outcome is defined as change in Mental subscale of Unified Parkinson's Disease Rating Scale(UPDRS Part I) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part I: Mentation, behavior and mood, consisting of 4 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score represents the sum of these 4 questions. A greater increase in score indicates a greater increase in disability. A total of 16 points are possible. 16 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.30 |
| Isradipine CR 5mg/Day | 0.76 |
| Isradipine CR 10mg/Day | 0.30 |
| Isradipine CR 20mg/Day | 0.03 |
The Modified Hoehn & Yahr Scale is an 8-level Parkinson's disease staging instrument. The outcome is defined as change in Modified Hoehn & Yahr Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. A greater increase in stage indicates a greater increase in disability. Stage ranges from 0-5 (also including 1.5 and 2.5) with 0 indicating no disability and 5 indicating maximum disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.27 |
| Isradipine CR 5mg/Day | 0.22 |
| Isradipine CR 10mg/Day | 0.12 |
| Isradipine CR 20mg/Day | 0.11 |
The Schwab & England scale is an investigator and subject assessment of the subject's level of independence at all scheduled study visits. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson's disease appeared. The outcome is defined as change in Schwab & England Independence Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Higher decrease in score indicates higher disability. Score ranges from 100% (complete independence) to 0% (total disability). (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -5.04 |
| Isradipine CR 5mg/Day | -5.56 |
| Isradipine CR 10mg/Day | -3.69 |
| Isradipine CR 20mg/Day | -3.76 |
The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. The outcome is defined as change in MoCA between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.58 |
| Isradipine CR 5mg/Day | 0.06 |
| Isradipine CR 10mg/Day | 0.11 |
| Isradipine CR 20mg/Day | 0.36 |
The outcome is defined as change in Motor subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part III) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part III: motor abilities at the time of the visit, consisting of 27 items (including 13 general questions and 14 sub-questions) each answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part III score represents the sum of these 27 items. A total of 108 points are possible. 108 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Isradipine CR 5mg/Day | 3.49 |
| Isradipine CR 10mg/Day | 3.91 |
| Isradipine CR 20mg/Day | 3.69 |
The PD Quality of Life Scale(PDQ-39) asks the subject to evaluate how Parkinson disease has affected their health and overall quality of life at that point in time. The total quality of life scale includes subscales relating to social role, self-image/sexuality, sleep, outlook, physical function and urinary function. The outcome is defined as change in PDQ-39 between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. It is scored on a scale of zero to 100, with lower scores indicating better health and higher scores more severe disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.28 |
| Isradipine CR 5mg/Day | 3.47 |
| Isradipine CR 10mg/Day | 3.00 |
| Isradipine CR 20mg/Day | 3.35 |
Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 12 or the time to require dopaminergic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first. The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 7.40 |
| Isradipine CR 5mg/Day | 7.44 |
| Isradipine CR 10mg/Day | 6.30 |
| Isradipine CR 15-20mg/Day | 5.40 |
Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | participants (Number) |
|---|---|
| Placebo | 25 |
| Isradipine CR 5mg/Day | 19 |
| Isradipine CR 10mg/Day | 19 |
| Isradipine CR 20mg/Day | 9 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | -0.38 |
| Isradipine CR 5mg/Day | -4.20 |
| Isradipine CR 10mg/Day | -5.14 |
| Isradipine CR 20mg/Day | -4.34 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | 0.09 |
| Isradipine CR 5mg/Day | -2.79 |
| Isradipine CR 10mg/Day | -4.54 |
| Isradipine CR 20mg/Day | -3.63 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Placebo | -0.08 |
| Isradipine CR 5mg/Day | -2.98 |
| Isradipine CR 10mg/Day | -2.29 |
| Isradipine CR 20mg/Day | -1.21 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Placebo | -0.42 |
| Isradipine CR 5mg/Day | -0.71 |
| Isradipine CR 10mg/Day | -0.52 |
| Isradipine CR 20mg/Day | 0.18 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | -4.77 |
| Isradipine CR 5mg/Day | -9.85 |
| Isradipine CR 10mg/Day | -7.75 |
| Isradipine CR 20mg/Day | -6.30 |
(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Placebo | -2.45 |
| Isradipine CR 5mg/Day | -8.59 |
| Isradipine CR 10mg/Day | -6.45 |
| Isradipine CR 20mg/Day | -7.01 |
144 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Parkinson Disease
| Article | Year |
|---|---|
The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the cognitive and motor functions in rodents: A systematic review and meta-analysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition; Disease Models, Animal; Mice; Park | 2022 |
Impact of Environmental Risk Factors on Mitochondrial Dysfunction, Neuroinflammation, Protein Misfolding, and Oxidative Stress in the Etiopathogenesis of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; DDT; Dieldrin; Herbicides; H | 2022 |
Rotenone-Induced Model of Parkinson's Disease: Beyond Mitochondrial Complex I Inhibition.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Electron Tr | 2023 |
Experimental models of chemically induced Parkinson's disease in zebrafish at the embryonic larval stage: a systematic review.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Larva; Models | 2023 |
Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Animals; Disease Models, Animal; Do | 2020 |
Parkinson's disease, aging and adult neurogenesis: Wnt/β-catenin signalling as the key to unlock the mystery of endogenous brain repair.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Astrocytes; Dopaminergic Neurons; Huma | 2020 |
Parkinson disease and the gut: new insights into pathogenesis and clinical relevance.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Enteric Nervou | 2020 |
The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2020 |
MPTP-induced mouse model of Parkinson's disease: A promising direction of therapeutic strategies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apoptosis; Disease Mode | 2021 |
Oxidative stress and regulated cell death in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
Classic animal models of Parkinson's disease: a historical perspective.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Oxidopamine; | 2019 |
A secret that underlies Parkinson's disease: The damaging cycle.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aldehydes; alpha-Synuclein; Antiparkinson Agents; Biog | 2019 |
The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Confounding Factors, Epidemiologic; DNA, Mitochondrial | 2019 |
What basal ganglia changes underlie the parkinsonian state? The significance of neuronal oscillatory activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Biological Clocks; Disease Mod | 2013 |
Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Dysk | 2015 |
Parkinson's disease and enhanced inflammatory response.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyto | 2015 |
The MPTP Story.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Hist | 2017 |
Estrogen and SERM neuroprotection in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Neuroprote | 2008 |
Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Central Nervous System; Disease Models, Anima | 2008 |
Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Disease Models, Animal; Dopamine; | 2008 |
Functional models of Parkinson's disease: a valuable tool in the development of novel therapies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Huma | 2008 |
Neuroprotective actions of sex steroids in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopamine Ag | 2009 |
Not lost in translation Sensing the loss and filling the gap during regeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Mesencephalon | 2009 |
[Pathogenesis of sporadic Parkinson's disease: contribution of genetic and environmental risk factors].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Glucosylceramidase; Humans; | 2009 |
alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain; Disease Models, Anima | 2010 |
The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Behavior, Animal; | 2011 |
[Pathophysiology of Parkinson's disease: an update].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomedical Research; Disease Models, Animal; | 2010 |
Meta-analysis of genetic and environmental Parkinson's disease models reveals a common role of mitochondrial protection pathways.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain; Databases, Bibliograp | 2012 |
Animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Animals, Genetically Modifie | 2012 |
Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Estrogens; Gonadal Steroid Hormones; Humans; | 2012 |
Adult neurogenesis in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Hipp | 2013 |
Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Models, Biological; MPTP Poisoning; Parkinson | 2013 |
Environmental factors in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Environment; Humans; Nerve D | 2002 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Mitochondria; Nitric Oxide; Oxidative | 2002 |
Homocysteine, folate deficiency, and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Folic Acid Deficiency; Homocysteine | 2002 |
An inflammatory review of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Gangliosides; Humans; Immunologic Surv | 2002 |
The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Parkinson Dis | 2003 |
Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspases; Cell Cycle; Inflammation | 2003 |
[Genetics and environmental factors of Parkinson disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Dopamine Agents; Environmental Exposu | 2002 |
Targeting programmed cell death in neurodegenerative diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Anim | 2003 |
[New aspects of neuroprotective effects of nonsteroidal anti-inflammatory drugs].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflamm | 2003 |
Interactions between environmental and genetic factors in the pathophysiology of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Progression; Dopamine; Environ | 2003 |
Nitric oxide and reactive oxygen species in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Mice; Nitric Oxide; Nitric Oxide Synt | 2003 |
What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain; Cell Death; Dopamine; | 2003 |
Animal models of Parkinson's disease in rodents induced by toxins: an update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Basal Ganglia; Brain Stem; | 2003 |
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Dise | 2004 |
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Huma | 2004 |
Autotoxicity, methylation and a road to the prevention of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Humans; Methylation; Niacina | 2005 |
The MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Mod | 2005 |
Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gene Expression; Huma | 2005 |
Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Humans; In | 2006 |
Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Environment; Estrogens; Gene | 2005 |
Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Disease Models, Animal; Disease Progre | 2006 |
Neural repair strategies for Parkinson's disease: insights from primate models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Transplantation; Deep Brain Stimulation; | 2006 |
Modeling neurodegenerative diseases in vivo review.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Hapl | 2005 |
alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Apoptosis; Cas | 2006 |
Epidemiology of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Female; Hazardous Substances; Humans; Incidence; | 2007 |
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Apoptosis; Disease Progression; Enzymes; Humans; Mitoc | 2008 |
Nonhuman primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavioral Symptoms; Disease Models, Animal; | 2007 |
Glial reactions in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Anti-Inflammatory Agents, No | 2008 |
Oxidative and inflammatory pathways in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Herbicides; Humans; Inflammation; Lipopolysac | 2009 |
Parkinson's disease in 1984: an update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Dementia; Drug Therapy, Combination; Dy | 1984 |
Deficiencies of NADH and succinate dehydrogenases in degenerative diseases and myopathies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Platelets; Cattle; Electron Transport C | 1995 |
Role of mitochondria in the etiology and pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Citric Acid Cycle; DNA, Mitochondrial; | 1995 |
The role of positron emission tomography in the assessment of human neurotransplantation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Basal Ganglia; Brain Tissue Transplan | 1993 |
Neuroprotection by dopamine agonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Bromocriptine; Dopamine Agonists; Huma | 1994 |
Neural degeneration and the transport of neurotransmitters.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amyotrophic Lateral Sclerosis; Animals; Biological Tra | 1993 |
What is it that l-deprenyl (selegiline) might do?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Monoamine Oxidase Inhibitors; Nervous | 1994 |
Glutamatergic drugs in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Excitatory Amino | 1994 |
Thirty years of dopamine research.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Dopamine; Humans; Neura | 1993 |
[Fetal and adrenal transplantation in Parkinson disease: theoretical bases and clinical results].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Aged; Animals; Dopamine; Fetal Tissue | 1993 |
[Parkinson's disease etiology: risk factors and protection].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Antioxidants; DNA, Mitochondrial; Female; | 1993 |
Trophism, transplantation, and animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Tissue Transplantation; Disease Models, | 1993 |
Nigral degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Haplorhini; Humans; Isoenzymes; Mon | 1993 |
Type B monoamine oxidase and neurotoxins.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Survival; Corpus Striatum; Dopamine; Hum | 1993 |
Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catalase; Corpus Striatum; Free Radicals; Glu | 1993 |
Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aging; Animals; Biologica | 1993 |
Transferrin receptor regulation in Parkinson's disease and MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Dopamine Plasma Membrane Tr | 1993 |
Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Blood Platelets; Corpus Striatum; Humans; Monoamine Ox | 1993 |
Reflex behavior and programming in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electromyography; Haplorhini; Humans; Muscle | 1993 |
Pathophysiology of parkinsonian motor abnormalities.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Brain Mapping; Cerebral Cortex | 1993 |
Tissue implants in treatment of parkinsonian syndromes in animals and implications for use of tissue implants in humans.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Basal Ganglia; Brain Tissue | 1993 |
Pathogenesis and animal studies of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Humans; Iron; Mito | 1993 |
The use of PET in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Antiparkinson Agents; Binding Sites; Brain; Cor | 1995 |
[Metabolic enzymes of neurotoxin: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Cytochrome P-450 Enzyme System; Monoamine Oxidase; Oxy | 1995 |
Metabolic disorders and neurotoxicology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Humans; Metabolic Diseases; Nerve D | 1995 |
Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antihypertensive Agents; Disease Models, Anim | 1995 |
The etiology of Parkinson's disease with emphasis on the MPTP story.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Parkinson Disease | 1996 |
[Current aspects of the etiology of Parkinson disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Cell Death; Dopamine Agents; Humans; Neurons; Parkinso | 1997 |
Biological imaging and the molecular basis of dopaminergic diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain; | 1997 |
[Neurotoxin candidates as pathogenic agents of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Disease Models, Anima | 1997 |
The role of the subthalamic nucleus in the origin of hemiballism and parkinsonism: new surgical perspectives.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Functional Laterality; Haplo | 1997 |
Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Environmental Health; Humans; Mutation; Parkins | 1998 |
Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electron Transport; Humans; Mitochondria; MPT | 1998 |
[Mitochondrial DNA and Parkinson disease. Methodologic review].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; DNA, Mitochondrial; Humans; MEDLINE; M | 1998 |
[Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Carbolines; Disease Models, Animal; Do | 1998 |
Cell culture models of neuronal degeneration and neuroprotection. Implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Culture Techniques; Dopamine; Growth Sub | 1998 |
A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antioxidants; Blood Pla | 1999 |
Experimental models of Parkinson's disease: insights from many models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Met | 1999 |
Oxidative stress and genetics in the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cell Death; Dopamine; Dopami | 2000 |
Mitochondrial dysfunction in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Calcium; Disease Models, Animal; D | 1999 |
Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Apomorphine; Chelating Agents; | 2000 |
The motor circuit of the human basal ganglia reconsidered.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Dopamine Agents; Globus Pallid | 2000 |
The parkinsonian models: invertebrates to mammals.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Genetically Modified; Apoptosis; Cel | 2000 |
Parkinson's disease--redox mechanisms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aldehyde Dehydrogenase; Animals; Dopamine; Humans; Mic | 2001 |
Neurochemical findings in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2001 |
Astrocytes and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biotransformation; Dopamine; Glio | 1992 |
Trichloroharmanes as potential endogenously formed inducers of Morbus Parkinson: synthesis, analytics, and first in vivo-investigations.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Carbolines; Humans; Molecular Structur | 1992 |
Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Cell Death; DNA, Mitochondrial; Electron Transport; Hu | 1992 |
Age-related decline in the dopaminergic nigrostriatal system: the oxidative hypothesis and protective strategies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Corpus Striatum; Dopamine; Humans; Neu | 1992 |
The use of thalamotomy in the treatment of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Dyskinesia, Drug-Induced; Fema | 1992 |
Selegiline--an overview of its role in the treatment of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Monoamine Oxidase; Parkinson Disease; Selegili | 1992 |
Pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Humans; Parkinson Disease; Parkinson Di | 1992 |
[Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1991 |
Oxidative stress as a cause of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Survival; Dopamine; Humans; Iron; | 1991 |
Liver enzyme abnormalities in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; L | 1991 |
Deprenyl: protective vs. symptomatic effect.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Humans; MPTP Poisoning; Park | 1991 |
[Parkinson's disease; etiology and animal model].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electron Transport; H | 1991 |
[Aging and Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aging; Animals; Humans; Mice; Middle Aged | 1991 |
Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; L | 1991 |
The visual system in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Contrast Sensitivity; Dopamine; Electroenceph | 1990 |
Clinical neuromythology VII. Artificial intelligence: the brain transplant cure for parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Artificial Intelligence; Cau | 1990 |
[Brain aging and Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aging; Brain; Humans; Parkinson Disease | 1990 |
Do environmental toxins cause Parkinson's disease? A critical review.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Amyotrophic Lateral Sclerosis; Environmen | 1990 |
The genetics of Parkinson's disease: a reconsideration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Diseases in Twins; Genes; Humans; Mitochondria; Parkin | 1990 |
Mechanism of the neurotoxicity of MPTP. An update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biotransformation; Disease Models, Animal; Hu | 1990 |
Etiology of Parkinson's disease: current concepts.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Atrophy; Brain; Cerebral Palsy; DNA Repair; Eosine Yel | 1986 |
The neurotoxicity of MPTP and its relationship to the pathophysiology of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; MPTP Poisoning; Nervous System; Nervous System | 1989 |
Mechanisms underlying neuronal degeneration in Parkinson's disease: an experimental and theoretical treatise.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Survival; Free Radicals; Humans; | 1989 |
Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Humans; Neurotoxins; Oxidation-Reducti | 1989 |
[Contribution of MPTP to studies on the pathogenesis of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electron Transport; Mice; Mitochondria; Nerve | 1989 |
Receptor changes during chronic dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Diseases; Bromocripti | 1988 |
[Pathogenic substances in Parkinson disease and new therapeutics considering the etiologic mechanism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biopterins; Dopamine Agents; Droxidopa; Human | 1988 |
[The life history of brain dopamine].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Brain; Corpus Striatum; Cricetinae; Do | 1985 |
Parkinson's disease: recent advances in therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Antiparkinson Agents; Carbidopa; Dopa | 1988 |
MPTP effects on dopamine neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biogenic Amines; Brain; Des | 1988 |
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1986 |
The role of MAO in MPTP toxicity--a review.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chemical Phenomena; Chemistry; Haplorh | 1986 |
R-(-)-deprenyl and parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benserazide; Clorgyline; Dopamine; Drug Therapy, Combi | 1987 |
Deprenyl as prophylaxis against Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitor | 1988 |
Early parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Diagnosis, Differential; Humans; Parkinson Disease; Pa | 1986 |
Neuromelanin and its possible protective and destructive properties.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Designer Drugs; Humans; Melanins; Neur | 1987 |
The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomechanical Phenomena; Disease Susceptibili | 1987 |
MPTP: insights into the etiology of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Parkinson Disease; Parkinson Disease, Secondar | 1987 |
5 trials available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Parkinson Disease
| Article | Year |
|---|---|
Fetal-tissue transplants in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Brain Chemistry; Caudate Nucleus; Dopamine; Fetal Tiss | 1992 |
Big first scored with nerve diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Designer Drugs; Humans; Levo | 1989 |
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Clinical Trials as Topic; Double-Blind Method; F | 1989 |
R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Drug Therapy, Combination; H | 1987 |
Clinical trial for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aged; Clinical Trials as | 1985 |
823 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Parkinson Disease
| Article | Year |
|---|---|
Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Denervation; Macaca mulatta; Parkinson Diseas | 2022 |
Silibinin ameliorates depression/anxiety-like behaviors of Parkinson's disease mouse model and is associated with attenuated STING-IRF3-IFN-β pathway activation and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Depression; Disease Models, Animal; | 2021 |
Deficiency of
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Astrocytes; Dermis; Disease Models, An | 2021 |
Effect of sex and gonadectomy on brain MPTP toxicity and response to dutasteride treatment in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Castration; Corpus Striatum; Disease Models, | 2021 |
Regulation of neurotoxicity in the striatum and colon of MPTP-induced Parkinson's disease mice by gut microbiome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colon; Corpus Striatum; Disease Models, Anima | 2021 |
Garcinol blocks motor behavioural deficits by providing dopaminergic neuroprotection in MPTP mouse model of Parkinson's disease: involvement of anti-inflammatory response.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2022 |
Neuroinductive properties of mGDNF depend on the producer, E. Coli or human cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Escherichia coli; Gan | 2021 |
Impaired mitochondrial functions and energy metabolism in MPTP-induced Parkinson's disease: comparison of mice strains and dose regimens.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Ener | 2021 |
Association of decreased triadin expression level with apoptosis of dopaminergic cells in Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Carrier Proteins; Cell Survival; D | 2021 |
Bach1 derepression is neuroprotective in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Antioxidant Response | 2021 |
Exposure to varenicline protects against locomotor alteration in a MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Male; Mice; Mice, Inb | 2021 |
Discovery of Resorcinol-Based Polycyclic Structures as Tyrosinase Inhibitors for Treatment of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Mice; Mice, Inbred C5 | 2022 |
Decrease in
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antigens, CD; Cell Line; Dis | 2021 |
Pharmacological Modulation of TRPM2 Channels via PARP Pathway Leads to Neuroprotection in MPTP-induced Parkinson's Disease in Sprague Dawley Rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Neuroprotection; Oxidative Stress; Parkinson | 2022 |
Vancomycin Pretreatment on MPTP-Induced Parkinson's Disease Mice Exerts Neuroprotection by Suppressing Inflammation Both in Brain and Gut.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Infl | 2023 |
TRPV4 contributes to ER stress and inflammation: implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
LINC00943 acts as miR-338-3p sponge to promote MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell | 2022 |
Programmed Death-1 Deficiency Aggravates Motor Dysfunction in MPTP Model of Parkinson's Disease by Inducing Microglial Activation and Neuroinflammation in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Prussian Blue Nanozyme as a Pyroptosis Inhibitor Alleviates Neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ferrocyanides; Inflammasomes; Mice; Mice, Inb | 2022 |
Neuroprotective effects of Tongtian oral liquid, a Traditional Chinese Medicine in the Parkinson's disease-induced zebrafish model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
SIRT1 attenuates neuroinflammation by deacetylating HSPA4 in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Cytokines; Disease Models, Anima | 2022 |
Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dyskinesia, Drug-Induced; Humans; Infl | 2022 |
Kurarinone alleviated Parkinson's disease via stabilization of epoxyeicosatrienoic acids in animal model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Epoxide Hydrolases; F | 2022 |
Corynoxine B derivative CB6 prevents Parkinsonian toxicity in mice by inducing PIK3C3 complex-dependent autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkaloids; Animals; Autophagy; Class III Phosphatidyli | 2022 |
Reduced dopaminergic neuron degeneration and global transcriptional changes in Parkinson's disease mouse brains engrafted with human neural stems during the early disease stage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2022 |
In situ analysis of acupuncture protecting dopaminergic neurons from lipid peroxidative damage in mice of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Disease Models, Animal; | 2022 |
Effect of Different MPTP Administration Intervals on Mouse Models of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Co-treatment with natural HMGB1 inhibitor Glycyrrhizin exerts neuroprotection and reverses Parkinson's disease like pathology in Zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Glycyrrhizic Acid; HM | 2022 |
Protective Effect of CP690550 in MPTP-Induced Parkinson's Like Behavioural, Biochemical and Histological Alterations in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytokines; Disease Models, Animal; Dopaminerg | 2022 |
Neuronal SH2B1 attenuates apoptosis in an MPTP mouse model of Parkinson's disease via promoting PLIN4 degradation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Aged; Animals; A | 2022 |
Human IPSC 3D brain model as a tool to study chemical-induced dopaminergic neuronal toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2022 |
Intestinal Dopamine Receptor D2 is Required for Neuroprotection Against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Dopaminergic Neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2022 |
Development of early diagnosis of Parkinson's disease on animal models based on the intranasal administration of α-methyl-p-tyrosine methyl ester in a gel system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Corpus Striatum; | 2022 |
Cerebroventricular Injection of Pgk1 Attenuates MPTP-Induced Neuronal Toxicity in Dopaminergic Cells in Zebrafish Brain in a Glycolysis-Independent Manner.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2022 |
Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an α7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson's Disease Mouse Models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti | 2022 |
Alpha-lipoic acid improved motor function in MPTP-induced Parkinsonian mice by reducing neuroinflammation in the nigral and spinal cord.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Resilin, an insect-derived elastomeric protein, protects dopaminergic neurons in Parkinson disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Disease Models, | 2022 |
Characterization of retinal function and structure in the MPTP murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2022 |
Chitosan oligosaccharides exert neuroprotective effects
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Chitosan; Disease Models, An | 2022 |
Spontaneous partial recovery of striatal dopaminergic uptake despite nigral cell loss in asymptomatic MPTP-lesioned female minipigs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2022 |
Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cholecystokinin; Colon; Dise | 2022 |
lncRNA NEAT1 promotes autophagy of neurons in mice by impairing miR-107-5p.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Mice; | 2022 |
Treating Parkinson's Disease via Activation of BDNF/TrkB Signaling Pathways and Inhibition of Delta-Secretase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Amyloid Precursor Protein Secretases; | 2022 |
Garcinia morella extract confers dopaminergic neuroprotection by mitigating mitochondrial dysfunctions and inflammation in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2022 |
Association between Decreased ITGA7 Levels and Increased Muscle α-Synuclein in an MPTP-Induced Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antigens, CD; Disease Models | 2022 |
Exogenous Otx2 protects midbrain dopaminergic neurons from MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Cell Survival; Dopami | 2022 |
Inhibition of miR-421 Preserves Mitochondrial Function and Protects against Parkinson's Disease Pathogenesis via Pink1/Parkin-Dependent Mitophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Mice; MicroRNAs; Mitochondria; Mitoph | 2022 |
The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson's disease via the microglial NLRP3 inflammasome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Circadian Clocks; CLOCK Proteins; Cytokines; | 2022 |
Effects of hCG on DA neuronal death of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chorionic Gonadotropin; Disease Models, Anima | 2022 |
N-cystaminylbiguanide MC001 prevents neuron cell death and alleviates motor deficits in the MPTP-model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cysteamine; Disease Models, Anima | 2022 |
Artemisia Leaf Extract protects against neuron toxicity by TRPML1 activation and promoting autophagy/mitophagy clearance in both in vitro and in vivo models of MPP+/MPTP-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2022 |
Mangiferin, a natural glucoxilxanthone, inhibits mitochondrial dynamin-related protein 1 and relieves aberrant mitophagic proteins in mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Disease Models, Anima | 2022 |
Cannabidiol Alleviates the Damage to Dopaminergic Neurons in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease Mice Via Regulating Neuronal Apoptosis and Neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cannabidiol; Disease Models, Anima | 2022 |
Beneficial effect of transient desflurane inhalation on relieving inflammation and reducing signaling induced by MPTP in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Desflurane; Disease Models, Animal; Glial Fib | 2022 |
GSNOR deficiency attenuates MPTP-induced neurotoxicity and autophagy by facilitating CDK5 S-nitrosation in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alcohol Dehydrogenase; Animals; Autophagy; Cyclin-Depe | 2022 |
Neuroprotective effects of TRPV1 by targeting GDF11 in the Mpp+/MPTP-induced Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bone Morphogenetic Proteins; Disease Models, | 2022 |
DiHuangYin decoction protects dopaminergic neurons in a Parkinson's disease model by alleviating peripheral inflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Increased Expression of Alpha-, Beta-, and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain Stem; gamma-Synuclein; | 2022 |
Microglial AIM2 alleviates antiviral-related neuro-inflammation in mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiviral Agents; Disease Models, Animal; DNA | 2022 |
Identification of ADP/ATP Translocase 1 as a Novel Glycoprotein and Its Association with Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylgalactosamine; Adenine Nucleotide Translocator 1 | 2022 |
Açai Berry Mitigates Parkinson's Disease Progression Showing Dopaminergic Neuroprotection via Nrf2-HO1 Pathways.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Disease Progression; | 2022 |
CircSV2b participates in oxidative stress regulation through miR-5107-5p-Foxk1-Akt1 axis in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line, Tumor; Cell Proliferation; In Situ | 2022 |
High-frequency stimulation of the subthalamic nucleus induces a sustained inhibition of serotonergic system via loss of cell phenotype.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calcium; Deep Brain Stimulation; Mice; Parkin | 2022 |
Expression profiles of microRNAs in midbrain of MPTP-treated mice determined by microRNA sequencing.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Acute MPTP treatment decreases dendritic spine density of striatal medium spiny neurons via SNK-SPAR pathway in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dendritic Spines; Disease Mo | 2022 |
Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Creatine; Curcumin; Disease Models, Animal; G | 2022 |
Dental follicle cells show potential for treating Parkinson's disease through dopaminergic-neuronogenic differentiation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adolescent; Adult; Animals; Cell Differentiation; Cell | 2022 |
Shikonin ameliorates oxidative stress and neuroinflammation via the Akt/ERK/JNK/NF-κB signalling pathways in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cyclooxygenase 2; Disease Models, Animal; Dop | 2022 |
Pyruvate Prevents Dopaminergic Neurodegeneration and Motor Deficits in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2022 |
Neuroprotective effects of human umbilical cord mesenchymal stromal cells in PD mice via centrally and peripherally suppressing NLRP3 inflammasome-mediated inflammatory responses.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytokines; Disease Models, Animal; Dopamine; | 2022 |
Quercetin Protects against MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Dopaminergic Neurons; Ferroptosis; | 2022 |
Isoalantolactone (IAL) Regulates Neuro-Inflammation and Neuronal Apoptosis to Curb Pathology of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Infla | 2022 |
Anti-Inflammatory and Neuroprotective Effects of Morin in an MPTP-Induced Parkinson's Disease Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2022 |
Defining Specific Cell States of MPTP-Induced Parkinson's Disease by Single-Nucleus RNA Sequencing.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Endothelial Cells; Mi | 2022 |
GPBAR1 preserves neurite and synapse of dopaminergic neurons via RAD21-OPCML signaling: Role in preventing Parkinson's disease in mouse model and human patients.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analgesics, Opioid; Animals; Bile Acids and Salts; Cel | 2022 |
Neurochemical, histological, and behavioral profiling of the acute, sub-acute, and chronic MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Hyp | 2023 |
Characterization of neurobehavioral pattern in a zebrafish 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model: A 96-hour behavioral study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2022 |
Targeting microglial NLRP3 in the SNc region as a promising disease-modifying therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Disease Models, | 2022 |
Analysis of m6A modification regulators in the substantia nigra and striatum of MPTP-induced Parkinson's disease mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2022 |
Single-cell RNA sequencing of CSF reveals neuroprotective RAC1
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Killer Cells, Natural; Mice; | 2022 |
Fucosylated Chondroitin Sulfate against Parkinson's Disease through Inhibiting Inflammation Induced by Gut Dysbiosis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Chondroitin Sulfates; Diseas | 2022 |
Neuroprotective Effects of Sodium Butyrate and Monomethyl Fumarate Treatment through GPR109A Modulation and Intestinal Barrier Restoration on PD Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Butyric Acid; Claudin-1; Cytokines; Disease M | 2022 |
Early onset of sleep/wake disturbances in a progressive macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Macaca fascicularis; Parkinson Disease; Sleep | 2022 |
HLDF-6 peptides exhibit neuroprotective effects in the experimental model of preclinical Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estradiol; Humans; Mi | 2022 |
Dexmedetomidine alleviates pain in MPTP-treated mice by activating the AMPK/mTOR/NF-κB pathways in astrocytes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Astrocytes; De | 2022 |
Feruloylated oligosaccharides ameliorate MPTP-induced neurotoxicity in mice by activating ERK/CREB/BDNF/TrkB signalling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Disease Mo | 2023 |
Inhibiting von Hippel‒Lindau protein-mediated Dishevelled ubiquitination protects against experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; beta Catenin; Caenorhabditis elegans; Disease | 2023 |
Gastric Enteric Glial Cells: A New Contributor to the Synucleinopathies in the MPTP-Induced Parkinsonism Mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Mice | 2022 |
Neuroprotective Effects of
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bifidobacterium; Bifidobacterium breve; Disea | 2022 |
CXCR4 knockout induces neuropathological changes in the MPTP-lesioned model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Mice; Mice, Inbred C57BL; Nervous System Dise | 2023 |
Association Between Decreased Srpk3 Expression and Increased Substantia Nigra Alpha-Synuclein Level in an MPTP-Induced Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2023 |
Intermittent fasting protects the nigral dopaminergic neurons from MPTP-mediated dopaminergic neuronal injury in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2023 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Mitochonic acid 5 ameliorates the motor deficits in the MPTP-induced mouse Parkinson's disease model by AMPK-mediated autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Autophagy; Dis | 2022 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Neuroprotective potential of plant derived parenchymal stem cells extract on environmental and genetic models of Parkinson disease through attenuation of oxidative stress and neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Disease Models | 2023 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
Epimedin B exerts neuroprotective effect against MPTP-induced mouse model of Parkinson's disease: GPER as a potential target.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Estrogens; Flavonoids | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
Probiotic
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain-Gut Axis; gamma-Aminob | 2022 |
Probiotic
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain-Gut Axis; gamma-Aminob | 2022 |
Probiotic
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain-Gut Axis; gamma-Aminob | 2022 |
Probiotic
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain-Gut Axis; gamma-Aminob | 2022 |
Transcriptomic and metabolomic analyses provide insights into the attenuation of neuroinflammation by nervonic acid in MPTP-stimulated PD model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arachidonic Acids; Disease Models, Animal; Hu | 2023 |
Transcriptomic and metabolomic analyses provide insights into the attenuation of neuroinflammation by nervonic acid in MPTP-stimulated PD model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arachidonic Acids; Disease Models, Animal; Hu | 2023 |
Transcriptomic and metabolomic analyses provide insights into the attenuation of neuroinflammation by nervonic acid in MPTP-stimulated PD model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arachidonic Acids; Disease Models, Animal; Hu | 2023 |
Transcriptomic and metabolomic analyses provide insights into the attenuation of neuroinflammation by nervonic acid in MPTP-stimulated PD model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arachidonic Acids; Disease Models, Animal; Hu | 2023 |
Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Mice; Mice, | 2023 |
Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Mice; Mice, | 2023 |
Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Mice; Mice, | 2023 |
Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Mice; Mice, | 2023 |
4-Aminopyridine Protects Nigral Dopaminergic Neurons in the MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 4-Aminopyridine; Animals; Disease Models, Animal; Dopa | 2023 |
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Disease Models, Animal; Dopaminergic Ne | 2023 |
Modeling of the Progressive Degradation of the Nigrostriatal Dopaminergic System in Mice to Study the Mechanisms of Neurodegeneration and Neuroplasticity in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2022 |
Cordycepin improved the cognitive function through regulating adenosine A
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Cognition; Disease Models, Animal; | 2023 |
Artemisinin exerts a protective effect in the MPTP mouse model of Parkinson's disease by inhibiting microglial activation via the TLR4/Myd88/NF-KB pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Animals; Artemis | 2023 |
Glimepiride Prevents 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Induced Dopamine Neurons Degeneration Through Attenuation of Glia Activation and Oxidative Stress in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diabetes Mellitus, Type 2; Disease Models, An | 2023 |
Gut Microbial Alteration in MPTP Mouse Model of Parkinson Disease is Administration Regimen Dependent.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Neuroprotective role of chloroquine via modulation of autophagy and neuroinflammation in MPTP-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Chloroquine; Disease Models, Anima | 2023 |
Protective Effects of Flavonoid Rutin Against Aminochrome Neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2023 |
Neuroprotective effects of fermented tea in MPTP-induced Parkinson's disease mouse model via MAPK signaling-mediated regulation of inflammation and antioxidant activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Inflammation; Mice; Mice, Inbre | 2023 |
Investigating Therapeutic Effects of Indole Derivatives Targeting Inflammation and Oxidative Stress in Neurotoxin-Induced Cell and Mouse Models of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Disease Models, | 2023 |
Anti-oxidative and anti-neuroinflammatory role of Necrostatin-1s and docosahexaenoic acid in RIP-1-mediated neurotoxicity in MPTP-induced Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Disease Models, Animal; Docosah | 2023 |
Endonuclease VIII-like 1 deficiency potentiates nigrostriatal dopaminergic neuron degeneration in a male mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Deoxyribonuclease (Pyrimidin | 2023 |
Paeoniflorin protects 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mice by inhibiting oxidative stress and neuronal apoptosis through activating the Nrf2/HO-1 signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Caspas | 2023 |
Whether the Subacute MPTP-Treated Mouse is as Suitable as a Classic Model of Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2023 |
Zinc Deficiency Exacerbates Behavioral Impediments and Dopaminergic Neuron Degeneration in a Mouse Model of Parkinson Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diet; Disease Models, Animal; Dopamine; Dopam | 2023 |
Rhynchophylline alleviates neuroinflammation and regulates metabolic disorders in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Metabolic Diseases; M | 2023 |
Suppression of neuroinflammation and α-synuclein oligomerization by rotarod walking exercise in subacute MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
Microarrays, Enzymatic Assays, and MALDI-MS for Determining Specific Alterations to Mitochondrial Electron Transport Chain Activity, ROS Formation, and Lipid Composition in a Monkey Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electron Transport; Enzyme Assays; Haplorhini | 2023 |
Novel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
NOD-like receptor NLRC5 promotes neuroinflammation and inhibits neuronal survival in Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2023 |
Zinc (Zn) and adipose-derived mesenchymal stem cells (AD-MSCs) on MPTP-induced Parkinson's disease model: A comparative evaluation of behavioral and immunohistochemical results.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Disease Mo | 2023 |
Involvement of Abnormal p-α-syn Accumulation and TLR2-Mediated Inflammation of Schwann Cells in Enteric Autonomic Nerve Dysfunction of Parkinson's Disease: an Animal Model Study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Autonomic Pathways; Disease | 2023 |
Apoptotic Factors and Mitochondrial Complexes Assist Determination of Strain-Specific Susceptibility of Mice to Parkinsonian Neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Dopaminergic Neurons; Mice; | 2023 |
Neuroprotective microRNA-381 Binds to Repressed Early Growth Response 1 (EGR1) and Alleviates Oxidative Stress Injury in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Disease Models, | 2023 |
Effect of Eleutheroside E on an MPTP-Induced Parkinson's Disease Cell Model and Its Mechanism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Mice; Mice, Inbred C5 | 2023 |
Treadmill Exercise Alleviates Cognition Disorder by Activating the FNDC5: Dual Role of Integrin αV/β5 in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Cognition | 2023 |
Morin exhibits a neuroprotective effect in MPTP-induced Parkinson's disease model via TFEB/AMPK-mediated mitophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Disease Models | 2023 |
The adenosine A
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Drug Invers | 2023 |
Necrosulfonamide exerts neuroprotective effect by inhibiting necroptosis, neuroinflammation, and α-synuclein oligomerization in a subacute MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
Orally Induced High Serum Level of Trimethylamine N-oxide Worsened Glial Reaction and Neuroinflammation on MPTP-Induced Acute Parkinson's Disease Model Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2023 |
A Low-Protein, High-Carbohydrate Diet Exerts a Neuroprotective Effect on Mice with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson's Disease by Regulating the Microbiota-Metabolite-Brain Axis and Fibroblast Growth Factor 21.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Diet; Disease Models, Animal; Dopamine | 2023 |
The Transcription Factor Nrf2 Mediates the Effects of
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Novel flavonoid 1,3,4-oxadiazole derivatives ameliorate MPTP-induced Parkinson's disease via Nrf2/NF-κB signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Disea | 2023 |
Casein Reactivates Dopaminergic Nerve Injury and Intestinal Inflammation with Disturbing Intestinal Microflora and Fecal Metabolites in a Convalescent Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caseins; Disease Models, Animal; Dopamine; Ga | 2023 |
Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gastrointestinal Micr | 2023 |
The molecular mechanism of three novel peptides from C-phycocyanin alleviates MPTP-induced Parkinson's disease-like pathology in zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Antioxidants; Disease M | 2023 |
Integrative multilevel exploration of the mechanism by which Er-Zhi-Wan alleviates the Parkinson's disease (PD)-like phenotype in the MPTP-induced PD mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, Liquid; Disease Models, Anima | 2023 |
Amelioration of Parkinson's disease by pharmacological inhibition and knockdown of redox sensitive TRPC5 channels: Focus on mitochondrial health.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Calcium; Dopamin | 2023 |
Vitamin E Analog Trolox Attenuates MPTP-Induced Parkinson's Disease in Mice, Mitigating Oxidative Stress, Neuroinflammation, and Motor Impairment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
HDAC6 Deficiency Has Moderate Effects on Behaviors and Parkinson's Disease Pathology in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2023 |
Low-Field Magnetic Stimulation Alleviates MPTP-Induced Alterations in Motor Function and Dopaminergic Neurons in Male Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2023 |
Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Corpus Striatum; Disease Models, Ani | 2023 |
Dopaminergic neuroprotective effects of inosine in MPTP-induced parkinsonian mice via brain-derived neurotrophic factor upregulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Dopamine; | 2023 |
BDNF alleviates Parkinson's disease by promoting STAT3 phosphorylation and regulating neuronal autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Brain-Derived Neurotrophic Factor; | 2023 |
Protective Effect of a New Monophenolic Antioxidant TS-13 in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Disease Models, Animal; Mice; M | 2023 |
Wuzi Yanzong Pill relieves MPTP-induced motor dysfunction and neuron loss by inhibiting NLRP3 inflammasome-mediated neuroinflammation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2023 |
The Involvement of Progranulin for α-Synuclein Reduction through Autolysosome Formation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
Investigation of rhodamine derivative on behavioral impairment in a double neurotoxin lesion of substantia nigra and locus coeruleus dysfunctional mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Neuroprotective effect of chlorogenic acid on Parkinson's disease like symptoms through boosting the autophagy in zebrafish.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Chlorogenic Acid; Disease Models, | 2023 |
Huperzine A injection ameliorates motor and cognitive abnormalities via regulating multiple pathways in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholinesterase; Animals; Cognition; Disease Mode | 2023 |
Whole Transcriptome Analysis of Substantia Nigra in Mice with MPTP-Induced Parkinsonism Bearing Defective Glucocerebrosidase Activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gene Expression Profi | 2023 |
N-acetyl-L-leucine protects MPTP-treated Parkinson's disease mouse models by suppressing Desulfobacterota via the gut-brain axis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Gut Axis; Disease Models, Animal; Dopam | 2023 |
Association between SGK1 and α-synuclein in skeletal muscle in an MPTP-induced Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2023 |
Oral administration of sophoricoside (SOP) inhibits neuronal damage and neuroinflammation to curb neurodegeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Administration, Oral; Ani | 2023 |
Novel HDAC inhibitors provide neuroprotection in MPTP-induced Parkinson's disease model of rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Histone Dea | 2023 |
TLR2 deficiency is beneficial at the late phase in MPTP-induced Parkinson' disease mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2023 |
Tuned to Tremor: Increased Sensitivity of Cortico-Basal Ganglia Neurons to Tremor Frequency in the MPTP Nonhuman Primate Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Female; Globus Pallidus; Neuro | 2023 |
Low-moderate dose whole-brain γ-ray irradiation modulates the expressions of glial fibrillary acidic protein and intercellular adhesion molecule-1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2023 |
Total Glucosides of White Paeony Capsule ameliorates Parkinson's disease-like behavior in MPTP-induced mice model by regulating LRRK2/alpha-synuclein signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Dopa | 2024 |
A primate nigrostriatal atlas of neuronal vulnerability and resilience in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2023 |
Extracellular microvesicles-derived from microglia treated with unaggregated α-synuclein attenuate mitochondrial fission and toxicity-induced by Parkinsonian toxin MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Cell Line, Tumor; Cell Survival; Cell | 2019 |
MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Anesthetics, Dissociative; | 2020 |
Neuroprotective and Neurotherapeutic Effects of Tetrahedral Framework Nucleic Acids on Parkinson's Disease
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Apoptosis; bcl-2-Associated | 2019 |
AAV-Mediated Expression of Dominant-Negative ULK1 Increases Neuronal Survival and Enhances Motor Performance in the MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy-Related Protein-1 Homolog; Behavior | 2020 |
Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Alanine Transaminase; Anim | 2020 |
2,3,5,4'-Tetrahydroxystilbene-2-O-β-d-glucoside attenuates MPP+/MPTP-induced neurotoxicity in vitro and in vivo by restoring the BDNF-TrkB and FGF2-Akt signaling axis and inhibition of apoptosis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Brain | 2019 |
Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Blood | 2019 |
RIP1/RIP3/MLKL mediates dopaminergic neuron necroptosis in a mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytokines; Disease Models, Animal; Dopaminerg | 2020 |
Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious precl
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Callithrix; Corpus S | 2020 |
Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson's disease mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Disease Models, Animal; DNA Glyc | 2020 |
Peripheral Delivery of Neural Precursor Cells Ameliorates Parkinson's Disease-Associated Pathology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Embryonic Stem Cells; | 2019 |
Enhanced neuroinflammation and oxidative stress are associated with altered hippocampal neurogenesis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2019 |
Comparative strategies for stem cell biodistribution in a preclinical study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Disease Models, A | 2020 |
Changes in thalamic dopamine innervation in a progressive Parkinson's disease model in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Axons; Dopamine; Haplorhini; Parkinson Diseas | 2020 |
Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Basal Ganglia; Bl | 2019 |
[Study on preventive and therapeutic effects of Erzhi Pills on mice with Parkinson's disease induced by MPTP].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Drugs, Chinese Herbal | 2019 |
NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cognition; Disease Mode | 2020 |
Pro-survival and anti-inflammatory roles of NF-κB c-Rel in the Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Case-Control Studies; Cell Line; Disease Mode | 2020 |
Activation of CB2R with AM1241 ameliorates neurodegeneration via the Xist/miR-133b-3p/Pitx3 axis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cannabinoids; Disease Models, Animal; Dopamin | 2020 |
Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2020 |
Chronic Infiltration of T Lymphocytes into the Brain in a Non-human Primate Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2020 |
LncRNA BDNF-AS promotes autophagy and apoptosis in MPTP-induced Parkinson's disease via ablating microRNA-125b-5p.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Brain-Derived Neurotrophic Factor; | 2020 |
Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; DEAD-box RNA Helicases; | 2020 |
Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Blood- | 2020 |
Gait Deficits and Loss of Striatal Tyrosine Hydroxlase/Trk-B are Restored Following 7,8-Dihydroxyflavone Treatment in a Progressive MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Flav | 2020 |
The Effect of Low-Intensity Transcranial Ultrasound Stimulation on Behavior in a Mouse Model of Parkinson's Disease Induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Disease Models, Anim | 2020 |
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2020 |
Lanthionine ketimine ester improves outcome in an MPTP-induced mouse model of Parkinson's disease via suppressions of CRMP2 phosphorylation and microglial activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids, Sulfur; Animals; Disease Models, Animal; | 2020 |
BMAL1 regulation of microglia-mediated neuroinflammation in MPTP-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; ARNTL Transcription Factors; Disease Models, | 2020 |
Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disabled Persons; Disease Models, | 2020 |
NLRP3 inflammasome and glia maturation factor coordinately regulate neuroinflammation and neuronal loss in MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cells, Cultured; Disease Models, A | 2020 |
Bruceine D elevates Nrf2 activation to restrain Parkinson's disease in mice through suppressing oxidative stress and inflammatory response.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2020 |
A Mouse Model of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Induced Parkinson Disease Shows that 2-Aminoquinoline Targets JNK Phosphorylation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aminoquinolines; Animals; | 2020 |
TAT-tagging of VIP exerts positive allosteric modulation of the PAC1 receptor and enhances VIP neuroprotective effect in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Allosteric Regulation; Animals; Cell Survival; Cell-Pe | 2020 |
Transcriptomic Profiling of Circular RNA in Different Brain Regions of Parkinson's Disease in a Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Computational Biology; Disease Models, | 2020 |
Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Clioquinol; Disease Models, Animal; Haplorhin | 2020 |
Down-regulation of DJ-1 Augments Neuroinflammation via Nrf2/Trx1/NLRP3 Axis in MPTP-induced Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Down-Regulation; Mice | 2020 |
Editorial for the Special Issue "Animal Models of Parkinson's Disease and Related Disorders".
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Early Diagnosis; Huma | 2020 |
Neuroprotective Effect of Chlorogenic Acid on Mitochondrial Dysfunction-Mediated Apoptotic Death of DA Neurons in a Parkinsonian Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Apoptosis; Behavior, Animal; Ch | 2020 |
Basal ganglia beta oscillations during sleep underlie Parkinsonian insomnia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Beta Rhythm; Cerebral Cortex; | 2020 |
Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Lactobacillus plantar | 2020 |
The insect molting hormone 20-hydroxyecdysone protects dopaminergic neurons against MPTP-induced neurotoxicity in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2020 |
Puerarin suppresses MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Isoflavones; Mice; Mice, Knockout; Motor Acti | 2020 |
Docosahexaenoic acid-acylated astaxanthin ester exhibits superior performance over non-esterified astaxanthin in preventing behavioral deficits coupled with apoptosis in MPTP-induced mice with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Brain; Disease Models, Animal; Doc | 2020 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Induced Parkinson's Disease in Mouse: Potential Association between Neurotransmitter Disturbance and Gut Microbiota Dysbiosis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dysbiosis; Gastrointestinal Microbiome; Mice; | 2020 |
Tristetraprolin destabilizes NOX2 mRNA and protects dopaminergic neurons from oxidative damage in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Dopaminergic Neurons; Humans; Mice | 2020 |
LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Brain; Cell Line; Enh | 2020 |
Molecular Regulatory Mechanism and Toxicology of Neurodegenerative Processes in MPTP/Probenecid-Induced Progressive Parkinson's Disease Mice Model Revealed by Transcriptome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Gen | 2021 |
Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Capsaicin; Disease Models, Animal; Dopaminerg | 2020 |
Functional validation of a human GLUD2 variant in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Transport System X-AG; Animals; Brain-Deriv | 2020 |
Korean Red Ginseng Regulates Intestinal Tight Junction and Inflammation in the Colon of a Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Colon; Disease Models, Anima | 2020 |
Therapeutic Potential of Repeated Intravenous Transplantation of Human Adipose-Derived Stem Cells in Subchronic MPTP-Induced Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intravenous; Animals; Disease Models, | 2020 |
2-Hydroxy-4-Methylbenzoic Anhydride Inhibits Neuroinflammation in Cellular and Experimental Animal Models of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Benzoates; Cell Surviva | 2020 |
Human Amniotic Epithelial Cells Alleviate a Mouse Model of Parkinson's Disease Mainly by Neuroprotective, Anti-Oxidative and Anti-Inflammatory Factors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2021 |
Ellagic Acid Prevents Dopamine Neuron Degeneration from Oxidative Stress and Neuroinflammation in MPTP Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2020 |
Brain Selective Estrogen Treatment Protects Dopaminergic Neurons and Preserves Behavioral Function in MPTP-induced Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Disease Models, Anima | 2021 |
Glycine nano-selenium prevents brain oxidative stress and neurobehavioral abnormalities caused by MPTP in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Behavior, Animal; Brain | 2021 |
Blood Exosomes Have Neuroprotective Effects in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2020 |
MPTP toxicity causes vocal, auditory, orientation and movement defects in the echolocation bat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Aromatic-L-Amino-Acid Decarboxylas | 2021 |
DNA Methyltransferase 1 Is Dysregulated in Parkinson's Disease via Mediation of miR-17.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line, Tumor; Disease Models, Animal; DNA | 2021 |
Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
Effects and potential mechanisms of rapamycin on MPTP-induced acute Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Mice; Mice, Inbred C57BL; Parkinson Disease; | 2021 |
Andrographolide upregulates protein quality control mechanisms in cell and mouse through upregulation of mTORC1 function.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Diterpenes; Gene Ex | 2021 |
Neuroprotective and Anti-Inflammatory Effects of Evernic Acid in an MPTP-Induced Parkinson's Disease Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Apoptosis; Astrocyt | 2021 |
Depression Induced by Chronic Unpredictable Mild Stress Increases Susceptibility to Parkinson's Disease in Mice via Neuroinflammation Mediated by P2X7 Receptor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Depression; Disease Models, Animal; Mice; Mic | 2021 |
Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease via Inhibition of A1 Reactive Astrocytes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Disease Models, Animal; Dopaminer | 2021 |
G-CSF reduces loss of dopaminergic neurons by inhibiting TNF-α and IL-1β in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2023 |
Transcranial Ultrasound Stimulation Suppresses Neuroinflammation in a Chronic Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzofurans; Body Weight; Disease Models, Ani | 2021 |
The association of enteric neuropathy with gut phenotypes in acute and progressive models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Cell Count; Chronic Disease; C | 2021 |
Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
The Neuroprotective Effects of GPR4 Inhibition through the Attenuation of Caspase Mediated Apoptotic Cell Death in an MPTP Induced Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Brain; Caspase 3; Caspases; Corpus | 2021 |
A Pilot Study of Changes in the Level of Catecholamines and the Activity of α-2-Macroglobulin in the Tear Fluid of Patients with Parkinson's Disease and Parkinsonian Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Area Under Curve; Biomarkers; Case-Control St | 2021 |
Generation of Mitochondrial Toxin Rodent Models of Parkinson's Disease Using 6-OHDA , MPTP , and Rotenone.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Male; Mice; | 2021 |
The neuroprotective effects of isoquercitrin purified from apple pomace by high-speed countercurrent chromatography in the MPTP acute mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Countercurrent Distribution; Disea | 2021 |
Epigenetic mechanisms involved in the neuroprotective effect of scorpion extract in a Parkinson's disease murine model based on multi-omics approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Epigenesis, Genetic; | 2021 |
The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Glucagon-Like Peptide | 2021 |
Thioredoxin-1 regulates calcium homeostasis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calcium; Disease Models, Animal; Homeostasis; | 2021 |
Brain-derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Cognitive | 2021 |
Silibinin attenuates motor dysfunction in a mouse model of Parkinson's disease by suppression of oxidative stress and neuroinflammation along with promotion of mitophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
PEP-1-GLRX1 Reduces Dopaminergic Neuronal Cell Loss by Modulating MAPK and Apoptosis Signaling in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell | 2021 |
4,4'-Dimethoxychalcone regulates redox homeostasis by targeting riboflavin metabolism in Parkinson's disease therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2021 |
Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; CD8 Antigens; CD8-Positive T-Lymphocyt | 2021 |
Neuroprotective effects of 2,4-dinitrophenol in an acute model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,4-Dinitrophenol; Animals; Cell Death; Dinitrophenols | 2017 |
Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Cell Line; Disea | 2017 |
Dysfunction of mitochondrial Lon protease and identification of oxidized protein in mouse brain following exposure to MPTP: Implications for Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aconitate Hydratase; Animals; Cell Death; Disease Mode | 2017 |
Effect of dental pulp stem cells in MPTP-induced old-aged mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Behavior, Animal; Cell Differentiation | 2017 |
Effects of a combination treatment of KD5040 and
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cyclic AMP Response Element-Binding Pr | 2017 |
Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cyclic AMP; Cyclic AMP Resp | 2017 |
MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2018 |
Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Ascorbic Acid; Benzothiazoles; | 2017 |
Neuroprotective effects of total flavonoid fraction of the Epimedium koreanum Nakai extract on dopaminergic neurons: In vivo and in vitro.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Cell L | 2017 |
Complete Comparison Display (CCD) evaluation of ethanol extracts of Centella asiatica and Withania somnifera shows that they can non-synergistically ameliorate biochemical and behavioural damages in MPTP induced Parkinson's model of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bioma | 2017 |
Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Calcium Channel Blockers; Calcium | 2017 |
Treadmill exercise produces neuroprotective effects in a murine model of Parkinson's disease by regulating the TLR2/MyD88/NF-κB signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Corpus Striatum; Disease Mod | 2017 |
A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Glucose; Body Weight; Brain; Calcium-Bi | 2017 |
Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Anti-Inflammatory | 2017 |
Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biomarkers; Callithrix; Dis | 2017 |
Decreased Rhes mRNA levels in the brain of patients with Parkinson's disease and MPTP-treated macaques.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Bipolar Disorder; Br | 2017 |
Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Brain-Derived Neurotrophic Factor; | 2017 |
Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aged, 80 and over; Animals; Cell Prolifer | 2017 |
[Effect of Shouwu Shudi Yin on dopaminegic neurons in MPTP induced Parkinson's disease mouse model].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2016 |
Objectively measuring effects of electro-acupuncture in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Apomorphine; Corpus Stri | 2018 |
Physical Exercise Modulates L-DOPA-Regulated Molecular Pathways in the MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Gene | 2018 |
Role of ethanolic extract of Bacopa monnieri against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced mice model via inhibition of apoptotic pathways of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Bacopa; Disease Models, Animal; Do | 2017 |
Overexpression of miR‑185 inhibits autophagy and apoptosis of dopaminergic neurons by regulating the AMPK/mTOR signaling pathway in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Apoptosis; Autophagy; C | 2018 |
Mild hyperbaric oxygen inhibits the decrease of dopaminergic neurons in the substantia nigra of mice with MPTP-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2018 |
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzene Derivatives; Disease Models, Animal; | 2018 |
MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytokines; Disease Models, Animal; Gene Expre | 2018 |
(-)-Epigallocatechin-3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catechin; Disease Models, Animal; Dopaminergi | 2018 |
The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Banisteriopsis; Callith | 2018 |
Whole-Transcriptome Analysis of Mouse Models with MPTP-Induced Early Stages of Parkinson's Disease Reveals Stage-Specific Response of Transcriptome and a Possible Role of Myelin-Linked Genes in Neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cluster Analysis; Disease Models, Animal; Exo | 2018 |
Naringenin Decreases α-Synuclein Expression and Neuroinflammation in MPTP-Induced Parkinson's Disease Model in Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Anti-Inflammatory Agents; Cy | 2018 |
In vivo GluCEST MRI: Reproducibility, background contribution and source of glutamate changes in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Transport; Disease Models, Animal; | 2018 |
Pharmacological Inhibition of Necroptosis Protects from Dopaminergic Neuronal Cell Death in Parkinson's Disease Models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Differentiation; Disease Mode | 2018 |
Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-Associated Death Protein; Brain; Fingolim | 2018 |
Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Autophagy; Caspase 3; Cell Line, Tumor; Cell Survival; | 2018 |
The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Anti-Inflammatory Agent | 2018 |
N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; alpha-Synuclein; Amides; Animals; Behavior, Ani | 2018 |
Regulatable Lentiviral Hematopoietic Stem Cell Gene Therapy in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Differentiation; Corpus Striatum; Diseas | 2018 |
Targeted deletion of the aquaglyceroporin AQP9 is protective in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aquaporins; Disease Models, Animal; Dopaminer | 2018 |
Neural Stem Cell Grafts Promote Astroglia-Driven Neurorestoration in the Aged Parkinsonian Brain via Wnt/β-Catenin Signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Astrocytes; Brain; Cell Death; Cell Di | 2018 |
TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arginase; Cell Line; Cell Polarity; Cytokines | 2018 |
Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gait; Hindlimb; Homeo | 2018 |
2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Astrocytes; Behavior, Animal | 2018 |
Down-regulation of natural resistance-associated macrophage protein-1 (Nramp1) is associated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/1-methyl-4-phenylpyridinium (MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; alpha-Synuclein; Animals; Cat | 2019 |
Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cell Line; Corpus Striatum; | 2018 |
MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Death; Disease Models, | 2019 |
PPARß/δ agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2019 |
Effect of Zishenpingchan granule prepared from Chinese medicinal substances on the c-Jun N-terminal protein kinase pathway in mice\
with Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cyclooxygenase 2; Disease Models, | 2017 |
Octanoic acid prevents reduction of striatal dopamine in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caprylates; C | 2018 |
Cell-penetrating artificial mitochondria-targeting peptide-conjugated metallothionein 1A alleviates mitochondrial damage in Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Sequence; Animals; Cell Death; Cell Line, T | 2018 |
Upgraded Methodology for the Development of Early Diagnosis of Parkinson's Disease Based on Searching Blood Markers in Patients and Experimental Models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Case-Control Studies; Catecholami | 2019 |
Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age of Onset; Animals; Callithrix; Circadian Rhythm; D | 2018 |
Modulation of mitochondrial phenotypes by endurance exercise contributes to neuroprotection against a MPTP-induced animal model of PD.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Disease Models, Animal; Exercise T | 2018 |
Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Ente | 2018 |
Comparative evaluation of extract of Bacopa monnieri and Mucuna pruriens as neuroprotectant in MPTP model of Parkinson’s disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bacopa; Disease Models, Animal; Mice; Mice, I | 2016 |
Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Animals; Apoptosis; Corpus | 2018 |
Proanthocyanidins exert a neuroprotective effect via ROS/JNK signaling in MPTP‑induced Parkinson's disease models in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Proliferation; Cell Survival; | 2018 |
Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Dopa | 2018 |
Anodal transcranial direct current stimulation prevents methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity by modulating autophagy in an in vivo mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Biomarkers; Brain-Derived Neurotro | 2018 |
Genetic suppression of collapsin response mediator protein 2 phosphorylation improves outcome in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2019 |
Nicotine promotes neuron survival and partially protects from Parkinson's disease by suppressing SIRT6.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Animals, Newborn; Ap | 2018 |
Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Astrocytes; Disease Models, | 2019 |
TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson's diseases in vivo model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cytokines; Disease Models, A | 2019 |
EriB targeted inhibition of microglia activity attenuates MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Nucleus; Cy | 2018 |
Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Behavior, Animal; Cognition; Corpu | 2019 |
5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells aga
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Humans; Inflam | 2019 |
The toxin MPTP generates similar cognitive and locomotor deficits in hTau and tau knock-out mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Alzheimer Disease; Animals; Brain; Co | 2019 |
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Female; Locomotion; M | 2019 |
Norfluoxetine Prevents Degeneration of Dopamine Neurons by Inhibiting Microglia-Derived Oxidative Stress in an MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2018 |
miR-9-5p modulates the progression of Parkinson's disease by targeting SIRT1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Cell Line, Tumor; Cell Survival; Gene Expression Regul | 2019 |
Apelin-13 protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through inhibiting endoplasmic reticulum stress and promoting autophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Apelin; Autophagy; Beclin-1; | 2019 |
An injectable conductive Gelatin-PANI hydrogel system serves as a promising carrier to deliver BMSCs for Parkinson's disease treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aniline Compounds; Animals; Brain-Derived Neurotrophic | 2019 |
Hippocampal damage and white matter lesions contribute to cognitive impairment in MPTP-lesioned mice with chronic cerebral hypoperfusion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Brain; Brain Ischemia; Carotid Ste | 2019 |
MicroRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Autophagy; Cell Line; Cell Line, T | 2019 |
Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cytochrome P-450 CYP2D6; Disease Models, Anim | 2019 |
Impairment of Nrf2- and Nitrergic-Mediated Gastrointestinal Motility in an MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2019 |
Kir6.1/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease via promoting mitophagy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Astrocytes; Corpus St | 2019 |
Role of microtubule-associated protein 6 glycosylated with Gal-(β-1,3)-GalNAc in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, Affinity; Disease Models, Ani | 2019 |
miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antagomirs; Disease Models, Animal; Dopamine; | 2019 |
Andrographolide alleviates Parkinsonism in MPTP-PD mice via targeting mitochondrial fission mediated by dynamin-related protein 1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line, Tumor; Cell Survival; Diterpenes; | 2019 |
Angiogenin in Parkinson disease models: role of Akt phosphorylation and evaluation of AAV-mediated angiogenin expression in MPTP treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Cell Line, Tumor; Dependovirus; D | 2013 |
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Case-Control Studies; Ceruloplasmin; De | 2013 |
Neuroprotective effects of puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease model in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2014 |
Survival and integration of neurons derived from human embryonic stem cells in MPTP-lesioned primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Differentiation; Chlorocebus aethiops; D | 2014 |
Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adoptive Transfer; Animals; CD4-Positive T-Lymphocytes | 2013 |
Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Brain; Corpus Striatum; | 2013 |
The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Brain | 2013 |
Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Circadian Rhythm; Cognition | 2013 |
Reduced cholinergic olfactory centrifugal inputs in patients with neurodegenerative disorders and MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Alzheimer Disease; Animals; C | 2013 |
Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2013 |
Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-2-Associated X Protein; Disease Models, A | 2013 |
Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis Regulatory Proteins; Ataxia; Behavi | 2013 |
Saffron pre-treatment offers neuroprotection to Nigral and retinal dopaminergic cells of MPTP-Treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Crocus; Disease Models, Animal; Dopaminergic | 2013 |
Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiogenesis Inducing Agents; Animals; Becaplermin; Ce | 2011 |
Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Basal Ganglia; Behavior, Ani | 2013 |
Imaging of superoxide generation in the dopaminergic area of the brain in Parkinson's disease, using mito-TEMPO.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Cyclic N-Oxides; Disease Models | 2013 |
Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Be | 2014 |
Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Estrogens; | 2014 |
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; | 2014 |
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Disease Models, | 2014 |
Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Gene-Environment Interaction; Genetic Predisp | 2014 |
Parkinson's disease, lights and melanocytes: looking beyond the retina.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Female; Light; Male; | 2014 |
PEP-1-HO-1 prevents MPTP-induced degeneration of dopaminergic neurons in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cell Line, Tumor; Disease Models, | 2014 |
Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Hypokinesia; Levodopa; Maca | 2014 |
Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allopurinol; Animals; | 2013 |
Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Dopami | 2014 |
Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Disease Models, Animal; Dopamine; | 2014 |
Neuroprotective effects of mesenchymal stem cells through autophagy modulation in a parkinsonian model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2014 |
BAX channel activity mediates lysosomal disruption linked to Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-2-Associated X Protein; Brain; Cells, Cul | 2014 |
Gene expression regulation of Bcl2, Bax and cytochrome-C by geraniol on chronic MPTP/probenecid induced C57BL/6 mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acyclic Monoterpenes; Animals; Apoptosis; bcl-2-Associ | 2014 |
Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Astrocytes; Chemistry, Pharmace | 2014 |
The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Blood-Brain Barrier; Brain; | 2014 |
Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calpain; Cell Death; Cells, Cultured; Cyclin- | 2014 |
Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2014 |
Regulation of the VHL/HIF-1 pathway by DJ-1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Embryo, Mammalian; Female; G | 2014 |
Guanosine exerts neuroprotective effects by reversing mitochondrial dysfunction in a cellular model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; bcl-2 | 2014 |
[P38 MAPK signaling pathway regulates nuclear factor-κB and inducible nitric oxide synthase expressions in the substantia nigra in a mouse model of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Imidazoles; MAP Kinas | 2014 |
PRDX6 Exacerbates Dopaminergic Neurodegeneration in a MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Behavior, Animal; Cells, Cultured | 2015 |
Effect of monocrotophos, an organophosphorus insecticide, on the striatal dopaminergic system in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2016 |
(1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2014 |
Endometrial stem cell transplantation in MPTP- exposed primates: an alternative cell source for treatment of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Cell Movement; Endometrium; Femal | 2015 |
A novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia and in Parkinson's disease animal model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Animals; Anti-In | 2015 |
Protective effects of PEP-1-Catalase on stress-induced cellular toxicity and MPTP-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Death; Cell Line; Cell Survival; | 2015 |
Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2014 |
Targeted toxicants to dopaminergic neuronal cell death.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Dise | 2015 |
Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Disease Models, Animal; Dopaminergic N | 2014 |
Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2015 |
Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Corpus Striatum; Diffusion Magnet | 2015 |
The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Amyotrophic Lateral Sclerosis; Animal | 2015 |
DJ-1-dependent protective activity of DJ-1-binding compound no. 23 against neuronal cell death in MPTP-treated mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzamides; Brain; Cell Death; Disease Models | 2015 |
Small peptide inhibitor of JNK3 protects dopaminergic neurons from MPTP induced injury via inhibiting the ASK1-JNK3 signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Sequence; Animals; Apoptosis; Arrestins; be | 2015 |
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; | 2015 |
Paeonolum protects against MPP(+)-induced neurotoxicity in zebrafish and PC12 cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Caspase 3; Cell Death; Cytochro | 2015 |
Phytic acid attenuates inflammatory responses and the levels of NF-κB and p-ERK in MPTP-induced Parkinson's disease model of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Calcium-Binding Pro | 2015 |
Transcranial Direct Current Stimulation Ameliorates Behavioral Deficits and Reduces Oxidative Stress in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopamine; Glut | 2015 |
Neuroprotective effects of ginkgetin against neuroinjury in Parkinson's disease model induced by MPTP via chelating iron.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antigens, CD; Ap | 2015 |
Neuroprotective effect of lycopene against MPTP induced experimental Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Carotenoids; Caspase 3; Caspase 8; | 2015 |
Pain perception in acute model mice of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Corpus Striatum; Disease Models, | 2015 |
Neuroprotective effects of Eucommia ulmoides Oliv. and its bioactive constituent work via ameliorating the ubiquitin-proteasome system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Cell Line | 2015 |
A dysfunction of CD4+ T lymphocytes in peripheral immune system of Parkinson's disease model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; CD4-Positive T-Lymphocytes; Cell Differentiat | 2014 |
Nrf2-ARE signals mediated the anti-oxidative action of electroacupuncture in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electroacupuncture; M | 2015 |
MPTP activates ASK1-p38 MAPK signaling pathway through TNF-dependent Trx1 oxidation in parkinsonism mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antibodies, Neutralizing; Corpus Striatum; Di | 2015 |
Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arachidonic Acids; Benzodioxoles; Brain; Cell | 2015 |
Zingerone activates VMAT2 during MPP(+) -induced Cell Death.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Corpus Striatum; Disease Models, | 2015 |
Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Autophagy; Cyclin-Dependent | 2015 |
Preferential Heme Oxygenase-1 Activation in Striatal Astrocytes Antagonizes Dopaminergic Neuron Degeneration in MPTP-Intoxicated Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Dopamine; Dopaminergic Neurons; E | 2016 |
Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Sequence; Animals; Cyclin-Dependent Kinase | 2015 |
Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Caspas | 2015 |
Preferential Extracellular Generation of the Active Parkinsonian Toxin MPP+ by Transporter-Independent Export of the Intermediate MPDP+.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Astrocytes; Biological Tr | 2015 |
Neurobehavioral Anomalies in the Pitx3/ak Murine Model of Parkinson's Disease and MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Disease Models, Anim | 2016 |
Unexpected toxicity of very low dose MPTP in mice: A clue to the etiology of Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopaminergic Neurons; Dose-Response Relations | 2016 |
Anti-apoptotic effect of modified Chunsimyeolda-tang, a traditional Korean herbal formula, on MPTP-induced neuronal cell death in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apoptosis; bcl-2-Associ | 2015 |
Protein-protein interaction networks identify targets which rescue the MPP+ cellular model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Apoptosis Regula | 2015 |
Neuroprotective effects of piperine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkaloids; Animals; Anti-Inflammatory Agents; Apoptosi | 2015 |
Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2016 |
Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Blood-Brain Barrier; Cell Li | 2016 |
Design and evaluation of mucoadhesive microemulsion for neuroprotective effect of ibuprofen following intranasal route in the MPTP mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adhesives; Administration, Intranasal; Animals; Corpus | 2016 |
Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Anti-Inflammatory Agents; Di | 2016 |
Aquaporin-4 deficiency diminishes the differential degeneration of midbrain dopaminergic neurons in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Aquaporin 4; Astrocytes; Chron | 2016 |
Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Brain; Disease Models, A | 2016 |
Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Dopamine; Dopam | 2016 |
Alteration of nuclear factor-kappaB pathway promote neuroinflammation depending on the functions of estrogen receptors in substantia nigra after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Calcium-Binding Proteins; Cell Co | 2016 |
Inhibition of p38 pathway-dependent MPTP-induced dopaminergic neurodegeneration in estrogen receptor alpha knockout mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 2016 |
Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Chronic Disease; Dis | 2016 |
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Cell Death; Disease | 2016 |
Gene dysregulation is restored in the Parkinson's disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calcium Signaling; Coordination Complexes; Di | 2016 |
[Effect of Baichanting Compound on Dopamine Contents in Parkinson's Disease Model Mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Drugs, Chin | 2016 |
Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Doco | 2016 |
Asiatic acid attenuated apoptotic and inflammatory stress in the striatum of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase 3; Corpus Striatum; Cycloo | 2016 |
Individual and Familial Susceptibility to MPTP in a Common Marmoset Model for Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Corpus Striatum; Disease Models, | 2016 |
Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Aged; Animals; Biomarkers; Corpus Stria | 2016 |
Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; alpha7 Nicotinic Acetylcholin | 2016 |
Molecular Mechanism of Regulation of MTA1 Expression by Granulocyte Colony-stimulating Factor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blotting, Western; Cell Line, Tumor; Dopamine | 2016 |
Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Methyltyrosine; Animals; Catecholamines; Early D | 2017 |
e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cadherins; Interleukin-6; Male; Mice, Inbred | 2016 |
The Isothiocyanate Isolated from Moringa oleifera Shows Potent Anti-Inflammatory Activity in the Treatment of Murine Subacute Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Biomarkers; Body We | 2017 |
MiR-144-3p and Its Target Gene β-Amyloid Precursor Protein Regulate 1-Methyl-4-Phenyl-1,2-3,6-Tetrahydropyridine-Induced Mitochondrial Dysfunction.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amyloid beta-Protein Precursor; Cell Line; Cell Surviv | 2016 |
Caspase-1 Deficiency Alleviates Dopaminergic Neuronal Death via Inhibiting Caspase-7/AIF Pathway in MPTP/p Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Chloromethyl Ketones; Animals; Apoptosis In | 2017 |
Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line; Flavonols; Glycogen Synthase Kinas | 2016 |
Effects of a higher dose of near-infrared light on clinical signs and neuroprotection in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergi | 2016 |
Neuroprotective Effect of Coptis chinensis in MPP[Formula: see text] and MPTP-Induced Parkinson's Disease Models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Survival; Coptis; Drugs, Chin | 2016 |
Beta-asarone protects against MPTP-induced Parkinson's disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Allylbenzene Derivatives; alpha-Synuclein; Animals; An | 2016 |
Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetophenones; Animals; Behavior, Animal; Brain-Derive | 2016 |
Human striatal recordings reveal abnormal discharge of projection neurons in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Aged; Aged, 80 and over; Animals; B | 2016 |
Dopaminergic Neurodegeneration in the Mouse Is Associated with Decrease of Viscoelasticity of Substantia Nigra Tissue.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Elasticity; Female; Hippocampus; Ma | 2016 |
Subthalamic, not striatal, activity correlates with basal ganglia downstream activity in normal and parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Basal Ganglia; Brain Waves | 2016 |
Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals | 2017 |
Protective role of 6-Hydroxy-1-H-Indazole in an MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2016 |
δ-Aminolevulinate Dehydratase Activity is Stimulated in a MPTP Mouse Model of Parkinson's Disease: Correlation with Myeloperoxidase Activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Male; Mice, Inbred C5 | 2017 |
FAF1 mediates regulated necrosis through PARP1 activation upon oxidative stress leading to dopaminergic neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Animals; Apoptos | 2016 |
Mulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α-synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Corpus Striatu | 2017 |
Puerarin prevents inflammation and apoptosis in the neurocytes of a murine Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Caspas | 2016 |
ASIC1a Deficient Mice Show Unaltered Neurodegeneration in the Subacute MPTP Model of Parkinson Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acid Sensing Ion Channels; Animals; Catecholamines; Di | 2016 |
Involvement of microRNA-135a-5p in the Protective Effects of Hydrogen Sulfide Against Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3' Untranslated Regions; Animals; Apomorphine; Astrocy | 2016 |
Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antidepressive Agents; Disease Models, Animal | 2018 |
Gynostemma pentaphyllum Ethanolic Extract Protects Against Memory Deficits in an MPTP-Lesioned Mouse Model of Parkinson's Disease Treated with L-DOPA.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclic AMP Response Ele | 2017 |
The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dop | 2017 |
Isobavachalcone Attenuates MPTP-Induced Parkinson's Disease in Mice by Inhibition of Microglial Activation through NF-κB Pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Cell Line; Chalcones; | 2017 |
Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amidohydrolases; Animals; Benzamides; Carbamates; Dise | 2019 |
Nesfatin-1 protects dopaminergic neurons against MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Calci | 2017 |
Regulation of glutamate transporter trafficking by Nedd4-2 in a Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Amino Acid Transport Syst | 2017 |
Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Brain; Cell Count; Cholesterol; C | 2017 |
Rapamycin upregulates glutamate transporter and IL-6 expression in astrocytes in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Transport System X-AG; Animals; Astrocytes; | 2017 |
Neuroprotective properties of icariin in MPTP-induced mouse model of Parkinson's disease: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromones; Corpus Striatum; Disease Models, A | 2017 |
The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; alpha-Synuclein; Animals; Autophagy; Cell | 2017 |
Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biphenyl Compounds; Corpus Striatum; Disease | 2017 |
Pramipexole restores depressed transmission in the ventral hippocampus following MPTP-lesion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzothiazoles; Dextroamphetamine; Disease Mo | 2017 |
The Cleavage Effect of Mesenchymal Stem Cell and Its Derived Matrix Metalloproteinase-2 on Extracellular α-Synuclein Aggregates in Parkinsonian Models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cell Line; Cell Survival; Cu | 2017 |
Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Points; Analysis of Variance; Animals; Bra | 2008 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antip | 2008 |
Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Analysis of Variance; Animals; Cell Death; Corp | 2008 |
Extranigral neurodegeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Calpain; Cell Line; Dipeptides; Hu | 2008 |
Methamphetamine fails to alter the noradrenergic integrity of the heart.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Denervation; Dopamine Agon | 2008 |
Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Benzothiazoles; Brain; | 2008 |
Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus | 2009 |
Identification of zebrafish A2 adenosine receptors and expression in developing embryos.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Base Seque | 2009 |
Transplantation of embryonic stem cell-derived dopaminergic neurons in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Survival; Disease Mode | 2009 |
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not elicit long-lasting increases in cyclooxygenase-2 expression in dopaminergic neurons of monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Count; Cyclooxygenase | 2009 |
Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Ataxia; Disease Models, Animal; | 2009 |
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Infarction; Cell Death; Cell Hypoxia; C | 2009 |
Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkaline Phosphatase; Animals; Astrocytes; Base Sequen | 2009 |
A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Astroc | 2009 |
Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Female; Genetic Thera | 2009 |
Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+ does not.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2009 |
In vitro dopaminergic neuroprotective and in vivo antiparkinsonian-like effects of Delta 3,2-hydroxybakuchiol isolated from Psoralea corylifolia (L.).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Ag | 2009 |
New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antibodies; Antiparkins | 2011 |
Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Callithrix; Disease Models, | 2009 |
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; C | 2009 |
Macroautophagy of the GPR37 orphan receptor and Parkinson disease-associated neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Gene Expression Regulation; Mice; | 2009 |
Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Animals; Blotting, Western; Cell Nucle | 2009 |
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2'-Deoxyguanosine; alpha-Synuclein; Analysis | 2009 |
The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype and nicotine-mediated neuroprotection.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Cytochrome P-450 CYP2D6; Cyt | 2009 |
JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anthracenes; Cell Death; Cyclooxygenase 2; Di | 2009 |
Quantification of Paraquat, MPTP, and MPP+ in brain tissue using microwave-assisted solvent extraction (MASE) and high-performance liquid chromatography-mass spectrometry.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chromatography, High Pressure Liquid; | 2009 |
Multipoint analysis of reduced (125)I-meta-iodobenzylguanidine uptake and norepinephrine turnover in the hearts of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-Iodobenzylguanidine; Animals; Dopamine; Mice; Myocar | 2009 |
Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chronic Disease; Disease Mo | 2009 |
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Age Factors; Animals; Cell Line; Disease | 2009 |
Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Gene Expression Regulation; Heme Oxygenase-1; | 2009 |
Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopamine Pl | 2009 |
TRPC1 inhibits apoptotic cell degeneration induced by dopaminergic neurotoxin MPTP/MPP(+).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Calcium; Cell Line, Tumor; Dopamin | 2009 |
Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; ATP Binding Cassette Tr | 2009 |
Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Hydrogen; L | 2009 |
Effects of pergolide mesilate on metallothionein mRNAs expression in a mouse model for Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Brain; Disease Models, Animal; | 2009 |
Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; alpha-Synuclein; Alternative Splici | 2010 |
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Cell Survival; Disease Models, Animal; | 2009 |
Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Dopamine Agents; Humans; Infrared R | 2010 |
Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Calibration; Copper; | 2010 |
AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Apoptosis; Cel | 2010 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiograph | 2010 |
Small peptide inhibitor of JNKs protects against MPTP-induced nigral dopaminergic injury via inhibiting the JNK-signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptor Proteins, Signal Transducing; Animals; Apoptos | 2010 |
Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Acute Disease; Animals; Bee Venom | 2010 |
Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3beta.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Blotting, Western; Cell Survival; | 2010 |
[Neuroprotective effects and mechanisms of Chuanxiong Chatiao pulvis against MPTP-induced dopaminergic neurotoxicity in mice model of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Drugs, Chin | 2009 |
Striatal spine plasticity in Parkinson's disease: pathological or not?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cerebral Cortex; Corpus Striatum; Dendritic S | 2009 |
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Death; Cycloheximi | 2010 |
Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in neuroprotection mechanism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Base Sequence; Caffeine; Disease M | 2010 |
Ethyl pyruvate has a neuroprotective effect through activation of extracellular signal-regulated kinase in Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apop | 2010 |
Post-MPTP treatment with granulocyte colony-stimulating factor improves nigrostriatal function in the mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2010 |
Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Behavior, Animal; Brain; Corticoster | 2010 |
Activation of ataxia telangiectasia muted under experimental models and human Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Apoptosis; Ataxia Te | 2010 |
Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cells, Cultured; Chromatography, | 2010 |
Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Birth | 2010 |
Endurance exercise training promotes angiogenesis in the brain of chronic/progressive mouse model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, CD34; Blood Vessels; Chronic Diseas | 2010 |
Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2010 |
Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Caspa | 2010 |
Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Caspase 3; Cell | 2010 |
Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Dopamin | 2010 |
Computational physiology of the basal ganglia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Basal Ganglia; Chlorocebus | 2010 |
Elevation of oxidized DJ-1 in the brain and erythrocytes of Parkinson disease model animals.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Catecholamines; Chromatography, High P | 2010 |
[Optimization of counting process of dopaminergic neurons in substantia nigra of parkinsonian mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Disease Models, Animal; Dopamine; | 2010 |
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Brain-Derived Neurotrophic Factor; Corp | 2010 |
Antioxidative and anti-inflammatory protection from carnosine in the striatum of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Carno | 2010 |
Minor retinal degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Hallucinations; Haplorhini; Humans; | 2011 |
Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase 3; Disease Models, Animal; | 2010 |
Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Inhalation; Animals; Apoptosis; Base S | 2011 |
Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Corp | 2010 |
In vivo imaging of retinal gliosis: a platform for diagnosis of PD and Screening of anti-PD compounds.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Progression; Dopamine Agents; Genotyp | 2010 |
Modeling the motor striatum under Deep Brain Stimulation in normal and MPTP conditions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Algorithms; Animals; Basal Ganglia; Corpus Striatum; D | 2010 |
Modeling the effects of Deep Brain Stimulation on sensorimotor cortex in normal and MPTP conditions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Algorithms; Animals; Cerebral Cortex; Deep Brain Stimu | 2010 |
Polygalae radix inhibits toxin-induced neuronal death in the Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Brain; Caspase 3; Cell Death; D | 2011 |
Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Nucleolus; Dopamine; Gene Deletio | 2011 |
[Effects of subchronic hemantane administration on dopamine and serotonin receptors in intact and MPP+-treated rat brain ex vivo].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Corpus Striatum; Disease Models, | 2010 |
Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aquaporin 4; CD4 Antigens; Cells, Cultured; C | 2011 |
Dispersed activity during passive movement in the globus pallidus of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Globus Pallidus; Movement; | 2011 |
Chronic dietary supplementation with turmeric protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated neurotoxicity in vivo: implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Curcuma; Diet; Dietary Supplements; Male; Mic | 2011 |
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease | 2011 |
The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Dopa | 2011 |
Molecular imaging of cell death in an experimental model of Parkinson's disease with a novel apoptosis-targeting peptide.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Apoptosis; Brain; Cell Count; Dis | 2012 |
Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dihydroxyphenylalanine; Dise | 2011 |
Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Coculture Techniques; Corpus | 2011 |
Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Ataxia; Corpus Striatum; Diseas | 2011 |
L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid D | 2011 |
Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Activity Cycles; Animals; Behavior, Animal; Cognition; | 2011 |
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Linolenic Acid; | 2011 |
Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Line; Disease Models, Animal; Fem | 2012 |
Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Animals; Antioxidants; Cell Death; Dopam | 2012 |
Acupuncture enhances the synaptic dopamine availability to improve motor function in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Points; Acupuncture Therapy; Animals; Beha | 2011 |
Dangguijakyak-san protects dopamine neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity under postmenopausal conditions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-2-Associated X Protein; Behavior, Animal; | 2012 |
Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Count; Corpus Stri | 2012 |
Experimental modeling of preclinical and clinical stages of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Dopaminergic N | 2011 |
Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease involves cross talk between inflammatory and Wnt/β-catenin signaling pathways: functional consequences for neuropr
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; beta Catenin; Cells, Cultured; Coculture Tech | 2012 |
No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Binding Sites; Corpus Striat | 2012 |
MRI/SPECT-based diagnosis and CT-guided high-intensity focused-ultrasound treatment system in MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; High-Intensity Focuse | 2013 |
Protective effect of extract of Acanthopanax senticosus Harms on dopaminergic neurons in Parkinson's disease mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Caspase 3; Chromatog | 2012 |
Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Chroma | 2012 |
Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Beha | 2012 |
L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Drug Interaction | 2012 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Docosahexaenoic Acids | 2012 |
Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-Associated Death Protein; Cell Death; Dis | 2012 |
Dopaminergic neurons from midbrain-specified human embryonic stem cell-derived neural stem cells engrafted in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Transplantation; Disease Models, Animal; | 2012 |
Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopaminergic Neurons; Haploinsufficien | 2012 |
Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Dopaminergic Neuron | 2012 |
The neuroprotective effect of overexpression of calbindin-D(28k) in an animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Blotting, Western; Calbindi | 2013 |
Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinson's disease: role of regulatory T cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bee Venoms; Disease Models, Animal; Dopaminer | 2012 |
Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Caeno | 2012 |
PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Callithrix; Disease | 2012 |
The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chemokine CX3CL1; Corpus Striatum; Disease Mo | 2012 |
Acorus gramineus inhibits microglia mediated neuroinflammation and prevents neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acorus; Animals; Anti-Inflammatory Agents; Cell Line; | 2012 |
Pgc-1α overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Cell Death | 2012 |
S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Case-Control Studies; Cell Line; Diseas | 2012 |
PEP-1-ribosomal protein S3 protects dopaminergic neurons in an MPTP-induced Parkinson's disease mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2013 |
The MPTP/probenecid model of progressive Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chromatography, High Pressu | 2013 |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agent | 2013 |
The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Calbindin 1; Calbindins; Cell Count; C | 2013 |
Da-Bu-Yin-Wan and Qian-Zheng-San, two traditional Chinese herbal formulas, up-regulate the expression of mitochondrial subunit NADH dehydrogenase 1 synergistically in the mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biogenic Monoamines; Cerebr | 2013 |
Biodistribution study of [99mTc] TRODAT-1 alone or combined with other dopaminergic drugs in mice with macroautoradiography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Cocaine; Dopamine Age | 2002 |
Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Cytoprotection; Dopamine; Do | 2002 |
The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disability Evaluation; Dopamine A | 2002 |
Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cell Count; Cell Survival; D | 2002 |
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; | 2002 |
Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cell Death; Cerebral Cortex; | 2002 |
Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Cell Count; Cell Death; Disease Models | 2003 |
Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 an | 2003 |
Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Animals; Clioquinol; Ferritins; Gen | 2003 |
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2003 |
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catalysis; Cyclooxygenase 2; Cyclooxygenase 2 | 2003 |
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 2003 |
Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Aged; Aged, 80 and over; Animals; Behavi | 2003 |
Evidence for neurogenesis in the adult mammalian substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antimetabolites; Apoptosis; Bromodeoxyuridine | 2003 |
Experimental study on the protective effect of puerarin to Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Estrogens; Female; Isoflavones; Mi | 2003 |
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-Hydroxybutyric Acid; Adenosine Triphosphate; Animals | 2003 |
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Antiparkinson Agents | 2003 |
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Animals; Blotting, Western; Chromatograp | 2003 |
Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Caber | 2003 |
Inactivation of acetylcholinesterase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcholine; Acetylcholinesterase; Brain; Cholineste | 2003 |
Deep brain stimulation for Parkinson's disease: potential risk of tissue damage associated with external stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Electric Stimulation; | 2004 |
Commentary on "Alpha-synuclein and mitochondria: a tangled skein".
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain; Dopamine Agents; Mice | 2004 |
Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Sequence; Animals; Humans; Mice; Mice, Knoc | 2004 |
Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice.
Topics: 1-Methyl-3-isobutylxanthine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; | 2004 |
Chemoarchitectonic heterogeneities in the primate zona incerta: clinical and functional implications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Chemistry; Dopamine A | 2004 |
Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apoptosis; Behavior, Animal; Dep | 2005 |
Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Brain-Derived Neurot | 2004 |
The neurotoxicology of hard foraging and fat-melts.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Disease Models, Animal; Fats; Hunger; | 2004 |
Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Cell Differentiation; Cell Line; | 2005 |
Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Mo | 2005 |
Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amyotrophic Lateral Sclerosis; Animals; Brain; Corpus | 2005 |
Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Electric Stimulation; Fema | 2005 |
Differential survival patterns among midbrain dopaminergic cells of MPTP-treated monkeys and 6OHDA-lesioned rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Cell Survival; Disease Mod | 2005 |
Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoquinones; Blotting, Western; Brain; Cell | 2005 |
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Levodopa; Male; Mice; Mice, Inbred C57BL; Mic | 2005 |
Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aged, 80 and over; Animals; Astrocytes; C | 2006 |
Effects of mitochondrial toxins on the brain amino acid concentrations.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Brain Chemistry; Cerebral Cortex | 2005 |
Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Biopterins; Cell Line; Cytochromes c; Dopamine; Humans | 2006 |
[Effects of yinxing pingchan recipe and its components on activity of mitochondrial enzyme complex in brain of mice with Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Drugs, Chinese Herbal; Electron Transp | 2005 |
Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Coculture Techniques; Dinopr | 2006 |
Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Chorea; Disease Models, Animal; F | 2006 |
Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Blotting, Western; Disease Models, | 2006 |
In vivo complementation of complex I by the yeast Ndi1 enzyme. Possible application for treatment of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dependovirus; Disease Models, Animal; Electro | 2006 |
Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Transport; Convection; Dependoviru | 2006 |
Doxycycline-regulated co-expression of GDNF and TH in PC12 cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Bacterial Agents; Dopamine; Doxycycline; | 2006 |
Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Cell Line; Coenzymes; Deferoxamine | 2006 |
Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Cell Count; Disease Mode | 2006 |
Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Amines; Cattle; Cell-Free System; Co | 2006 |
Evidence of apoptosis in the subventricular zone and rostral migratory stream in the MPTP mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase 3; Caspases; Cell Count; C | 2006 |
Methoxyflavones protect cells against endoplasmic reticulum stress and neurotoxin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Survival; Cells, Cultured; Cyclic AMP; C | 2007 |
M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Dopamine Agents; Humans; Hyd | 2006 |
Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acetylcholinesterase; | 2006 |
Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Corpus Striatum; Diseas | 2007 |
Mitochondrial complex-1 in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Electron Transport Complex I; Humans; Lymphocytes; Par | 2006 |
A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cells, Cultured; Dopamine; Matrix | 2007 |
3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Astrocytes; Behavio | 2006 |
Identification of genes related to Parkinson's disease using expressed sequence tags.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Cell Death; Chromogranins; Cytosk | 2006 |
Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Anesthetics, Combined; Animals; Biogenic Monoamines; C | 2007 |
The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Analysis of Variance; Ani | 2007 |
'Rejuvenation' protects neurons in mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antiparkinson Agents; Calcium; Calcium | 2007 |
Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Azetidines; Behavior, A | 2007 |
[Effect of phosphorylated c-Jun expression on COX-2 expression in the substantia nigra of MPTP mouse model of subacute Parkinson disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anthracenes; Blotting, Western; Cell Death; C | 2007 |
Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of parkinsonism with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Calorimetry, Indirect; Citr | 2007 |
Microarray analysis of laser capture microdissected substantia nigra pars compacta after a single administration of MPTP in common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Cell Death; Dopamine; Down-Regula | 2007 |
Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Disea | 2008 |
Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Disease Mo | 2007 |
Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-X Protein; Disease Models, Animal; Dopami | 2008 |
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Disease Models, Animal; Diseas | 2007 |
Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cystamine; Disease Models, Animal; Dru | 2008 |
Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Survival; Cytoplasm; Dopamine Agents; Mi | 2008 |
Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Curcumin; Dis | 2008 |
Aetiology of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Biopterins; Dihydropteridine Reductase; Dopamine; Free | 1984 |
Parkinson's disease, 1984.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Levodopa; Parkinson Disease; Parkinso | 1984 |
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Disease Models, Anima | 1983 |
The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Glutathione; Humans; Melanins; Parkinson Dise | 1984 |
High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Binding Sites; Brain; Monoam | 1984 |
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigrostriatal lesion in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Corpus Striatum; De | 1984 |
Monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Animals; Cats; Disease Models, Animal; Haplorhi | 1983 |
Trail of ironies to Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Haplorhini; Humans; P | 1984 |
Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Diseases; Disease | 1984 |
Defective utilization of sensory input as the basis for bradykinesia, rigidity and decreased movement repertoire in Parkinson's disease: a hypothesis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Afferent Pathways; Animals; Cats; Humans; Mechanorecep | 1984 |
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Carbidopa; Drug Combinations; Female; Hallucina | 1984 |
Alteration of corticotropin-releasing factor immunoreactivity in MPTP-treated rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amygdala; Animals; Corticotropin-Releasing Hormone; Di | 1995 |
Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Autoradiography; Callit | 1995 |
Inhibition of alpha-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Dose-Response Re | 1995 |
The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 1993 |
1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol inhibits tyrosine hydroxylase activity in rat striatal synaptosomes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biopterins; Chromatography, High Pressure Liq | 1994 |
Advances in the understanding of the cause of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Dopamine; Humans; Neurons; Parkinson Disease; S | 1994 |
External and implanted pumps for apomorphine infusion in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Animals; Apomorphine; Female; Humans; Inf | 1993 |
Clinical and preclinical PET correlates of parkinsonism with 11C-WIN 35,428.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbon Radioisotopes; Cocaine; Humans; Parkin | 1994 |
Transplantation of autologous cervical sympathetic ganglion into the brain with Parkinson's disease: experimental and clinical studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Animals; Corpus Striatum; Female; Humans; | 1994 |
Presence of tetrahydroisoquinoline-related compounds, possible MPTP-like neurotoxins, in parkinsonian brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Biotransformation; Culture Techniques; Dopamine; Front | 1993 |
The visual system in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Contrast Sensitivity; Dopamine; Electroenceph | 1993 |
GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopa | 1995 |
Long latency postural reflexes are under supraspinal dopaminergic control.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Age of Onset; Antiparkinson Agents; Antipsychot | 1995 |
Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Line; Dose- | 1995 |
Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Autoradiography; Bas | 1995 |
Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Female; Globus Pallidus; Glu | 1996 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cyto | 1996 |
Functional recovery in parkinsonian monkeys treated with GDNF.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Female; Glial Cell Line-Derived Neu | 1996 |
No NO prevents parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Enzyme Inhi | 1996 |
Iron-dependent enzymes in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aged, 80 and over; DNA, Mitochondrial; El | 1995 |
Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Benzopyrans; Disease Models, Anim | 1996 |
High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Globus Pallidus; Maca | 1996 |
Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Female; Globus Pallidus; In Situ Hybridizatio | 1996 |
SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Carrier Proteins; Cocaine; Con | 1997 |
Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cells, Cultured; Chickens; | 1997 |
Presymptomatic revelation of experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Kyn | 1997 |
Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzophenones; Catechol O-Methyltransferase; | 1997 |
Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenoviridae; Animals; Corpus Striatum; Dopamine; Dopa | 1997 |
Application of gene therapy for Parkinson's disease: nonhuman primate experience.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; beta-Galactosidase; Blood-Brain Barrier; Brai | 1998 |
Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1997 |
Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Stem; Corpus Striatum; Glutathio | 1997 |
(E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aldehydes; Animals; Brain Stem; Cross-Lin | 1998 |
Effects of nicotine on 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced depression of striatal dopamine content and spontaneous locomotor activity in C57 black mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Dopamine Agents; Male; Mice; Mice, | 1998 |
In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Chloroc | 1998 |
Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Corpus Striatum; Dopamine Ag | 1998 |
[Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Aged; Animals; Antiparkinso | 1998 |
Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Azepines; Brain; Disease Models, Animal; Dopa | 1998 |
[125I]EGF binding in basal ganglia of patients with Parkinson's disease and progressive supranuclear palsy and in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Basal Ganglia; Brain | 1998 |
Endogenous dopamine-derived neurotoxins and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Dopamine; Humans; Isoquinolines; M | 1998 |
An endogenous MPTP-like dopaminergic neurotoxin, N-methyl(R)salsolinol, in the cerebrospinal fluid decreases with progression of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Biomarkers; Disease Progression; Dopamine Agents | 1999 |
Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Biomarkers; Cocaine; Disease Models, An | 1999 |
A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Availability; Body Weight; Circadi | 1999 |
Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Albumins; Animals; Antiparkinson Agents; Disease Model | 1999 |
Apomorphine protects against MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; A | 1999 |
Alteration of neurotensin receptors in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Corpus Striatum; Dopamine; D | 1999 |
Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 1999 |
A new video/computer method to measure the amount of overall movement in experimental animals (two-dimensional object-difference method).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Callithrix; Computer Storage Dev | 1999 |
Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Brain; Chelating Agents; Dopamin | 1999 |
Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Disease Models, | 1999 |
Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alcohol Dehydrogenase; Antioxidants; Apoptosis; Catala | 1999 |
Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Corpus | 1999 |
Pesticide study aids Parkinson research.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Insecticides; | 1999 |
Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-Iodobenzylguanidine; Aged; Animals; Autonomic Nervou | 2000 |
Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Apoptosis; Blotting, | 2000 |
Striatal enkephalin gene expression does not reflect parkinsonian signs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cats; Caudate Nucleus; Corp | 2000 |
Ethylenebisdithiocarbamate enhances MPTP-induced striatal dopamine depletion in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; D | 2000 |
Excitotoxic ablation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Drug D | 2000 |
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2000 |
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antigens, CD; Dihydroxyphenylalanine; | 2000 |
Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Axons; Chlorocebus aethiops; Dopamine; Globus | 2000 |
Hepatic disposition of neurotoxins and pesticides.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Transport; DDT; Hepatocytes; Human | 2000 |
Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Drug Evaluation, | 2001 |
Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Chloromethyl Ketones; Amino Acid Substituti | 2001 |
Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Base Sequence; bcl-2-Associated X Protein; Di | 2001 |
Gene therapy to the rescue in Parkinson's disease. Response from Kordower and Aebischer.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine Agents; Genetic Therapy; Glia | 2001 |
Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Caspase 8; Caspase 9; Caspases; Di | 2001 |
Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Progression; Dopamine; Dopamine Agent | 2001 |
Prosaptide D5, a retro-inverso 11-mer peptidomimetic, rescued dopaminergic neurons in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cells, Cultured; | 2001 |
Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino | 2001 |
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru | 2001 |
Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; DNA, Compl | 2001 |
Evidence for target-specific outgrowth from subpopulations of grafted human dopamine neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Tissue Transplantation; Disease Models, | 2001 |
An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Apoptotic Protease-Activating Fact | 2001 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. 1990.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Dopamine Agonists; History, | 2001 |
Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Brain; Cell Survival; Corpus Stri | 2002 |
Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Callithrix; Disease Models, | 2002 |
Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Dependo | 2002 |
[Treatment of neurodegenerative diseases: new perspectives].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Corpus Striatum; De | 2001 |
The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Copper; Disease Models, Animal | 2002 |
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; alpha-Synuclein; Amphetamine; Animals; Behavior | 2002 |
Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antiparkinson Agents; Cell Count; Corp | 2002 |
Therapy of Morbus Parkinson and radical-induced neurotoxicity in the rat--in vivo voltammetric studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 1992 |
A method for quantitating motor deficits in a nonhuman primate following MPTP-induced hemiparkinsonism and co-grafting.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Caudate Nucleus; Female; Mac | 1992 |
Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adult; Aged; Aged, 80 and | 1992 |
Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenylyl Cyclases; Aged; Aged, 80 and over; Animals; B | 1992 |
Endogenous synthesis of N-methylsalsolinol, an analogue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, in rat brain during in vivo microdialysis with salsolinol, as demonstrated by gas chromatography-mass spectrometry.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Gas Chromatography-Mass Spectrometry; | 1992 |
Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adrenal Glands; Animals; | 1992 |
Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Brain Tissue Transplantation; Caudate Nucleus; Dihydro | 1992 |
A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Deoxyglucose; Female; Globus Pal | 1992 |
Lack of major olfactory dysfunction in MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Female; Humans; Injections, Intravenous; Male; | 1992 |
Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Carotid Arteries; Do | 1990 |
MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Corpus Striatum; Disease Models, Anima | 1990 |
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1991 |
Dopamine and basal ganglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Dopamine; gamma-Aminobutyric A | 1991 |
Chemically induced Parkinson's disease. III: A study of a possible role of singlet molecular oxygen in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Free Radicals; Lasers; Monoamine Oxidase; Oxygen; Parg | 1991 |
A lot of "excitement' about neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Alzheimer Disease; Animals; Dizocilpine Maleate | 1991 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: partial protection against striato-nigral dopamine depletion in C57BL/6J mice by cigarette smoke exposure and by beta-naphthoflavone-pretreatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoflavones; beta-Naphthoflavone; Corpus St | 1991 |
Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Tissue Transplantatio | 1991 |
Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Cerebra | 1991 |
Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Autoradiography; Basal Ganglia; Carrier | 1991 |
1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Chemistry; Isoquinoli | 1991 |
[Parkinson's disease--the molecular mechanism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acid Sequence; Animals; Base Sequence; Brain Che | 1990 |
Change of tyrosine hydroxylase in the parkinsonian brain and in the brain of MPTP-treated mice as revealed by homospecific activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Corpus St | 1990 |
Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Brain; | 1990 |
Changes of tyrosine hydroxylase in parkinsonian brains and in the brains of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Humans; Mice; Parkins | 1990 |
Gangliosides prevent MPTP toxicity in mice--an immunocytochemical study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Gangliosides; Male; M | 1990 |
Inhibition of human benzylamine oxidase (BzAO) by analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benzylamine Oxidase; Carbidopa; Dopamine Agents; Human | 1990 |
Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Biogenic Amines; Brain Chemis | 1991 |
6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Dihydroxyphenylalanin | 1990 |
Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biotransformation; Brain; Humans; In Vitro Te | 1990 |
GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1990 |
MAO-B and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Platelets; Disease Models, Animal; Huma | 1990 |
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Carbidopa; Corpus Str | 1990 |
Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Tissue Transplantation; Caudate Nucleus | 1990 |
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Anima | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Analgesics; Animals; Callitrichinae; Dopamine Ag | 1989 |
The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Corpus Striatum; Dopamine; Female; Homovanillic | 1985 |
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1985 |
Endogenous urinary monoamine oxidase inhibitor excretion in Parkinson's disease and other neurological disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aged, 80 and over; Female; Humans; Isatin | 1989 |
Studies on the interactions of MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) with the cytochrome P-450 enzyme system--clues to a possible aetiological factor in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aryl Hydrocarbon Hydroxylases; Brain; Cytochr | 1989 |
Parkinson's disease, vitamin E, and mitochondrial energy metabolism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Energy Metabolism; Humans; Mitochondria; Neur | 1989 |
Aetiology of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Parkinson Disease; Pyridines; Rats | 1985 |
MPTP-like molecules and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chemical Phenomena; Chemistry; Humans; Parkin | 1985 |
Normal MPTP binding in parkinsonian substantial nigra: evidence for extraneuronal toxin conversion in human brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Amyotrophic Lateral Sclerosis; Autoradiography; | 1985 |
Methyltetrahydro-beta-carbolines and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Humans; Parkinson Disease; Pyridines | 1985 |
Does an endogenous methylpyridinium analogue cause Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Chemical Phenomena; Chemistry; Humans; Methylation; Pa | 1985 |
Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotrophic interaction between ageing and environment?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aging; Alzheimer Disease; Animals; Environmenta | 1986 |
Timing of levodopa therapy: evidence from MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Levodopa; Macaca fasc | 1987 |
Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Humans; Lisuride; Mac | 1987 |
Reversal of parkinsonism by fetal nerve cell transplants in primate brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorocebus aethiops; Corpus Striatum; Fetus; | 1987 |
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholinesterase; Dop | 1988 |
Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Culture Techniques; Dopamine; Humans; | 1987 |
Nigral and adrenal grafts in parkinsonism: recent basic and clinical studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Caudate Nucleus; Chromaffin | 1987 |
Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Epinep | 1986 |
[L-threo-DOPS therapy and parkinsonism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antiparkinson Agents; Brain; Dopamine; Droxidopa; Huma | 1986 |
The potential use of vitamin E and selenium in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Hydroxydopami | 1986 |
The MPTP story: an introduction.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Haplorhini; Humans; P | 1986 |
MPTP: clinical implications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Basal Ganglia; Benserazide; Drug Combinations; D | 1986 |
(-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Arylsulfotransferase; Blood Platelets; Humans; Monoami | 1986 |
Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Carbidopa; Chromatography, High Pressure | 1986 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Hu | 1987 |
Parkinson's disease: current view.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Humans; Monoamine Oxidase; Monoamine O | 1987 |
4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callitrichinae; Carbolines; Corpus Striatum; | 1987 |
Selegiline and the prophylaxis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chemical Phenomena; Chemistry; Humans; | 1987 |
Autotransplantation of the superior cervical ganglion into the brain. A possible therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Caudate Nucleus; Cerebral Cor | 1988 |
L-deprenyl in prevention of MPTP induced depletion of striatal enkephalins in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Enke | 1988 |
Biochemical aspects of Parkinson-dementia complex.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dement | 1988 |
[Biochemistry of the physiopathologic and clinical aspects of free radicals in cerebral degenerative diseases such as Alzheimer's and Parkinson diseases].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alzheimer Disease; Animals; Catecholamines; Free Radic | 1988 |
[New clues to the etiology of Parkinson disease: parkinsonism induced by the neurotoxin MPTP].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Humans; Mice; Nerve Degenera | 1986 |
[Pethidine and parkinsonism. 1-Metyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a new neurotoxin].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Parkinson Disease; Pyridines; Recepto | 1986 |
Toxin-induced parkinsonism: recent developments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Humans; Illicit Drugs; Male; Parkinson Disease; Parkin | 1986 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Ther | 1986 |
Monoamine oxidase B, smoking, and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Platelets; Brain; Humans; Hydrazines; I | 1986 |
MPTP and the aetiology of Parkinson's disease. Clinical implications. London, June 27, 1985.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Parkinson Disease; Parkinson Disease, | 1986 |
Recent research advances in Parkinson's disease: Part I.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Levodopa; Par | 1986 |
[11C]MPTP: a potential tracer for Parkinson's disease research in laboratory animals.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbon Radioisotopes; Macaca nemestrina; Park | 1986 |
Age factors loom in parkinsonian research.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Animals; Humans; Parkinson Disease; Pyrid | 1986 |
Accumulation of a parkinsonism-inducing neurotoxin in melanin-bearing neurons: autoradiographic studies on 3H-MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Melatonin; Neurons; Neurotox | 1986 |
[Treatment of Parkinson disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antiparkinson Agents; Brain; Drug Therapy, Combination | 1986 |
Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corpus | 1987 |
Development of new pharmacological approaches in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cysteinyldopa; Delayed- | 1987 |
Older dopaminergic neurons do not recover from the effects of MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Corpus Striatum; Dopamine; Male; Mice; | 1987 |
Symposium on a Long Time Clinical Care of Parkinson's Disease. Tokyo, April 12, 1986. Proceedings.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Parkinson Disease; Parkinson Disease, | 1987 |
Transplantation of fetal dopamine neurons in primate brain reverses MPTP induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Dopamine; Fetus; | 1987 |
Metabolic aspects of aging brain and related disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Alzheimer Disease; Animals; Brain; Cerebral Cor | 1987 |
Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |
MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antibodies, Monoclonal; Brain; Cytochrome P-4 | 1987 |
Alterations of the muscarinic cholinergic (mACh) receptors in the striatum of the MPTP-induced parkinsonian model in mice: in vitro quantitative autoradiographical analysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Corpus Striatum; Disease Mod | 1987 |
Chronic alterations in jejunal myoelectric activity in rats due to MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Caudate Nucleus; Electromyogr | 1987 |
Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Adult; Carbidopa; Chronic Disease; Drug | 1985 |
Similar distribution of monoamine oxidase (MAO) and parkinsonian toxin (MPTP) binding sites in human brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Autoradiography; Binding Sites; Brain; Humans; M | 1985 |
Parkinson's disease: an environmental cause?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Haplorhini; Humans; Mice; Parkinson Disease; | 1985 |